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Background: Oxidative stress is now believed to play a role in the evolution of 
epilepsy and antioxidants have been proposed as putative antiepileptic agents. 
The experimental evidence suggested that nuclear factor, erythroid 2 like 2 
(Nrf2) could be a promising therapeutic target for epilepsy. The main aims of 
this study were to investigate the effects of common AEDs on oxidative stress 
biomarkers in a human SH-SY5Y cell-line, and to explore the association of 
common variants in the (NFE2L2) gene with clinical characteristics of epilepsy. 
Methods: SH-SY5Y human cells were exposed to H2O2 (0-1000µM), LPS (0-
100 µg/ml), and pilocarpine (0-100 µM) for 1, 4, and 24 hours. Cells were 
exposed to carbamazepine (CBZ; 0-100µM)), valproic acid (VPA; 0-1000µM) 
levetiracetam (LEV; 0-300µM), and lamotrigine (LTG; 0-100µM) for 1, 4, and 
24hrs, with or without 100µM H2O2 for further 4hrs. AED effects were assessed 
against basal oxidative stress, determined by malondialdehyde (MDA) 
concentration, superoxide dismutase (SOD) activity, and reduced/oxidised 
glutathione (GSH/GSSG) ratio. The expression of Nrf2, haemoxygenase-1 (HO-
1) and NADPH quinone oxidoreductase-1 (NQO-1) was determined using real 
time PCR and western blot. The genotyping of the five SNPs in NFE2L2 gene 
was carried out using TaqMan® genotyping assays.  
Results: MDA level was increased in a time and concentration-dependent 
manner up to maximum of 3-fold, following exposure to H2O2, LPS, and 
pilocarpine. However, SOD activity, GSH/GSSG ratio decreased by 5-fold, 15-
fold, respectively, after exposure to H2O2, LPS, and pilocarpine. MDA level was 
elevated in a concentration-dependent-manner, up to a maximum of 13-fold, 5.5-
fold, 15-fold and 9.5-fold, following exposure to CBZ, VPA, LEV and LTG, 
respectively. In contrast, SOD activity was reduced, again in a concentration-
dependent manner, by a factor of up to 2, 2.5, 1.5 and 1.3 after incubation with 
CBZ, VPA, LEV and LTG, respectively. The GSH/GSSG ratio was also reduced 
after exposure to CBZ (up to 5.8-fold), VPA (up to 4-fold) LEV (up to 5-fold), 
and LTG (up to 3-fold). Further exposure to 100µM H2O2 amplified AEDs 
effects on MDA concentration, SOD activity and GSH/GSSG ratio by up to 3-
fold. Expression of the Nrf2 gene was increased by 4-fold following exposure to 
both 100µM CBZ and 1000µM VPA, while expression of HO-1 was increased 
by 2.7-fold and 3-fold, respectively. NQO-1 gene expression was increased after 
incubation with 100µM LTG and 1000µM VPA by 2.3-fold and 2.9-fold, 
respectively. Additional exposure to 100µM H2O2 augmented AED effects on 
Nrf2, HO-1 and NQO-1 gene expression by up to 5-fold. Relative expression of 
Nrf2, HO-1 and NQO-1 proteins was increased by 1.3-fold, 1.2-fold and 1.2-
fold after exposure to CBZ, VPA and LTG, respectively. There was no effect of 
LEV. Small additional increases (up to 10%) in protein expression were seen 
after further 24 hours incubation with 100µM H2O2. Association was observed 
between NFE2L2 genotype, rs2886161, and the remission on any AED. 
Nonetheless, a multivariate predictive model did not show any significant 
contribution of NFE2L2 SNP genotypes, demographic and clinical predictors 
and the response to AED treatment.  
Conclusions: These findings imply that several existing AEDs have pro-oxidant 
rather than antioxidant effects, albeit at relatively high concentrations. This may 
limit their antiseizure activity and/or contribute to their adverse effect profile. 
There was no evidence from this pharmacogenomics investigation that common 
variants in the NFE2L2 gene have any influence on the presentation of epilepsy 























1.1 Historical overview 
The very early deliberated depiction of epilepsy was revealed in ancient Babylonian 
medical texts known as Sakikku “All Diseases” (1067-1046 B.C.). They used special 
terms for all types of seizure and epilepsy such as Antasubba and Miqtu. Precise details 
referred to prognosis, diagnosis and treatment, and petit and grand mal, febrile seizures, 
ictal and post-ictal periods, auras, partial seizures and status epilepticus were fully 
described (Edward et al., 1990; Reynolds and Wilson, 2008).     
The plate which is a part of the Babylonian sets in the British museum (figure 1.1) 
includes surprisingly well-explained clinical perceptions of almost all of the common 
types of seizure and a few rarer epilepsy syndromes which are well known nowadays. 
 
Figure 1.1 Clay tablet 26 about epilepsy from the Neo-Babylonian collection in the 
British Museum, London. BM47753 (adopted from Edward et al., 1990). 
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The Babylonian role on the clay tablet represented miqtu “fall or epilepsy”, hayyatu 
“fit” and sibtu “seizure” as an extraordinary disorder that is due to infringement of the 
body by evil spirits (Edward et al., 1990; Reynolds and Wilson., 2008). This conception 
of epilepsy remained authoritative until the 5th century BC when the initial steps toward 
epilepsy recognition commenced. Hippocrates, in his book, On the Sacred Disease, was 
the first to defy the divine view of epilepsy by saying that epilepsy is a disease, just like 
other diseases, and has its etiological factors, hereditary malady, signs and symptoms 
(Magiorkinis et al., 2010).    
Since then, the conception of epilepsy as a brain disorder started to develop and by the 
early 19th century a consensus was emerging, especially with the development of 
healthcare systems in Europe and the introduction of bromide as antiepileptic drug 
(AED) in Europe and USA, (figure 1.2) (Goldensohn et al., 1997). 




The discovery of the human electroencephalogram (EEG) in 1929 by the German 
neurologist Hans Berger (1873-1941) allowed noticeable progress to be achieved and 
confirmed the electrical principle of epilepsy which had been suggested previously by 
Robert Bently Todd (1809-1860) (Goldensohn et al., 1997; Magiorkinis et al., 2014). 
By the second half of the 20th Century, there had been a prominent progression in the 
diagnosis and treatment aspects of epilepsy, which was marked by increased focus on 
the basic mechanisms behind seizure and epilepsy. This was facilitated by evolutions in 
genetics, neurophysiology, molecular biology and other important techniques 
(Goldensohn et al., 1997). In spite of all these advances, a great challenge still exists in 
our knowledge regarding the mechanisms of epileptogenesis and the pathophysiology of 
epilepsy. A major goal of epilepsy research remains the identification of reliable 
prognostic and diagnostic biomarkers and of new therapeutic targets with the potential 
of modifying or curing the disease, rather than merely inhibiting seizures (Baulac et al., 
2015). 
1.2  Definitions of epilepsy and epileptic seizures 
Epilepsy is a chronic brain disorder or a group of brain disorders characterised by a 
tendency to generate at least one epileptic seizure (Fisher et al., 2005). Epilepsy affects 
people worldwide and can cause long lasting disruption of cerebral structure and / or 
function. This brain disturbance appears clinically as several types of seizures, which 
are often the net result of an unstable, convoluted process (epileptogenesis) where 
normal cerebral structure and function are modified resulting in a permanent state which 
leads to the generation and propagation of abnormal electrical activity and recurrent 
seizures (Goldberg and Coulter, 2013). An epileptic seizure is defined as a brief episode 
of unpredictable involuntary movement or sensation, associated with abnormal and 
excessive output from a group of neurons in the brain, in the absence of aggravating 
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factors and that may affect part of the body (partial or focal seizure) or the entire body 
(generalized seizure). These episodes are occasionally accompanied by an alteration in 
consciousness, motor, sensory, autonomic, psychological and behavioural comorbidities 
(Fisher et al., 2005). In 2014, the International League against Epilepsy (ILAE) 
suggested a new practical definition of epilepsy to replace the previous one proposed in 
2005 (Fisher et al., 2014). The updated definition represented epilepsy as a brain disease 
that is defined by any one of the following characteristics (Fisher et al., 2014):  
1. Two unprovoked (or reflex) seizures happening more than 24 hours apart.  
2. One unprovoked seizure (or reflex) seizure with a high risk of recurrence (more than 
60%) which is similar to the general recurrence risk after two unprovoked seizures.  
3. Diagnosis of epilepsy syndrome.  
There are several significant updates in this new definition. Firstly, the new definition 
points to epilepsy as a disease rather than a disorder. This reflects the critical nature and 
sequelae of epilepsy, as the word disease notifies a more lasting disturbance of normal 
brain function. Secondly, the inclusion of reflex seizures, which are seizures provoked 
by external pathological factors (such as tumours or trauma), provided that there is 
abnormal and enduring liability to have seizures (Neligan et al., 2012; Fisher et al., 
2014). Additionally, the new definition strongly emphasises recurrence risk after the 
first unprovoked seizure; patients with identifiable brain lesions, such as brain trauma, 
infection or tumours, have a risk of recurrence after a single seizure that is similar to 
those who have experienced two unprovoked seizures. This change to the definition 
encourages earlier diagnosis and treatment of symptomatic epilepsy, avoiding the 
complications of physical injury and the social consequences of seizure recurrence. 
Finally, the modified definition emphasises the importance of the diagnosis of epilepsy 
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syndromes, including those with a low risk of recurrent seizures and high rates of 
spontaneous remission (Fisher et al., 2014). In this regard, epilepsy is considered to be 
resolved if the patient is free from seizures for 10 years and off medication for at least 5 
years  
1.3 Epidemiology of epilepsy 
Epilepsy is the most common chronic brain disease globally, and it affects people of all 
ages, races and social groups. Currently, around 50 million people worldwide have 
epilepsy and 80% of them live in developing countries (Gretchen et al., 2012). In high-
income countries, the incidence of epilepsy is between 30 and 50 newly diagnosed cases 
per 100,000 people per year and this is doubled in low- and middle-income countries 
(Forsgren et al., 1996; Banerjee et al., 2009). Although the onset of epilepsy can occur 
at any age, it is more common in children, young people and in the elderly (Olafsson et 
al., 2005). The mortality rate in people with epilepsy is approximately two to three 
times greater than in the general population and life expectancy is shortened by two to 
ten years (Tomson et al., 2005; Hitiris et al., 2007). The highest mortality rate occurs in 
those with symptomatic epilepsy and persistent neurological deficits (Kenneth et al., 
2014). Sudden unexpected death in epilepsy (SUDEP) is the most common cause of 
death in patients with chronic epilepsy. The incidence of sudden death is reported to be 
20 times greater in people with epilepsy compared with the general population (Shankar 
et al., 2013). SUDEP is relatively uncommon in patients with new-onset epilepsy and in 
those in remission from seizures, with incidence estimated at 0.1 to 0.35 cases per 1000 
person-years in population-based cohorts of epilepsy patients. SUDEP is considerably 
more common in patients with chronic epilepsy, with an incidence of 1 to 2 cases per 
1000 person-years, and highest among those with severe, refractory seizures at 3 to 9 
cases per 1000 person-years (Shankar et al., 2013). SUDEP may occur at all ages but is 
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most often observed in those between 20 and 40 years. In most cases, SUDEP appears 
to be seizure-related (Tomson et al., 2005). 
1.4 Classification of the epilepsies 
Classification of the epilepsies is very important as it is the crucial tool used clinically 
to manage a patient who is presenting with seizures. It is very helpful to understand the 
type of seizure that a patient has, other seizures that are likely to arise in that patient, the 
possible precipitating factors for their seizures, approaches to management, and the 
likely prognosis. Moreover, classification of epilepsy is an important part in predicting 
the hazards of comorbidities and mortality in epilepsy patients and often gives insight 
into AED selection (Scheffer et al., 2017). The new 2017 ILAE classification of 
epilepsy is built in three levels according to seizure type, epilepsy type and syndrome 




Figure 1.3 Classification of epilepsy types (adapted from Scheffer et al., 2017). 
 
1.4.1 Classification of epileptic seizures 
Older classifications (ILAE, 1981; ILAE, 1989) classified seizures based on clinical 
features and EEG findings. Seizures were divided into either generalised or partial. 
Depending on the level of retained consciousness, partial seizures were subdivided into 
simple and complex. With considerable progress in recognising the pathogenesis of 
epilepsies and seizures, modification of the 1981 and 1989 classification systems has 
taken place and several papers have been published suggesting a revision of the now 
outdated classification of seizures and epilepsies (Luders et al., 1998; Engel., 2001; 
Engel., 2006). The ILAE Commission on Classification and Terminology published a 
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new, modified classification system in 2011 in which the most novel connotation was 
the manner of seizure commencement (Berg et al., 2011). According to this new 
classification, seizures should be classified into focal, generalized, and unknown (Berg 
et al., 2011).  
Focal (or partial) seizures refer to the electrical and clinical manifestations of seizures 
that arise from a specific of the brain. The clinical manifestations of a particular focal 
seizure depend on the part of the brain that is activated (Fisher et al., 2017). The EEG 
typically indicates a localised discharge over the area of onset. Focal seizures most 
commonly arise from the temporal lobe. Simple focal seizures are those in which 
consciousness is preserved. New terminology suggests that these should now be called 
'focal aware' seizures. Complex focal seizures include memory loss for the clinical 
event and impaired responsiveness at the time of the event. New terminology suggests 
that these should now be called 'focal impaired awareness' seizures. Focal seizures may 
also evolve into secondary generalised seizures (Fisher et al., 2017).  
A generalized tonic-clonic seizure (GTCS) is a seizure type that is identified by specific 
clinical and EEG criteria (ILAE, 1981). Clinically, this seizure type involves loss of 
consciousness and a phasic tonic stiffening of the limbs (either symmetrically or 
asymmetrically), followed by repetitive clonic jerking. The vast majority of these types 
of seizure are self-limiting without intervention. The observed manifestations of the 
seizure are correlated on the EEG with bisynchronous epileptiform activity in both 
cerebral hemispheres. These seizures can occur either in a primary fashion (with onset 
in a widespread or bilateral distribution) or in a secondary fashion (with onset in one 
hemisphere or region) subsequent to an initial focal seizure (Fisher et al., 2017). 
Unknown seizures are those that are not readily classifiable into either focal or 
generalised because of a lack of clinical history or the results of investigations. This 
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might include seizures with EEG and/or clinical evidence to suggest that origin of the 
seizure is within, and which rapidly engages, a bilaterally distributed network. If the 
source of the seizure cannot be determined with at least 80% confidence by the 
clinician, EEG or other scanning technique, it should be classified as ‘unknown onset’. 
As new information becomes available, it may be possible to change this classification 
to either focal or generalised (Liyanagedera et al., 2017). 
1.4.2 Classification of epilepsy type 
The new classification of epilepsy type is derived from the earlier 2014 definition 
(Fisher et al., 2014). It includes a new category of “Combined Generalised and Focal 
Epilepsy” in addition to the well-established and distinct generalized epilepsy and focal 
epilepsy classifications and also an “Unknown” category. Many types of epilepsy 
include multiple types of seizures and the diagnosis of epilepsy type is based on a 
combination of clinical history, clinical examination and EEG findings. As discussed 
above in relation to seizure type, the term “unknown” in this case refers to an epilepsy 
type which is difficult to classify into either generalized or focal because of insufficient 
information or uninformative EEG findings (Scheffer et al., 2017) (figure 1.3). 
1.4.3 Syndromic classification of epilepsy 
An epilepsy syndrome is a complex of clinical signs and symptoms that include seizure 
type, EEG and imaging features that determine unique epilepsy status. Age-related 
features such as age at onset and age at remission, provoking factors, and diurnal 
variation in seizures may be specified where known (Scheffer et al., 2018). 
Furthermore, peculiar comorbidities and aetiological and prognostic features may be 
identifiable for specific epilepsy syndromes. The most recent classification system 
(Scheffer et al., 2017) has established two major epilepsy syndrome groupings, 
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idiopathic generalized epilepsies (IGEs) and self-limiting focal epilepsies. The IGEs, in 
turn, comprise four well established epilepsy syndromes; childhood absence epilepsy, 
juvenile absence epilepsy, juvenile myoclonic epilepsy, and generalized tonic-clonic 
seizures alone. Likewise, several self-limiting focal epilepsy syndromes have been 
identified, including focal epilepsy with centrotemporal spikes plus frontal, temporal, 
parietal and occipital lobe epilepsies (Scheffer et al., 2017). 
1.4.4 Aetiologic classification of epilepsy 
The older aetiological classification of epilepsy into idiopathic, symptomatic and 
cryptogenic was associated with substantial contradictions and discrepancies among 
clinicians. The aetiological classification has been reappraised, with a focus on the 
causes and mechanisms of epilepsy (Shorvon, 2011). New aetiological terms were 
suggested by the 2017 ILAE report, as follows; genetic, structural, infectious, 
metabolic, immune and unknown (Scheffer et al., 2017).  
Genetic aetiology: A classification of genetic epilepsy is applied when epilepsy is the 
result of a well-defined or presumed genetic defect (Berg et al., 2011; Moshe et al., 
2015). The best known example of genetic epilepsy is Dravet syndrome in which more 
than 80% of patients have a mutation in the α1 subunit of the neuronal voltage-gated 
sodium channel (SCN1A) gene (Scheffer et al., 2017). In addition to Dravet syndrome, 
SCN1A gene mutations have been recognised in generalized epilepsy with febrile 
seizure plus (GEFS+) and in intractable childhood epilepsy with generalised tonic-
clonic seizures (Mullen and Scheffer., 2009; Brunklaus et al., 2013). Other examples of 
gene mutations associated with epilepsy are CHNRA4 gene mutation was associated 
with Autosomal dominant noctural frontal lobe epilepsy (ADNFLE) and GABRA1 gene 
mutations which have been recognised in Autosomal dominant juvenile myoclonic 
epilepsy (JME) (Scheffer et al., 2017). A genetic contribution to epilepsy does not 
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preclude an environmental factor. It is well known that environmental factors contribute 
to seizure disorders; for instance, many epilepsy patients are likely to have a seizure 
with stress, illness or sleep disorders. So, a genetic factor indicates the pathogenic 
mutation of crucial effect in giving rise to epilepsy (Scheffer et al., 2017). 
Structural aetiology: Many structural abnormalities of the brain are linked to a markedly 
increased risk of epilepsy development. These structural abnormalities are ordinarily 
visible by computerised tomography (CT) scan or magnetic resonance image (MRI). 
Structural aetiologies are either acquired, such as trauma, stroke and infection, or 
genetic, as is the case in many cerebral malformations (Scheffer et al., 2017). There are 
several well-defined associations with structural aetiologies within the epilepsies. These 
include, mesial temporal lobe seizures with hippocampal sclerosis, gelastic seizures 
with hypothalamic hamartoma, Rasmussen’s syndrome, and hemiconvulsion-
hemiplegia-epilepsy (Berg et al., 2011). Recognition of these associations is important 
in ensuring that brain scans from epilepsy patients are carefully examined for a 
particular structural lesion. This might influence decisions about brain surgery if 
medical therapy fails (Scheffer et al., 2017).  
Metabolic aetiology: Metabolic causes allude to a well-defined metabolic disorder with 
manifestations or biochemical changes in the body, such as uremia, aminoacidopathies, 
porphyria, and pyridoxine-dependent seizures. Most of the metabolic epilepsies have 
genetic basis, but some may be acquired like cerebral folate deficiency seizures 
(Scheffer et al., 2017). It is extremely important to identify the metabolic cause of 
epilepsy in order to treat it effectively and prevent any intellectual impairment. 
Infectious aetiology: Globally, known infectious agents are the most common causative 
factors in epilepsy (Singhi et al., 2011; Vezzani et al., 2016). In this case, infectious 
causes refer to patients with established epilepsy, rather than those experiencing 
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seizures as a manifestation of acute infections such as encephalitis and meningitis. 
Examples of infections that can give rise to epilepsy in particular regions in the world 
are neurocysticercosis, tuberculosis, HIV, cerebral malaria, cerebral toxoplasmosis and 
congenital infections such as cytomegalovirus and Zika virus. These infectious causes 
might sometimes have a related structural aetiology (Singhi et al., 2011). 
Immune aetiology: The immunological epilepsies typically result from immune 
disorders in which seizures are one of several symptoms of the disease. Immune 
epilepsy has been identified in both children and adults and is usually associated with 
the evidence of auto-immune central nervous system inflammation (Vezzani et al., 
2016). With the development of broad-spectrum antibody testing, accurate diagnosis of 
these auto-immune encephalitides, including anti-NMDA receptor encephalitis and anti-
LGI1 encephalitis, is increasing (Lancaster et al., 2012). This subgroup of epilepsies has 
targeted treatment options with specific immunotherapy. 
Unknown aetiology: There are many epilepsy patients with unknown cause in whom the 
epilepsy diagnosis is built on clinical and neuroimaging techniques. So, the extent of the 
aetiology of the epilepsy depends on the extent of the assessment available to the patient 
and this differs across the world in different countries and healthcare systems (Scheffer 
et al., 2017).  
1.5 Neurobiology of seizures and epilepsy 
Awareness of the basic principles of neurobiology provides a platform with which to 
understand the principal mechanisms behind seizures, epileptogenesis and epilepsy. The 
initiation and propagation of seizure activity involves some of the most fundamental 
aspects of nerve cell function, such as action potential generation, the electrical basis of 
trans membrane potential, and neuronal synchronisation.  
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1.5.1 Molecular mechanism of seizures 
Many mechanisms can result in seizures. However, at the most basic level, it is widely 
accepted that seizures develop when there is a disturbance in the balance between 
inhibitory and excitatory neurotransmission. Any disruption of this balance that either 
suppresses inhibition or enhances excitation can produce seizures. In contrast, blockade 
of excitatory firing or enhancement of inhibitory neurons usually protects against 
seizures. Control of these mechanisms can occur at several different levels within the 
nervous system: firstly at the level of ion transport across cell membranes, secondly at 
the level of neuronal cell circuits and synapses, and thirdly within neuronal networks. 
Electrical basis of nerve cells: The nervous system preserves ionic and chemical 
gradients that generate the platform for electrical activity. Neurons are not continuously 
active but are typically close to the threshold for firing (resting potential), meaning that 
action potentials, which are fundamental to central nervous system function, can be 
generated with relative ease. The robustness of the resting potential is however crucial 
to restrain excessive firing which is usually associated with seizures (McCormick et al., 
1994) (figure 1.4).  
In the normal state, neurons have a high intracellular concentration of potassium ions 
and a high extracellular concentration of sodium ions, leading to a clear transmembrane 
potential (McCormick et al., 1994). Any disruption of this ionic balance results in 
generation of an action potential, which travels down the axon and causes depolarisation 
of nerve terminals, neurotransmitter release, and thus cell-cell communication (Lodish 
et al., 2000). Essential pumps, such as sodium-potassium ATPase, are found in the cell 
membrane to maintain the ionic gradients. Likewise, glial cells play an important role in 
controlling extracellular ion concentrations, which has led scientists to consider that 
glial cells are as important as neurons in the generation of seizure activity (Duffy et al., 
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1999; Fellin et al., 2005). Any abnormality in ion pumps, glial cells or membrane-bound 
ion channels, such as the voltage-gated sodium channel implicated in GEFS+, could 
potentially facilitate seizures (Meisler et al., 2001). Thus, the modulation of voltage-
gated ion channels and the preservation of transmembrane ionic gradients provide 
targets for existing and new anticonvulsants. 
 
 
Figure 1.4: Resting potential and action potential in neuronal cells. As an action 
potential (nerve impulse) travels down an axon there is a change in polarity across 
the cell membrane. Sodium (Na+) and potassium (K+) gated ion channels open and close 
as the membrane reaches its threshold potential. Na+ channels open at the beginning of 
the action potential, and Na+ ions move into the axon, causing depolarization. 
Repolarization occurs when the K+ channels open and K+ ions move out of the axon, 
creating a change in polarity between the outside of the cell and the inside. The impulse 
travels down the axon in one direction only, to the axon terminal where it signals other 




Synaptic transmission: In epilepsy, a great deal of attention is paid to mechanisms 
linked to synaptic transmission because of its significant role in maintaining the balance 
between neuronal excitation and inhibition. The inhibitory neurotransmitter gamma-
aminobutyric acid (GABA) has been explored in great detail in terms of its contribution 
to epilepsy, as has the excitatory neurotransmitter glutamate. Chloride (Cl-) is the major 
ion that is responsible for the generation of ionic currents via GABAA receptors, with a 
net influx causing hyperpolarisation of the neuronal cell membrane. However, K+-Cl- 
co-transporters (KCCs), which are essential for maintaining the chloride ion gradient, 
are not stably expressed and may be influenced by insults to the CNS (figure 1.5). This 
has led to evidence that the transporter NKCCL may be an important contributor to 
seizures in early life. An increase in expression of NKCC1, and a corresponding 
decrease in KCC2 expression, leads to an increase in intracellular Cl–, a reduction in 
GABAergic inhibition and greater susceptibility to seizures (Dzhala et al., 2005). Added 
to this, excitatory neurotransmission mediated by glutamate is not always consistent. 
Because glutamatergic synapses supply both glutamatergic and GABA-ergic neurons, 
exposure to glutamate might have a strong excitatory effect, little excitatory effect, or it 
may inversely raise the level of inhibition via indirect activation of GABA-ergic 
pathways. Thus, it can be very difficult to anticipate how modulation of either GABA-




Figure 1.5: The role of NKCC1 (A) and KCC2 (B) in maintaining chloride balance.  
In traumatic brain injury, up-regulation of the sodium-potassium-chloride co-transporter 
(NKCC1) and down-regulation of the potassium-chloride co-transporter (KCC2) leads 
to increased intracellular concentrations of Cl– (C). Elevated NKCC1 transporter 
expression is known to facilitate early post-traumatic brain injury seizures. KCC2: K+-
Cl– cotransporter 2; NKCC1: Na+-K+-Cl– cotransporter 1; TBI: traumatic brain injury 
(adapted from Liang et al., 2017). 
 
Synchronization: An excessive but otherwise isolated neuronal discharge does not lead 
to seizures by itself. It requires the interconnection of a synchronized neuronal network. 
The association between electrographic recordings at the cortical surface during seizures 
and paroxysmal depolarization shifts (PDSs) occurring synchronously within cortical 
pyramidal cells was first illustrated by Matsumoto and  Ajmone-Marsan (1964). Such 
studies give an insight into how neurons can start to fire in harmony when 
conventionally they do not, and several theories have been proposed to explain the 
mechanisms that can result in synchronization. Many of these theories point to 
glutamatergic networks and the implication that the PDS is simply a “giant” excitatory 
postsynaptic potential which is manifest by high levels of inter-connectivity between 
cortical pyramidal cells that release glutamate as a neurotransmitter (Brown and 
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Johnston, 1984). Another possible mechanism behind synchronisation is the 
contribution of gap junctions on cortical neurons, which permit non-synaptic 
communication between neuronal cells via direct ion flow, such that these neurons can 
be rapidly and efficiently synchronized. Many studies suggest that even small numbers 
of gap junctions may have a great influence on neuronal interconnection (Roger et al., 
2004). 
Another mechanism of synchronization comprises, conversely, inhibition. Large 
numbers of GABA-ergic neurons that supply pyramidal cells of cortex have an 
extensive network of connections to neighbouring pyramidal cells. Thus, any discharge 
from a solitary neuron can synchronously hyperpolarize many other pyramidal cells. As 
GABA-ergic inhibition diminishes, inactive voltage-dependent currents, such as those 
mediated by T-type calcium channels, become activated and the result is a coordinated 
excitation of a group of pyramidal cells (Cobb et al., 1996). Promotion of 
synchronisation might result from developmental brain changes in epilepsy patients. 
These changes involve outgrowth of axon collaterals from excitatory neurons which use 
glutamate as a principal neurotransmitter. Such changes might be one of the causes of 
recurrent seizures, although there is debate over whether seizures can arise through 
augmentation of both recurrent inhibition and recurrent excitation (figure 1.6) (Sloviter 
et al., 2006). Nevertheless, the fact remains that development of new synaptic excitatory 
networks, which are insignificant or absent in normal cerebrum (Nadler et al., 2003), 
supports synchronization and potentially clarifies how the flexibility of the central 
nervous system may participate in epileptogenesis (Sutula et al., 2007). 
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Figure 1.6: The stereotypical synchronized response of each neuron in a seizure focus. 
The depolarization phase occurs due to glutamate and calcium ion activation, while the 
repolarization phase occurs due to inhibition of action potential by activation of 
inhibitory GABA receptors and potassium channels (adapted from Iqbal. 2016). 
 
1.5.2 Molecular mechanism of epilepsy 
In general, the mechanisms that have been identified to explain epilepsy are either 
idiopathic, due to genetic causes or developmental malformations, or symptomatic 
(acquired) as a response to an acute insult or injury. Approximately 50% of epilepsy 
patients have acquired epilepsy, linked to preceding neurological insult (Delorenzo et 
al., 2005).   
Acquired epilepsy is more prevalent than either genetic or developmental epilepsies, 
which mainly influence ion channels or mitochondria, respectively (Martinc et al., 
2012). There are numerous genetic factors that contribute to increasing neuronal 
excitability in idiopathic epilepsies. Any mutation in mitochondrial respiratory chain 
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complexes, synapses, voltage- or ligand–gated ion channels, or neurotransmitter 
receptors may modify the normal excitability of the brain and lead to epileptic seizures 
(Martinc et al., 2012). Thus, epilepsy is multifactorial – it can emerge from genetic or 
acquired causes or a combination of the two. In addition, aetiological factors vary with 
age and geographical distribution (Martinc et al., 2012). In general, there are three 
major phases which comprise the development of acquired epilepsy: the acute phase (or 
insult), the latent phase (or epileptogenesis), and the chronic phase (or recurrent 
epilepsy) (Pitkanen and Sutula, 2002). 
The acute phase – injury: The process of epileptogenesis in acquired epilepsy can be 
initiated by a several types of cerebral lesions and these aetiologies may vary with age. 
Such lesions may themselves be caused by infections, trauma, tumours, childhood 
febrile convulsions, stroke, hypoxia, status epilepticus and neurodegenerative disorders. 
All of these insults, injuries and illnesses increase the occurrence of acquired epilepsy. 
Brain trauma, cerebrovascular accident (CVA) and status epilepticus are the most three 
significant aetiological factors in acquired epilepsy (Delorenzo et al., 2005). Despite 
significant heterogeneity in the nature of these precipitating events, they are associated 
with a common mechanism for generating cerebral injury, i.e. excitotoxicity caused by 
an excess in extracellular glutamate concentrations. This leads to sustained stimulation 
of α-amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA) receptors, 
recruitment of N-methyl-D-asparate (NMDA) receptors, a massive increase in 
intracellular calcium (Ca2+) concentration, and activation of Ca2+ signalling pathways 
resulting in neuronal death (Choi, 1988; Michaels and Rothman, 1990). 
The latent phase – epileptogenesis: Epileptogenesis refers to the transition processes 
involved in the development of the epileptic condition following an initial cerebral 
insult. These processes might take years or even decades after the initial event and 
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almost certainly involves a host of molecular and cellular changes (Patel et al., 2004; 
Pitkanen et al., 2009). Additionally, epilepsy is ordinarily not a stagnant condition, but 
develops through the lifespan (Scharfman et al., 2007). 
Despite huge advancement in the understanding of neuroscience in the last few decades, 
the precise pathophysiological mechanisms of epileptogenesis are still not known 
(Guerrini et al., 2003). Neuronal cell damage, as a response to initial insult, has received 
considerable attention as the primary aetiological factor that may result in epilepsy. 
However, the actual role of cell damage in epileptogenesis is still a matter of debate. It 
can be either a cause or a consequence of seizures or both, supported by the fact that 
surgical resection of the damaged hippocampus can alleviate the symptoms of temporal 
lobe epilepsy (Shin and McNamara., 1994).  
Initial brain injury results in a cascade of physiological, structural, and biochemical 
changes, including disturbance of the blood-brain barrier, alteration in brain blood flow, 
raised intracranial pressure, cerebral haemorrhage, inflammation and necrosis 
(Willmore et al., 2009). In traumatic epilepsy, for instance, it has been proposed that 
following intracerebral haemorrhage there is a localised breakdown of red blood cells 
and release of haemoglobin (Hb) and iron ions (Fe2+ and Fe3+) into brain parenchyma, 
which results result in generation of reactive oxygen species (ROS) (Willmore et al 
2009). Increased ROS production, consequently, stimulates a series of pathological 
changes that can lead to increased neuronal hyperexcitability or to neuronal cell death 
(Gupta et al., 2006). Recently, a great deal of attention has been paid to the effect of 
oxidative stress on neuronal cell death as a common pathogenic process that can 
contribute to epileptogenesis and to the development and progression of spontaneous 
recurrent seizures (Chuang et al., 2010). 
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Additionally, many convulsant chemicals and methods had been used as an initial 
precipitating injury in many animal models of epileptogenesis, through administration 
of convulsant chemicals such as pilocarpine or kainic acid (Ben-Aft et al., 1980; 
Cavalheiro et al., 1982; Turski et al., 1983) or by sustained electrical stimulation of the 
hippocampus and other limbic regions (McIntyre et al., 1982; Brandt et al., 2003). 
Neuronal damage secondary to SE is the result of neuronal hyper-excitability that is 
characterised by an increased frequency of discharges leading to depolarization of 
membrane potential, an excessive generation of free radicals due to high metabolic rate, 
and a considerable increase in extracellular glutamate (Sherwin et al., 1999). Together, 
these variables lead to an increase in intracellular Ca2+ concentration that can 
precipitate neuronal cell damage and death. Multiple experimental studies have shown 
an association between SE, neuronal cell damage and an increase in extracellular 
glutamate (Pena and Tapia, 1999; Ueda et al., 2002). This is supported by animal model 
studies in which selective inhibition of glutamate receptors during SE is neuroprotective 
(Ebert et al., 2002). Likewise, Ca2+ concentrations remain elevated during the chronic 
epilepsy phase, contributing to the sporadic generation of recurrent seizures. High Ca2+ 
concentrations also lead to alterations in the functionality of inhibitory GABAA 
receptors, changes in gene transcription and protein expression, and neurogenesis 
(Morris et al., 1999; Blair et al., 2004). Thus, glutamate excitotoxicity and increased 
Ca2+ level, plus other pathophysiological effects, play a significant role in development 
of spontaneous recurrent seizures. 
The chronic phase – recurrent epilepsy: As shown by epidemiological studies, 
several types of brain insult can lead to epileptogenesis (Herman. 2002). In chronic 
phase, which is the recurrent seizures phase, there is a failure of repair enzymes such as 
complex I, aconitase, and reduced / oxidised glutathione (GSH/GSSG) redox status 
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which may further exacerbate oxidative damage by continuous O2
- and H2O2 liberation 
during the chronic phase of epileptogenesis (Rowley and Patel. 2013). Subsequently 
these molecular changes might contribute to the cellular damage and chronic epilepsy 
(figure 1.7).  
 
Figure 1.7: Mitochondrial oxidative stress during the acute, latent and chronic phases 
of epileptogenesis. During the acute phase, shortly following an inciting injury 
increased production of reactive oxygen species (ROS) such as superoxide, hydrogen 
peroxide and hydroxyl radicals via Fenton chemistry and oxidative damage to 
mitochondrial targets and altered redox status occur. ROS production returns to control 
values during the latent period during which seizure probability is low; however 
mitochondrial and cellular redox environment remains persistently altered. ROS 
production and oxidative damage returns during the chronic phase accompanied by 
spontaneous recurrent seizures. Failure of repair enzymes may further exacerbate 
oxidative damage during the chronic phase of epileptogenesis. GSH=glutathione; 
GSSG=glutathione disulfide; α-KGDH= α-ketoglutarate dehydrogenase; CI= complex I; 
ATP= adenosine triphosphate; mtDNA= mitochondrial DNA; [Ca++]m= mitochondrial 





1.6  The role of mitochondrial dysfunction in epilepsy 
1.6.1 Mitochondrial structure 
Mitochondria are subcellular organelles with inner and outer membranes, separated by 
the inter-membranous matrix, that are responsible for many important functions in 
almost all eukaryotic cells (Koehler et al., 2004). The outer membrane pores are 
permeable to specific small molecules. However, large molecular weight proteins 
require a specific signalling sequence to be transported across this membrane (Benz et 
al., 1994). The inner membrane contains ion channels and transporter systems and is 
highly selective for solutes and ions. It has a high protein to phospholipid ratio and is 
extensively folded, which increases its surface area. Furthermore, the inner membrane 
hosts enzymes responsible for ATP synthesis and the electron transport chain (ETC) 
and generates the mitochondrial membrane potential (MMP). Mitochondrial DNA 
(mtDNA) is a highly specific, unique and independent genome which is inherited 
maternally (Leonard & Schapira, 2000). However, most mitochondrial proteins are 
encoded by nuclear DNA (nDNA) (DiMauro & Schon., 2003). Due to its 
hypermobility, mtDNA can be directed on the basis of metabolic demands (Saxton and 
Hallenbeck. 2005), which increase with epileptic seizures.   
1.6.2 Mitochondrial function in CNS 
In the CNS, the mitochondrion is the major subcellular organelle of neuronal cells. Its 
primary function is to provide cells with energy via the metabolic processes of the 
electron transport chain (ETC) and tricarboxylic acid (TCA) cycle. Mitochondria have 
multiple functions; primarily they provide cells with energy by generation of adenosine 
triphosphate (ATP) via the process of oxidative phosphorylation (OXPHOS) through 
the synchronous action of five enzyme complexes (I–V) found in the inner membrane of 
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mitochondria. Mitochondria are also involved in; (i) the liberation of ROS which play 
important role in cellular signalling, (ii) maintenance of pre- and post-synaptic calcium 
concentrations which play an important role in the turnover of free radicals, (iii) 
regulation of programmed cell death through pro-apoptotic factors, and (iv) synthesis of 
metabolites, lipids and amino acids involved in neurotransmission and oxidation of fatty 
acids (Schapira, 2002). The generation of ATP by OXPHOS starts by passing of 
electrons from Reduced nicotinamide adenine dinucleotide (NADH) and Reduced flavin 
adenine dinucleotide (FADH2)to complex I and II respectively, then subsequently to 
complex III and IV via cytochrome C and coenzyme Q10, and then to molecular oxygen 
to produce water. Complexes I to IV act as proton pumps, producing an electrochemical 
gradient across the inner membrane of mitochondria that is exploited by complex V to 
generate ATP, ADP and inorganic phosphate (Enrique and Kelvin, 2000). The majority 
of ATP generated by the mitochondria in excitable cells is used to drive Na+/K+ ATPase 
which maintains the membrane potential and prevents hyperexcitability. The ETC 
phosphorylates ADP and produces ATP by the expeditious transport of electrons. 
However, leakage of electrons from this process can react with molecular oxygen to 
form superoxide radicals (O2
.-), predominantly at complex I and III (Muller et al., 2004). 
Furthermore, the action of monoamine oxidase on the outer membrane is associated 
with reduction of two electrons of oxygen (O2) to form hydrogen peroxide (H2O2) 
(Hauptmann et al., 1996) (figure 1.8). The steady state level of superoxide ion (O2.-) in 
the mitochondria relies on the rate of (O2.-) generation by the ETC and the level of 
mitochondrial antioxidant manganese superoxide dismutase (MnSOD) enzyme. 
Intrinsically, mitochondria are the main source of intracellular reactive oxygen species 
(ROS) with estimates ranging from 0.1 to 4% of total oxygen utilization dedicated to 
O2.- production (Boveris, 1984). 
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All of the mitochondrial functions discussed above are crucial for the maintenance of 
normal brain activity, and any dysfunction in one or more of these could potentially 
result in neuronal hyperexcitability and epileptogenesis.  
 
Figure 1.8: Mitochondrial function and neuronal excitability. Superoxide anion (O2
●-) 
production by complexes I and III of the ETC leads to the production of ONOO− in a 
reaction with NO, and H2O2 through dismutation by the antioxidant MnSOD. H2O2 is 
membrane permeable and able to diffuse out of the mitochondria causing widespread 
oxidative damage. Excessive O2
●- production also damages Fe–S containing enzymes 
involved in the TCA cycle, such as aconitase. Hydroxyl radicals (OH•) can be formed 
from H2O2 through Fenton chemistry and lead to further oxidative damage of 
macromolecules such as ETC complexes and mtDNA. Oxidative damage to mtDNA 
can lead to increased mutation rates and a decrease in ETC subunit expression encoded 
by the mitochondrial genome. Alterations in the redox status of GSH/GSSG and 
CoASH/CoASSG can cause an inability to protect against the deleterious effects of 
ROS. Modification of neurotransmitter biosynthesis within the mitochondria can affect 
levels of neuronal excitability/inhibition. Oxidative damage to these targets can result in 
increased neuronal excitability resulting from decreased mitochondrial membrane 
potential and ATP levels affecting the Na+/K+ ATPase and the release of cyto C leading 
to apoptosis. mNa+Ca2+E = mitochondrial sodium calcium exchanger; mCU = 
mitochondrial calcium uniporter; mNICE = mitochondrial sodium independent calcium 
exchanger; MPTP = mitochondrial permeability transition pore; GSH = glutathione; 
GSSG = glutathione disulfide; CoASH = coenzyme A; CoASSG = coenzyme A 
glutathione disulfide; GR = glutathione reductase; GPx = glutathione peroxidase; cyto C 
= cytochrome C; ψm = mitochondrial membrane potential (adopted from Waldbaum 
and Patel, 2010) 
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1.6.3 Mitochondrial dysfunction 
Primary mitochondrial dysfunction: In general terms, primary mitochondrial disorders 
are those that are caused by genetic variations, affecting the structural composition and 
function of the ETC. These disorders disrupt mitochondrial OXPHOS, with the 
phosphorylation of ADP to ATP significantly affected. The ETC is a unique metabolic 
pathway and the only pathway under the control of both nuclear (nDNA) and 
mitochondrial (mtDNA) genomes. As such, mitochondrial disorders can be transmitted 
via mitochondrial genetics or Mendelian genetics, with the former affected by critical 
considerations such as mitotic segregation, heteroplasmy, maternal inheritance, and 
threshold effect (Dimauro and Davidzon. 2005). 
nDNA-based primary mitochondrial diseases are complex and mostly inherited in an 
autosomal recessive pattern, although x-linked and dominant inheritance patterns have 
also been described (Carrozo et al., 1998). Some primary mitochondrial disorders, such 
as Leigh syndrome, are characterised by multigenic mutations, while others including 
Alpers-Huttenlocher syndrome (POLG) and mitochondrial neurogastrointestinal 
encephalomyopathy (MNGIE) are linked to mtDNA depletion and deletions. 
Nuclear gene mutations are increasingly recognised as the main cause of paediatric 
mitochondrial disorders (Dimauro and Davidzon. 2005), largely because of the 
predominance of mitochondrial proteins that are synthesized by nDNA (~850 genes) in 
comparison to mtDNA (~13 genes) (Cotter et al., 2004). 
Nuclear genes involved in mitochondrial disease encode proteins which are structural 
subunits of mitochondrial enzyme cofactors, complexes, translation factors, assembly 
factors, mtDNA maintenance factors, and factors that are critical for the cleavage and 
incorporation of this essential organelle (Alston et al., 2017). However, the causative 
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genetic defect remains to be identified in most patients with suspected mitochondrial 
disease. For instance, the genetic basis of complex I defect, which is the largest and the 
most significant ETC disorder, and coenzyme Q10 deficiency are still ambiguous in 
50% of patients (Quinzii et al., 2006). 
Primary mitochondrial dysfunction arising from mtDNA is purely maternally inherited. 
This inheritance follows the threshold-effect which reflects the attribution of normal to 
mutant mtDNA in the cells where mitochondrial dysfunction occurs (Vu et al., 2002). 
For example, Leber hereditary optic neuropathy and neuropathy, ataxia and retinitis 
pigmentosa (NARP) are caused by mtDNA mutations in cells of the nervous system and 
retina, whereas myoclonic epilepsy with ragged-red fibres (MERRF) results from 
mutations in mitochondrial tRNA. 
All of the mitochondrial-related diseases discussed above are associated with mutations 
in mtDNA that occur prior to conception, are hereditary, and result in primary 
mitochondrial dysfunction. If these mutations occur after conception, they are 
considered acquired, for instance due to environmental factors or oxidative stress, and 
result in secondary mitochondrial dysfunction (Niyazov et al., 2016). 
Secondary mitochondrial dysfunction: Secondary mitochondrial dysfunction includes 
any abnormal mitochondrial function other than those considered primary. It does not 
include inborn genetic disorders which control OXPHOS and which usually happen 
after conception (Niyazov et al., 2016). Instead, secondary mitochondrial dysfunction 
results from the influence of external mechanisms such as environmental or 
pharmacological toxins that can damage the mtDNA (DiMauro et al., 2008). 
The effects of pathological processes on the mitochondrial function, as shown in many 
acquired or inherited disorders (i.e. non-primary mitochondrial dysfunction disorders), 
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can weaken the capability of the mitochondrion to produce ATP and attenuate 
mitochondrial dynamics such as fission and fusion that are highly involved in 
mitochondrial disorders (Juan et al., 2017),. Mechanisms underlying mitochondria-
related disease states have predominantly focused on nDNA, mtDNA damage, and ROS 
generation (Pieczenik and Neustadt 2007). 
The brain is commonly involved in mitochondrial diseases because of its high energy 
demand (Rahman, 2012). Mitochondria in brain are responsible for supplying ATP for 
neurotransmission, regulation of pre- and post-synaptic calcium (Ca2+) concentrations, 
and ROS signalling (Wei et al., 2001). The pathophysiological mechanisms that 
underlie mitochondrial-induced injury are primarily driven by ROS produced by 
mitochondria themselves (Wei et al., 2001). 
1.6.4 Mitochondrial oxidative stress and epileptogenesis 
Oxidative stress arises from an imbalance between pro-oxidants and anti-oxidants, in 
favour of the former. Free radicals (either ROS or RNS) are a group of atoms/molecules 
that have one or more unpaired electron in their outer orbital, giving them a very strong 
ability to interact with other biomolecules by accepting or donating an outer shield 
electron to saturate their orbital (Halliwell and Gutteridge, 2007). ROS are products of 
normal, aerobic mitochondrial respiration, constantly produced as unpaired electrons are 
released from complexes I and III of the mitochondrial ETC (Muller et al., 2004).  
It is estimated that nearly up to 2% of all oxygen molecules used by cells is converted to 
ROS, mainly superoxide anion (O2
●-) which is the primary ROS generated by ETC 
complex I and III (Boveris and Chance., 1973). O2
●- is converted into H2O2 by 
spontaneous dismutation via superoxide dismutase (SOD). Consequently, H2O2 is 
broken down into H2O and O2 by glutathione peroxidase and catalase. If this step does 
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not happen, either due to lack of antioxidant enzymes or excessive liberation of H2O2, 
the Fenton reaction can occur via the interaction of H2O2 with divalent cations, such as 
iron (Fe2+) and copper (Cu2+) to release a highly reactive hydroxyl radical (OH●-) which 
readily oxidizes proteins, lipids and DNA (Figure 1.9). 
 
Figure 1.9: Oxidative stress mechanism. Superoxide radical anion (O2
●-) reacts with 
cellular lipids, leading to the formation of lipid peroxides that are metabolized to 
malondialdehyde (MDA) and 4-hydroxynonenal (4-HNE). Other cellular molecules, 
such as DNA and proteins, may also may be modified by O2
●-, however peroxidation of 
lipids is more intense because it has chain reaction properties. Nitric oxide synthase 
(NOS) produces nitric oxide (NO), which reacts with O2
●- to produce peroxynitrite 
(ONOOO●). ONOOO● also participates in formation of lipid peroxides. Superoxide 
dismutase (SOD) catalyzes the dismutation of superoxide anion O2
●- into less noxious 
hydrogen peroxide (H2O2), which is further degraded by glutathione peroxidase (GPx) 
and cooperating glutathione reductase (GR). The reduction of H2O2 into water by GPx 
is accompanied by the conversion of glutathione from its reduced form (GSH) into its 
oxidized form (GSSG). GR restores the pool of GSH by reduction of GSSG, by means 
of reduced nicotinamide adenine dinucleotide phosphate (NADPH). Another enzyme - 
catalase - also participates in H2O2 neutralization, releasing oxygen (O2). Antioxidants, 
such as vitamins C and E, flavonoids and carotenoids, counteract reactive oxygen 
species (ROS) generation. (adopted from Kwiecien et al., 2013). 
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ROS are temporary, unstable and highly reactive to cellular components, making their 
direct quantification very difficult. Instead of this, the measurement of ROS has been 
done through the estimation of indirect markers of oxidative damage such as 
malondialdehyde (MDA) which is the by-product of lipid peroxidation, free radical 
antioxidant enzymes activity (i.e. SOD, catalase),  glutathione (reduced/oxidized ratio), 
and transcription factor Nrf2 and its related genes (Patel., 2004). 
Recently, mitochondrial dysfunction (primary and secondary) in CNS has gained 
substantial attention as a possible cause of epileptic seizures and has been described in 
humans (Kunz et al., 2000; Lee et al., 2008) and in many experimental models (Chuang 
et al., 2004; Sleven et al., 2006). It is proposed that oxidative stress influences a number 
of metabolic processes might result in neuronal hyper-excitability and potentially be an 
source of active epilepsy. Likewise, several mechanisms have been suggested to 
contribute to the latent period of epileptogenesis, including derangement in 
mitochondrial redox status resulting in irreversible oxidation, mtDNA destruction, 
mitochondrial respiration failure, and a drop in ATP production. In turn, decreased ATP 
production leads to a decrease ATP-dependent Na+/K+ ATPase activity and in the 
expression of glutamate transporters and glutamate synthetase and may be an additional 
factor linked to increased neuronal excitability (Fighera et al., 2006). 
1.6.5 Oxidative damage to cellular macromolecules 
Most of the data that supports the influence of mitochondrial oxidative stress in the 
epilepsies has come from studies of animal models in which recurrent seizures are 
induced by exposure to chemoconvulsant agents, such as kainic acid and pilocarpine, or 
via the kindling method in which repeated electrical stimulation of the limbic system 
gives rise to spontaneous seizures. Both approaches result in an increase in ROS 
production in the brain, while the hippocampal slice culture model has also been shown 
57 
 
to be suitable for assessing macromolecular (i.e. protein, lipid and nuclear) changes 
associated with oxidative stress (Sashindranath et al., 2011). 
Protein oxidation: Oxidative damage can alter the structure, function, and activity of 
structural proteins and key enzymes (Stadtman et al., 2001). The brain is highly 
susceptible to oxidative damage due to its large quantity of mitochondria, high oxygen 
consumption, lack of some antioxidant enzymes, poor repair mechanisms, and richness 
in polyunsaturated fatty acids (Halliwell et al., 1992).  
Mitochondrial complex I (CI), alpha-ketoglutarate dehydrogenase (α-KGDH), and 
aconitase are the most common proteins that are affected, either by post-translational 
modifications or inhibition by ROS during the epileptogenic period (Rowley and Patel. 
2013). Mitochondrial aconitase is a TCA cycle enzyme that catalyses the 
interconversion of citrate to isocitrate via cis-aconitate during the second stage of the 
TCA cycle. It contains an iron-sulphur (Fe-S) cluster which facilitates the elimination of 
the hydroxyl (OH) group (Dupuy et al., 2006) and is highly liable to oxidation by O•- 
and other related free radicals. Quantification of endogenous aconitase activity can 
indicate both the O•- level and the extent of protein oxidative damage (Gardner et al., 
1997). A consequence of oxidative aconitase inhibition is the release of iron and 
formation of H2O
2 and consequently OH•-, leading to further oxidative damage. This 
vicious cycle can be stopped with iron-chelating agents that provide neuroprotection in 
the kainate experimental model (Jarrett et al., 2008). 
CI plays an important role in the initiation of the electron cascade in the mitochondrial 
ETC. A recent study showed an oxidative stress-induced post-translational 
modification, mediated by carbonylation, of CI in experimental TLE (Ryan et al., 2012). 
Mass spectrophotometric analysis recognised a specific type of carbonylation called 
metal-catalysed oxidation (MCO) that is typically produced by oxidative stress in the 
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presence of highly abundant metals such as iron. Involvement of this process in kainate-
induced TLE models is supported by previous reports that demonstrated an increase in 
the Fenton reaction, H2O2 and iron, and the neuroprotective effects of HBED, which is 
an iron chelator (Jarrett et al., 2008). Other authors have shown that CI is both a target 
and source of O•-, leading to further mitochondrial damage and further production of 
ROS (Kudin et al., 2002; Murphy et al., 2009). 
Membrane proteins are also susceptible to oxidative damage and to changes in local 
ATP concentrations. Several such proteins, including glutamine synthetase, glutamate 
transporters and Na+/K+ ATPase, are also known to be associated with neuronal 
hyperexcitability (Rowley and Patel, 2013). GLT-1 and GLAST (glutamate 
transporters) are regulated by extracellular ATP in the hippocampus, are involved in 
maintaining extracellular glutamate concentrations (Perego et al., 2000), and oxidative 
stress can impair their transport activity (Trotti et al., 1998). Decreased GLT-1 and 
GLAST expression coincides with mitochondrial oxidative stress and increased 
susceptibility to experimental seizures (Liang and Patel, 2004) and has also been 
demonstrated in human epilepsy patients (Meldrum et al., 1999). 
Lipid peroxidation: Lipids are a well-known target for oxidative damage during 
epileptogenesis as a consequence of the initial insult. Lipid peroxidation is initiated by 
abstraction of hydrogen from polyunsaturated fatty acids (PUFA) by OH•- to form 
PUFA radicals, which are highly unstable and react eagerly with molecular oxygen to 
create peroxyl-PUFA radicals. These radicals are also unstable and react strongly with 
free PUFA to generate more PUFA radicals and lipid peroxides in chain reaction. 
Termination of this chain reaction can be effected by endogenous antioxidants, such as 
vitamin E, SOD, and peroxidase (figure 1.8) (Madhura et al., 2015). Malondialdehyde 
(MDA), 4-hydroxy-2-(E)-nonenal (4-HNE), F2-isoprostanes (IsoPs) and isofurans 
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(isoPs) are by-products of PUFA peroxidation and major indicators of lipid 
peroxidation. MDA is a ubiquitous compound produced in considerable quantity in 
mammalian cells as a result of PUFA peroxidation and also prostaglandin and 
thromboxane biosynthesis (Madhura et al., 2015). It can react with structural proteins to 
form a variety of adducts, and with DNA to form mutagenic compounds. Furthermore, 
MDA itself has been reported to be toxic and carcinogenic (Hemminki et al., 1994). In 
experimental epilepsy models involving the administration of chemoconvulsants, MDA 
acts as a marker of ongoing lipid peroxidation in the cerebral cortex, hippocampus and 
other brain regions within 4 hours of an initial insult, and for up to 24 hours thereafter 
(Waldbaum and Patel, 2010). This suggests that lipid peroxidation occurs as a result of 
seizures and that it may also be involved in the early stages of epileptogenesis. 
Oxidative mtDNA damage: mtDNA is highly susceptible to oxidative damage for two 
reasons. First, mtDNA does not have histones which play an important role in 
chromatin regulation and in keeping DNA strands compact. Second, it lies close to the 
inner mitochondrial membrane where the ROS are liberated (Rowley and Patel, 2013). 
It has been shown that increased ROS generation can result in mtDNA damage and 
potentially a decrease in the efficiency of the ETC (Esposito et al., 1999). Several 
studies have focused on oxidative damage to mtDNA following experimental seizures. 
One month after pilocarpine treatment, there is a significant decrease in mtDNA copy 
number in CA1 and CA3 regions of the hippocampus (Kudin et al., 2002). There is also 
an increase in mtDNA damage after kainate administration, with a corresponding 
increase in mitochondrial 8- hydroxyl-2-deoxyguanosine (mt-8-OHdG), a by-product of 
DNA oxidation, relative to a total 2-deoxuguanosine (2-dG) (Jarrett et al., 2008). 
Additionally, endogenous DNA repair systems are activated by kainate-induced 
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seizures and epileptogenesis, which suggests a constant adaptive restoration and 
response to oxidative insult (Rowley and Patel, 2013). 
1.7 Seizure-induced changes in endogenous antioxidant defence and redox status 
1.7.1  Seizure-induced changes in antioxidant mechanism 
The endogenous antioxidant defence is a complex integrated system that protects cells 
against the destructive and deleterious pro-oxidant effects of ROS. When this 
physiological antioxidant system fails to get rid of ROS efficiently, cellular oxidative 
damage occurs and accumulates, especially in the mitochondria (James and Murphy, 
2002). 
SOD is an endogenous antioxidant enzyme that has been shown to neutralize O•- and 
protect cells against programmed death (Greenlund et al., 1995). SOD is found in three 
forms; SOD1 (CuZnSOD) localized in cytoplasm, SOD2 (MnSOD) localized in 
mitochondria, and SOD3 (ECSOD), localized in the extracellular matrix. Under normal 
physiological conditions, O•- undergoes dismutation by SOD to H2O2 which is further 
broken down to O2 and H2O by CAT and glutathione peroxidase (GPx), with GSH as a 
co-factor. However, if this process is not controlled adequately, excessive O•- release 
can result in the formation of more deleterious oxidants, such as OH•-, which can cause 
further oxidative destruction and cell death (Waldbaum and Patel, 2011). 
Seizures are associated with a change in the antioxidant defence mechanism. However, 
it is still controversial if the endogenous antioxidant level is increased or decreased. In 
the pilocarpine model, SOD activity in the hippocampus has been shown to decrease at 
24 hours and during the chronic phase of epilepsy, whereas the activity of GPx is 
increased (Bellissimo et al., 2001). However, it has also been reported that the activities 
of CAT, GPx and SOD were increased at two hours after pilocarpine induction of status 
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epilepticus (Tejada et al., 2007). Other authors demonstrated that hippocampal CAT 
activity, but not that of SOD, was reduced at 24 hours after pilocarpine, proposing that 
the hippocampus does not use SOD as a key antioxidant but more likely CAT and/or 
GSH instead (Freitas et al., 2005). Similar findings have been reported by Erakovic et al 
(2000), who showed a decrease in total brain antioxidant levels 48 hours after acute 
administration of kainate. In contrast, however, Bruce and Baudry (1995) reported an 
increase in CAT and SOD activity in both hippocampus and piriform cortex at 48 hours 
and again at five days after kainate. Considering the wide discrepancies in results 
obtained from different seizure models at different times, the issue of whether there is 
endogenous antioxidant compensation in response to seizure activity remains to be 
settled. 
1.7.2  Seizure-induced changes in Nrf2 regulated-redox status 
Nrf2 is increasingly recognized as an important redox-sensitive transcription factor that 
regulates anti-oxidant protection and cellular integrity in many tissues (Baird, 2011). All 
biological cells have an intrinsic ability to combat ROS, which is dynamically under the 
control of Nrf2, the master regulator of the phase II cellular antioxidant response 
(Nguyen et al., 2003).  
Recently, it has been shown that Nrf2 could have an anti-inflammatory action, improve 
mitochondrial function, enhance xenobiotic detoxification, and influence autophagy. 
Therefore, modulating Nrf2 might be expected to be helpful in the prevention and 
treatment of dozens of common chronic disorders such as neurodegenerative diseases, 
chronic lung diseases, chronic renal diseases, multiple sclerosis, type 2 diabetes, and 
epilepsy (Martin et al., 2015). 
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Physiologically, Nrf2 is rendered inactive in the cytoplasm through binding to Kelch-
like ECH associated protein 1 (Keap1) (Howden et al., 2013). Any oxidative stress 
induced elevation in ROS oxidizes cysteine residues within the Keap1 active site, 
preventing Nrf2 attachment. This encourages cytoplasmic accumulation of Nrf2, which 
then translocates to the nucleus where it first complexes with musculoaponeurotic 
fibrosarcoma (Maf) proteins and then binds to antioxidant response elements (AREs) in 
the promoter region of selected genes. ARE activation results in transcription of Nrf2-
related genes, such as those encoding NADPH dehydrogenase (NQO-1), haem 
oxygenase 1 (HO-1), glutareduxin-1 (Grx-1), and thioredoxin-1 (Trx-1) (Kasper et al., 
2009) (Figure 1.9). Enzymes responsible for ROS neutralization, such as SOD and 
CAT, and those involved in GSH biosynthesis and regeneration are also under 
transcriptional control by Nrf2. GSH is the most important non-enzymatic intracellular 
defence against ROS in most organs including the brain and alongside glutathione 
disulfide (GSSG), can also be considered one of the most important markers oxidative 
stress in biological systems (Patel et al., 1995). Glutathione peroxidase (Gpx) catalyses 
the degradation of H2O2 via oxidation of GSH to GSSG, with GSSG then recycled to 
GSH via the action of glutathione reductase (GR) in the presence of NADPH (Patel et 
al., 1995). In this respect, the activity of GR is crucial to maintaining GSH levels and 









Figure 1.10: The mechanism underlying the response of the Nrf2-Keap-1 signalling 
pathway to oxidative stress. Under homeostatic conditions, Nrf2 signalling is repressed 
by Kelch-like ECH-associated protein 1 (Keap1). Nrf2 is bound to Keap1 and 
sequestered in the cytoplasm, where it is susceptible to degradation by ubiquitination. 
Under stress conditions, Nrf2 is released and translocates into the nucleus, where it 
initiates a series of anti-oxidant responses. It first forms a complex with a group of 
small musculoaponeurotic fibrosarcoma (Maf) proteins and then binds to antioxidant 
response elements (AREs), which are a cis-acting enhancers in the promoter region of 
selected genes, that leads to the expression of downstream antioxidants genes, such as 
HO-1 and NQO-1(adapted from Ye et al., 2016),  
 
Recent studies have revealed that the Nrf2-ARE pathway is an important target in 
protecting brain from oxidative and inflammatory damage induced by ischemic stroke 
(Shih et al., 2005a; Zhao et al., 2007) and kainate toxicity (Kraft et al., 2006). Seizures 
are a major cause of oxidative stress and recent evidence suggests that the expression of 
Nrf2 and some of its downstream target enzymes (i.e. NQO-1 and HO-1) is significantly 
increased in rat hippocampus after rapid kindling (Wang et al., 2016). This suggests that 
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activation of the Nrf2-ARE pathway might play an important role at the early stages of 
epilepsy. Targeting this pathway might be of benefit in treating seizures associated with 
oxidative stress or in preventing the development of epilepsy following insults that are 
known to cause oxidative stress (Wang et al., 2016). 
1.8. Potential therapeutic approaches to targeting metabolic pathways and ROS in 
epilepsy 
It is evident that oxidative damage and ROS play a role in the pathogenesis and 
progression of epilepsy, and contribute to seizure-induced neuronal damage (Rowley 
and Patel, 2013). There are, however, two significant issues associated with therapeutic 
targeting of mitochondrial metabolic pathways; (1) the ubiquitous role of mitochondrial 
function in cell signalling, and (2) redundancies within and adaptive control of 
metabolic agitation. Nevertheless, the efficacy of the KD suggests that targeting 
mitochondrial oxidative stress may be useful in controlling established seizures, and 
perhaps also in delaying or preventing epileptogenesis, by switching mitochondrial fuel 
utilization (Rowley and Patel, 2013). 
More than a dozen new AEDs have been licensed in the past three decades but one third 
of epilepsy patients remain refractory to conventional therapy. The aim of traditional 
AED treatment has been to decrease neuronal hyperexcitability and thus control the 
incidence of epileptic seizures (Waldbaum and Patel, 2009). The hyperexcitability 
associated with seizures causes an excessive Ca2+ uptake which has been shown to 
increase mitochondrial ROS, inhibit ATP production, activate the MPTP, and promote 
cytochrome C release, resulting in cell death (Sullivan et al., 2005). Several licensed 
AEDs have selective effects on Ca2+ flux, which might directly impact the downstream 
involvement of mitochondria following seizures, and all AEDs limit neuronal 
hyperexcitability and therefore potentially reduce the involvement of mitochondria and 
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alleviate their potential to cause oxidative damage and cell death. However, this remains 
speculative and the extent to which any current AED can impact on mitochondrial 
oxidative stress, either directly or indirectly, is currently unclear.   
1.8.1 Antiepileptic drugs and oxidative stress 
There are currently 25 drugs licensed for the treatment of epilepsy in the UK but these 
are effective in only 60-70% of patients, irrespective of whether they are used in 
monotherapy or in combination. Although AED monotherapy is preferred, polytherapy 
can occasionally be successful where individual drugs have failed but is frequently 
associated with enhanced risk of neurological side effects. Thus, there is an urgent need 
for new, better-tolerated AEDs that are effective against refractory epilepsy (Brigo et 
al., 2012). 
In terms of mechanism of action, AEDs essentially restore the balance between 
neuronal excitation and inhibition. Three major classes of mechanism are recognised: 
modulation of voltage-gated ion channels; enhancement of gamma-aminobutyric acid 
(GABA)-mediated inhibitory neurotransmission; and attenuation of glutamate-mediated 
excitatory neurotransmission. The principal pharmacological targets of currently 








Table.1.1 List of established AEDs, year of introduction, and primary mechanism(s) of 
action. Data is from Schmidt and Schachter (2014). 
AED Year Presumed mechanism of action 
Potassium bromide 1857 GABA potentiation? 
Phenobarbital 1912 GABA potentiation 
Phenytoin 1938 Na
+
 channel blockade 
Primidone 1954 GABA potentiation 
Ethosuximide 1958 T-type Ca
2+
 channel blockade 
Diazepam 1963 GABA potentiation 
Carbamazepine 1964 Na
+
 channel blockade 
Valproate 1967 Multiple mechanisms: GABA potentiation, glutamate (NMDA) 
inhibition, Na
+ 
channel and T-type Ca
2+
 channel blockade 
Clonazepam 1968 GABA potentiation 
Clobazam 1975 GABA potentiation 
Vigabatrin 1989 GABA potentiation 
Lamotrigine 1990 Na
+
 channel blockade 
Oxcarbazepine 1990 Na
+
 channel blockade 
Gabapentin 1993 Ca
2+
 channel blockade (α2 subunit) 





  channel blockade 
Levetiracetam 2000 SV2A modulation 
Zonisamide 2000 Na
+
 and T-type Ca
2+
 channel blockade 
Stiripentol 2002 GABA potentiation 
Pregabalin 2004 Ca
2+
 channel blockade (α2 subunit) 
Rufinamide 2004 Na
+
 channel blockade 
Lacosamide 2008 Na
+
 channel blockade (enhanced slow inactivation) 
Eslicarbazepine 2009 Na
+
 channel blockade (enhanced slow inactivation) 
Perampanel 2012 Glutamate (AMPA) inhibition 
 
As discussed above, seizures are associated with alterations in the balance between 
intracellular pro-oxidants and antioxidants and there is some evidence to suggest that 
AEDs can, at least in part, further impair the endogenous antioxidant system (Martinc et 
al., 2012). This would suggest that AED treatment can reduce the ability of neuronal 
cells to counteract oxidative damage, either by inhibiting specific antioxidants, 
increasing ROS production, or a combination of the two. However, the precise 




1.8.2 Effect of commonly used AEDs on oxidative stress markers in experimental 
studies 
An in vitro study of oxidative stress markers in rat primary astrocyte cultures has shown 
that a broad range of AEDs, including carbamazepine (CBZ), gabapentine (GBP), 
lamotrigine (LTG), levetiracetam (LEV), oxcarbazepine (OXC), topiramate (TPM) and 
tiagabine (TGB), can increase intracellular levels of MDA, ROS and nitric oxide, and 
decrease concentrations of GSH, suggesting that AEDs, as a class, have pro-oxidant 
effects (Pavone et al., 2003). In addition, VPA has been shown to increase ROS level 
TBARs, HO-1, and NQO-1 expression in rats (Abdalla et al., 2016) and oxcarbazepine 
(OXC) reported to cause neuronal swelling and cell damage due to increased ROS 
production in isolated hippocampal neurons (Araujo et al., 2004). 
Turning to in vivo models, CBZ has been shown to increase MDA concentrations and 
decrease GSH levels and SOD activity in the kindled rat model of epilepsy whereas 
LTG was interestingly without effect (Arora et al., 2009). Treatment of mice with CBZ 
and phenytoin caused a significant increase in the expression of transcription factors 
that specifically recognise oxidative stress genes, such as those encoding GSTM1 and 
heat shock proteins, and which are related to Keap1-Nrf2-ARE signalling pathway (Lu, 
2017). Similarly, CBZ, phenytoin, felbamate, and VPA have been shown to elevate 
Nrf2-related gene expression in rat liver (Leone et al., 2007). 
1.8.3 Effect of commonly used AEDs on oxidative stress markers in clinical 
studies 
Most of the studies of oxidative stress in patients with epilepsy have been performed on 
peripheral tissues. However, ROS may originate from different sources in the body and 
peripheral samples might not precisely reflect oxidative insults in the brain. 
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Nevertheless, there is evidence that experimental seizures induced by direct injection of 
kainate into rat brain can cause an increase in MDA concentrations both in the CNS and 
in blood (Singh et al., 1990; Bruce and Baundry, 1995). The reverse has also been 
shown, with peripheral ROS generation causing oxidative damage in CNS (Aytan et al., 
2008). 
In terms of drug studies, increased levels of MDA, a by-product of lipid peroxidation, 
have been demonstrated in the serum of epilepsy patients treated with phenytoin (Liu et 
al., 1998). Likewise, it has been reported that several AEDs, including phenytoin and 
topiramate, are able to weaken the OXPHOS process when assessed by respiratory 
chain complexes (II-IV), enzymatic activity, and mitochondrial ATP synthesis (Benz, 
1994).   
Valproic acid (VPA) is one of the most widely prescribed AEDs and is primarily used 
to treat generalized epilepsy but is also effective in focal epilepsy, bipolar disorder, 
neuropathic pain and in migraine (Rossi, 2013). VPA is a broad spectrum AED and its 
main mechanism of action is believed to be the potentiation of GABAergic activity. It 
also has effects on voltage-gated Na+ channels and on low voltage activated (LVA) Ca2+ 
channels (Johannessen, 2000). VPA has been shown to exacerbate oxidative stress by 
reducing TAC and enhancing total oxidant status (TOS) (Hamed et al., 2004; Schulpis 
et al., 2006). Furthermore, Gpx (Niketic et al., 1995; Yuksil et al., 2001), GR (Sobaniec 
et al., 2006), and serum selenium (Graf et al., 1998), all of which are known 
endogenous, enzymatic and non-enzymatic antioxidant molecules, have been reported 
to be decreased in the serum of adults and children treated with VPA. Similarly, 
increased serum levels of MDA (Yuksil et al., 2000; Schulpis et al., 2006) and 15F-2t-
isoP (Michoulas et al., 2006), both of which are by-products of lipid peroxidation, and 
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8-OHdG (Schulpis et al., 2006), which is a nucleic acid marker, are increased in patients 
with epilepsy treated with VPA. 
CBZ is a commonly used AED, indicated for focal and generalised tonic-clonic 
seizures. It is a voltage-gated Na+ channel blocker, which is considered as the most 
common target among AEDs and is responsible for the upstroke of the action potential 
in neurons and other excitable cells (Brodie et al., 2011). The effect of CBZ on 
endogenous pro- and anti-oxidant mechanisms in epilepsy patients is controversial. 
CBZ has been shown to increase MDA levels in adults and children with epilepsy 
(Hamed et al., 2004; Aycicek and Iscan, 2007) and also levels of 8-OHdG (Varoglu et 
al., 2010). Moreover, CBZ decreases TAC (Hamed et al., 2004), GSH in plasma (Ohno 
et al., 2000), and Gpx and CAT activities in erythrocytes (Niketic et al., 1995). 
However, there have also been several studies that failed to identify any oxidative 
effects of CBZ (Hamed et al., 2004) and some that reported an anti-oxidant action (Liu 
et al., 1998). 
LEV is a relatively new, broad spectrum AED which is clinically effective against 
partial and generalized seizures (Oliveira et al., 2004). The mechanisms of action of 
LEV remain unclear, although some reports suggest that its cellular effects are unrelated 
to conventional AED mechanisms of action (Oliveira et al., 2007).  Elegant studies have 
shown that synaptic vesicle protein 2A (SV2A) is the binding site for LEV in the brain 
(Laxmikant and Deshpande. 2014). SV2 proteins are believed to act as transporters of 
common constituents of the vesicles, such as Ca2+ or ATP. As such, modulation of SV2 
proteins could protect against seizures through effects on synaptic release of Ca2+ 
(Deshpande and Delorenzo, 2014). However, there is also evidence that LEV may act as 
a histone deacetylase inhibitor, which might confer anti-inflammatory and antioxidant 
properties (Safar et al., 2010). This hypothesis is potentially discredited by a study 
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which showed an increase in serum levels of 15F-2-isoprostane, a marker of oxidative 
damage, following initiation of LEV treatment in epilepsy patients, suggesting that it 
might actually induce oxidative stress (Ozden et al., 2010). 
LTG is another of the new generation of AEDs which is predominantly used in the 
treatment of focal epilepsy seizures, seizure associated with Lennox-Gastaut syndrome, 
and bipolar affective disorders (Schiller and Krivoy. 2009). It is thought to act by 
reducing the excitability of individual neurons and inhibiting the release of glutamate, 
an excitatory neurotransmitter, via inhibition of voltage-sensitive sodium channels 
(Schiller and Krivoy. 2009). 
1.9 Aims 
Oxidative stress and oxidative damage to neuronal cells is increasingly recognised as a 
potential cause and/or consequence of epileptic seizures and may be an attractive target 
for development of much needed new treatments for epilepsy. However, it is important 
to first understand the effect of conventional AEDs on endogenous pro- and anti-
oxidant systems to better predict the likely outcome of manipulating these systems in an 
effort to alleviate the hyperexcitability associated with seizures and epilepsy. 
As such, this thesis describes a series of experiments that aimed to characterise the 
effects of the four most commonly prescribed drugs for epilepsy, namely CBZ, VPA, 
LTG and LEV, in terms of their effects on oxidative stress markers in mammalian cells. 
Much of the work was performed using the human immortalised neuroblastoma cell line 
SH-SY5Y, which is a widely used preparation in experimental neuroscience and 
neuropharmacology. Oxidative stress was induced by a number of approaches, 
including H2O2, pilocarpine and lipopolysaccharide (LPS), and was assessed by 
conventional biochemical assays for MDA concentration, SOD activity and GSH/GSSG 
71 
 
concentration ratio and also by the expression of Nrf2 and its downstream targets NQO-
1 and HO-1 at both mRNA and protein level. A final series of experiments took 
advantage of local access to an extensive collection of DNA samples from people with 
epilepsy and explored common variants in the Nrf2 gene and their association with 
clinical characteristics of epilepsy and its response to AED treatment. 
Specific aims relating to individual results chapters were as follows: 
Chapter 2: Effect of H2O2, lipopolysaccharide, and pilocarpine on oxidative stress 
markers in SH-SY5Y cell line 
1- Investigate the effects of different concentrations of LPS, H2O2 and pilocarpine 
on MDA levels as a marker of lipid peroxidation, on the reduced/oxidized 
glutathione (GSH/GSSG) ratio as a marker of the antioxidant defence system, 
and on superoxide dismutase (Cu-Zn-SOD) activity as a marker of antioxidant 
enzyme activity in SH-SY5Y cell line.   
2- Explore the optimum conditions (inducer, concentration, time) for induction of 
oxidative stress in SH-SY5Y cells to be employed in further investigations. 
3- Choose between differentiated and undifferentiated SH-SY5Y cells for use in 
further investigations. 
Chapter 3: Effects of commonly used antiepileptic drugs on markers of oxidative stress 
in a human neuroblastoma cell line 
1- Explore the effects of CBZ, VPA, LEV and LTG on MDA concentration, as a 
marker of lipid peroxidation, in the SH-SY5Y cell line under basal conditions 
and following induction of oxidative stress by H2O2. 
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2- Explore the effects of CBZ, VPA, LEV and LTG on SOD activity, as a marker 
of antioxidant enzyme activity, in the SH-SY5Y cell line under basal conditions 
and following induction of oxidative stress by H2O2. 
3- Explore the effects of CBZ, VPA, LEV and LTG on the reduced/oxidized 
glutathione (GSH/GSSG) ratio, as a marker of the antioxidant defence system, in 
the SH-SY5Y cell line under basal conditions and following induction of 
oxidative stress by H2O2. 
Chapter 4: Effects of oxidative stress inducers and selected AEDs on Nrf2, HO-1 and 
NQO-1 gene expression in SH-SY5Y cells 
1- Investigate the effects of LPS, H2O2 and pilocarpine on Nrf2, HO-1, and NQO-1 
gene expression as a marker of phase II detoxification antioxidant response in 
the SH-SY5Y neuroblastoma cell line.   
2- Choose optimum conditions (inducer, concentration of inducer, duration of 
exposure) for induction of oxidative stress in SH-SY5Y cells to be employed in 
further investigations. 
3- Explore the effects of carbamazepine (CBZ), valproic acid (VPA), levetiracetam 
(LEV), and lamotrigine (LTG) on the expression of Nrf2, HO-1 and NQO-1 
genes in the SH-SY5Y cell line.   
Chapter 5: Effects of selected AEDs on Nrf2, HO-1, and NQO-1 protein expression in 
SH-SY5Y cells 
The present study aimed to investigate the effects of CBZ, VPA, LTG and LEV on the 
expression of Nrf2, HO-1 and NQO-1 proteins as a marker of phase II detoxification 
antioxidant response in the SH-SY5Y cell line.   
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Chapter 6: Association between NFE2L2 gene variants and treatment outcome in 
people with epilepsy 
To assess the association between AED treatment outcome (remission on any AED) and 
genotype of selected SNPs in the NFE2L2 gene, demographic variables and clinical 








Effect of H2O2, lipopolysaccharide, and 
pilocarpine on oxidative stress markers in SH-














2.1 Introduction  
Oxidative stress is a condition under which an imbalance exists between the factors that 
promote oxidation, such ROS and RNS, and antioxidant defences, including GSH, Nrf2, 
which is a master regulator of intracellular redox status, antioxidant enzymes such as 
SOD and catalase (CAT), and dietary antioxidants (Jones, 2006). ROS including 
superoxide anion O-, hydrogen peroxide H2O2, singlet oxygen O
., and hydroxyl radical 
OH- in low or moderate levels have several beneficial physiological functions such as 
tissue repair, killing pathogens and cancer cells, and wound healing. However, 
disruption of normal redox balance by excessive generation of ROS or RNS, and/or 
impairment of enzymatic and non-enzymatic antioxidant defence systems might result 
in several systemic diseases, such as peptic ulcer, inflammatory bowel disease, 
pulmonary fibrosis, lung cancer, Parkinson’s disease, and Alzheimer dementia, (Park et 
al., 2009; Bhattacharyya  et al., 2014).    
The role of oxidative insult in neurological disorders, such as epilepsy is of major 
interest since cells in the brain are particularly susceptible to damaging effects of ROS 
and RNS. Moreover, antioxidant protection mechanisms in the CNS, such as CAT, Gpx, 
vitamin E, and GSH, are relatively poor (Shivakumar et al., 1991). This is important 
because the brain is rich in mitochondria, is characterised by high aerobic metabolic 
activity and a high ratio of membrane to cytoplasmic volume, and consumes 20% of 
total body oxygen despite accounting for only 2% of total body mass (Mahadik et al., 
1996). The brain is also rich in iron, and oxidative damage releases iron ions capable of 
catalysing the Fenton reaction which results in further cellular damage (Halliwell, 1992) 
Free radicals can react with the lipid bilayer of the cell membrane leading to 
peroxidation of polyunsaturated fatty acids and release of toxic aldehyde by-products, 
such as MDA, which can bind covalently to proteins leading to enzyme inactivation and 
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disturbances of cellular function (Choi et al., 1993; Patel et al., 2004; Bhattacharyya et 
al., 2014). ROS may trigger nucleic acid damage; they can break DNA strands and 
modify nitrogenous bases resulting in cellular dysfunction and/or cell death (Facchinetti 
et al., 1998). RNA is most liable to oxidative damage, as it is single stranded, less 
protected by antioxidants, and not protected by hydrogen bonding. RNA damage may 
result in protein alterations and/or abnormalities in gene expression (Nunomura et al., 
2007). Mitochondrial DNA (mtDNA) is also highly vulnerable to oxidative stress 
because of poor repair mechanisms, a lack of protection by histones, and its proximity 
to the site of ROS generation. mtDNA disruption leads to mitochondrial damage and 
disturbed cellular function (Nunomura et al., 2007). Oxidative insults may alter primary, 
secondary, and tertiary structure of proteins leading to functional impairment after 
exposure to free radicals (Rowley and Patel, 2013).  
Antioxidant mechanisms, such as SOD enzyme and GSH-scavenging reactions, provide 
a primary defence against ROS, and the activities of these enzymes and detoxifying 
agents are known to decrease under ROS-induced oxidative stress (Michiels et al., 
1994). GSH is a scavenger of free radicals, including OH- and O- species, whereas SOD 
is responsible for the dismutation of two O- molecules to form H2O2 and O2 (Halliwell  
and Gutteridge, 2007). 
Oxidative stress can be induced in living systems (such as cell cultures) by 
administration of several chemicals, including H2O2 (Coyle et al., 2006), pilocarpine 
(Santos et al., 2011), and LPS (Noworyta et al., 2013) and as a toxic effect of many 
drugs, such as paracetamol (Stirnimann et al., 2010), diclofenac (Hickey et al., 2001; 
Boelsterli, 2003), and cisplatin (Pabla and Dong, 2003).H2O2 is one of the most 
important ROS generated through oxidative stress. It is a by-product of NADPH 
oxidase, SOD activity, and catecholamine’s oxidation that produces highly reactive 
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hydroxyl radicals, such as OH-, via the Fenton reaction (Forman et al., 2007).  It has 
been reported that H2O2 induced depletion of antioxidant mechanisms in SH-SY5Y 
cells, which are a cell line widely used as in vitro model in neurological disorders 
(Nirmaladevi et al., 2014). These cells are human in origin, derived from neuroblastoma 
cell source, and possess several chemical, physiological, and functional properties of 
neuronal cells (Borland et al., 2008).  
LPS is a major constituent glycolipid component of the outer cell wall of Gram-negative 
bacteria, covering up to 75% of its outer surface (Zha et al., 2007). Intraperitoneal LPS 
injection induces inflammation and oxidative stress in male Swiss albino mice (Ruiz-
Miyazawa et al., 2015).  It also induces neurodegeneration through modulation of the 
intrinsic apoptotic cascade in the cortex and hippocampus of Swiss albino mice, 
resulting in elevated levels of lipid peroxidation with subsequent depletion in the 
antioxidant status (Santhana et al., 2015). 
Pilocarpine is a muscarinic agonist drug, targeting mainly M1 receptors (expressed in 
CNS and exocrine glands), and M3 receptors (expressed in endocrine and exocrine 
glands, lungs, pancreas, and CNS). The major medical uses are for dry mouth, 
particularly in Sjogrens syndrome, after head and neck radiation which causes dry 
mouth as a side effect, and in chronic open and close angle glaucoma (Katzung et al., 
2012). Common side effects are excessive secretions, including salivation, sweating and 
bronchial mucous secretion, plus bronchospasm and bradycardia (Katzung et al., 2012). 
It has been suggested that pilocarpine induced seizures were associated with increased 
lipid peroxidation and nitrite formation which could be responsible for the GABAergic 
and glutamatergic receptor changes during SE (Freitas et al., 2004). It has been found 
that there was an accumulation of free radicals in rat hippocampus after seizure 
induction by pilocarpine (Tome et al., 2010). This finding suggested that seizures 
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induced by pilocarpine have a large influence on brain oxidative stress which is closely 
related to the mechanism of evolution and/or maintenance of epilepsy focus produced 
by pilocarpine (Tome et al., 2010). 
 
2.1.1 Aims and objectives 
     The present study was planned to: 
1- Investigate the effects of different concentrations of LPS, H2O2 and pilocarpine 
on MDA levels as a marker of lipid peroxidation, on the GSH/GSSG ratio as a 
marker of the antioxidant defence system, and on Cu-Zn-SOD activity as a 
marker of antioxidant enzyme activity in SH-SY5Y cell line.   
2- Explore the optimum conditions (inducer, concentration, time) for induction of 
oxidative stress in SH-SY5Y cells to be employed in further investigations. 













2.2 Materials and Methods  
2.2.1 Chemicals 
Dulbecco’s modified eagle’s medium (DMEM) W/O L-glutamine, trypsin / EDTA 
solution 0.25%, fetal bovine serum (FBS), L-glutamine, phosphate-buffered saline 
(PBS), bicinchoninic acid assay (BCA) protein assay kit and penicillin-Streptomycin 
Solution were purchased from Thermo Fisher Scientific, Loughborough, UK. Premix 
water soluble tetrazolium 1 (WST-1) cell proliferation assay system was purchased 
from Abcam, Cambridge, UK. Pilocarpine hydrochloride, lipopolysaccharides (LPs) 
from Escherichia coli, 1X butylated hydroxytoluene (BHT), malondialdehyde 
tetrabutylammonium salt, oxidised glutathione (GSSG), β-nicotinamide adenine 
dinucleotide 2′-phosphate reduced tetrasodium salt hydrate (NADPH), 5,5′-Dithiobis(2-
nitrobenzoic acid)  (DTNB), sulfosalicylic acid, metaphosphoric acid, triethanolamine, 
2-vinylpyridine, sodium phosphate, diethylenetriamine-penta acetic acid (DEPAC), 
catalase, xanthine oxidase, bovine Cu/Zn SOD, MTT (3-[4,5-dimethylthiazol-2-yl]-2,5 
diphenyl tetrazolium bromide),  hypoxanthine, radio-immune precipitation assay 
(RIPA) buffer, sodium dodecyl sulphate  (SDS), glutathione reductase from Baker’s 
Yeast, SH-SY5Y cell line from the European Collection of Authenticated Cells Culture 
(ECACC), retinoic acid (RA), and reduced glutathione (GSH) were purchased from  
Sigma-Aldrich Co., Dorset, UK. 
2.2.2 Cell Culture  
SH-SY5Y cells were stored frozen in liquid nitrogen before culturing. Cells were grown 
as a monolayer in T-75 flasks that contained 15 mL of DMEM supplemented with 1% 
penicillin/streptomycin (pen/strep), 1% L-glutamine and 10% FBS. Cultured cells were 
placed in an incubator chamber containing humidified 95% air and 5% CO2 at 37
oC. For 
passage, 80-90 % confluent cells were washed twice with pre-warmed 15 ml of PBS. 
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Then, the cells were detached with 5.0 mL trypsin-EDTA, 0.25 % solution. After that, 5 
ml of culture medium was added and spinned at 250 x g for 5 minutes. The pellet was 
re-suspended in 5 mL of culture medium and 10 µl was taken for cell counting by using 
Countesstm Automated Cell Counter. This procedure was performed by mixing 10µl of 
cell suspension with 10µl trypan blue dye in 500µl Eppendorf. Thereafter 10µl of 
mixture was loaded into a Countess Cell chamber slide that was then inserted into the 
slide inlet on the instrument. After approximately 30 seconds, live, dead, and total cells 
and viability percentage was displayed in the screen and then the number of cells 
needed was calculated according to the initial seeding densities in different culture 
vessels (table 2.1). 
 
 Table 2.1 Surface areas, number of cells, and recommended working volumes for 
different cell culture vessels. Approximate confluent growth is 1.25 X 105 cells / 
cm2.Initial plating density is 104 cells / cm2.Trypsinization volume is 0.05ml / cm2. 
Working volume is 0.2 ml / cm2.   
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2.2.3 Cells differentiation 
Undifferentiated SH-SY5Y cells were grown in T-75 flasks until 80-90 % confluent. 
Cells were then plated in 12-well plates at a density of 4x104 cells/well and 10µM of 
all-trans retinoic acid was added to the culture medium. The cells were then incubated 
for 3-5 days, with the medium replaced every 48 hours, to induce differentiation into a 
neuronal phenotype (Cheung et al., 2009).  
2.2.4   Induction of oxidative stress 
SH-SY5Y cells were seeded in 12-well plates at a density of 4x104 cells / well in 1 ml 
culture medium and placed in an incubator containing humidified 95% air and 5% CO2 
at 37oC for 2-3 days until 80-90 % confluent. Thereafter, the existing medium was 
aspirated and the cells treated with H2O2 (0, 10, 30, 100, 300 and 1000 µM), pilocarpine 
(0, 1, 3, 10, 30 and 100 µM) or LPS (0, 1, 3, 10, 30 and 100 µg/ml) in serum free 
medium (DMEM with 1% pen/strep and 1% L-glutamine, without FBS) for 1, 4 or 24 
hours. 
2.2.5 Lipid peroxidation assay 
SH-SY5Y cell lysates was assayed for lipid peroxidation by a modified thiobarbituric 
reactive substance (TBARS) method for measuring MDA which forms a colorimetric 
product after reaction with TBA in acidic media (Devasagayam et al., 2003). The cells 
were washed twice with PBS after aspiration of growth media and then scraped in 1ml 
PBS containing 5mM BHT to prevent oxidation. MDA standards were prepared in a 
range of 1.25 to 10 nM in PBS containing 5mM BHT. A 100 µl aliquot of both MDA 
standards  and unknown samples was mixed with 100 µl of 10% SDS and 250 µl of 70 
mM TBA reagent (pH is 3) in a 1.5 ml Eppendorf and incubated at 95oC for 60 minutes. 
Then, after cooling on ice, a 200 µl aliquot from both MDA standards and samples was 
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transferred (in duplicate) to a 96 well-plate, shaken briefly, and then read at 535 nm at 
room temperature in a microplate reader. 
2.2.6 GSH/GSSG assay 
Intracellular GSH and GSSG level was measured using a modification of the method of 
Tietze (Rahman et al., 2007). Confluent cells in 12 well plates were washed twice with 
1 ml of pre-warmed PBS and then scraped cells in 1 ml of pre-warmed PBS. After that, 
cells were centrifuged at 1000 x g for 5 minutes, the supernatant was discarded and the 
pellet was re-suspended in 500 µl ice-cold extraction buffer (0.1% Triton-X and 0.6% 
sulfosalicylic acid) in 0.1 M potassium phosphate buffer containing 5mM EDTA (KPE 
buffer). GSH standards were prepared in a range of 1.65 to 26.4 nM in KPE buffer. A 
20 µl aliquot of both standards and unknown samples was transferred (in duplicate) to a 
96 well-plate. Then, 100 µl of 5mM DTNB and 0.5 units of glutathione reductase were 
added to each well. Finally, a 60 µl aliquot of 2.4 mM NADPH was added to each well 
immediately prior to the measurement of absorbance at 414 nm using microplate reader 
at 0, 30, 60, 90, and 120 seconds. 
For the GSSG assay, 20 µl of the samples and standards were treated with 2μl of 95% 
2-vinylpyridine, and mixed rapidly to derivatize GSH. The reaction was allowed to take 
place in a fume hood for one hour. Then, 6μl of 98% triethanolamine was added to the 
side of the tube and the solution mixed vigorously. Absorbance was read at room 
temperature at 414 nm in a microplate reader on one occasion only. The GSH/GSSG 
ratio was calculated from the equation:  





2.2.7 SOD assay 
SOD activity was determined according to method of Peskin & Winterbourn (Peskin et 
al., 2000). After aspiration of growth medium and washing twice with 1 ml pre-warmed 
PBS, SH-SY5Y cells were scraped with 1 ml PBS and transferred to 2 ml Eppendorf 
tubes. After spinning down at 2500 xg at 40C for 5 minutes, supernatants were 
transferred to clean tubes and placed on ice. SOD standards ranging from 0.625 to 
10U/ml were then prepared in PBS. A reaction mixture was prepared immediately 
before use, containing  sodium phosphate, 50mM, pH 8.0, 0.1 mM diethylenetriamine-
pentaacetic acid (DEPAC), and 0.1 mM hypoxanthine (HOX), 4.5mU/ml xanthine 
oxidase, 100 µl of catalase (4000U/ml), and 100 µl of water soluble tetrazolium (WST-
1). A 5 µl aliquot from both standards and samples was added to a 96-well plate, 200 µl 
reaction mixture was added to each well, and the absorbance was read immediately at 
450 nm at room temperature and again every 5 minutes for 20 minutes.  
2.2.8 Protein quantitation  
Protein in cell lysates was quantified by BCA Protein Assay Kit 
(https://www.thermofisher.com/order/catalog/product/23225). In this protocol, the 
following formula was used to determine the final volume of working reagent (WR) 
required for the assay: total volume WR required (µl) = (number of standards + number 
of unknowns) × number of technical replicates × 80. WR was then prepared by 
combining 50 parts of BCA reagent A with 1 part of BCA reagent B (both reagents 
provided with the BCA Protein Assay Kit). Thereafter, 10μl of each standard and 
unknown sample was pipetted in duplicate onto a 96 well plate, 80μl of WR was added 
to each well, and the plate was mixed thoroughly on a plate shaker for 30 seconds. The 
plate was then covered with aluminium foil and incubated at 37°C, 5% CO2 for 30 
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minutes. After allowing the plate to cool to room temperature, the absorbance was 
measured at 595 nm using microplate reader.  
2.2.9 Analysis of cell viability using MTT assay 
The MTT assay was performed as described previously by Abate and colleagues (Abate 
et al., 1998). The MTT assay is based on the conversion of the tetrazolium salt MTT 
into a coloured and water-soluble formazan. Inherent dehydrogenase enzyme activity of 
viable cells reduces the yellow MTT solution to a purple colour at 37oC. The amount of 
formazan produced is directly proportional to the number of living cells and provides a 
good indication of cell viability. Briefly, cells were seeded onto 96-well plates (0.4x104 
cells/well) and cultured for 24-48 hours until they reached 80-90% confluence. The 
media was then aspirated, and the cells were treated with various concentrations (see 
above) of H2O2, pilocarpine or LPS in serum free medium for 1, 4 or 24 hours. 
Thereafter, 20 µl of 5 mg/mL MTT stock was added to each well. After 4 hours of 
incubation, the existing media was removed, and 100 µl of 0.3% DMSO was added to 
each well. After 10 min, the 96-well plate was placed in a microplate reader (at room 
temperature) and the absorbance at 595nm was measured. 
2.2.10 Statistical analysis 
All experiments were performed using two technical replicates (i.e. all analyses 
performed in duplicate) and three biological replicates (i.e. n=3 per group). Results were 
reported as mean ± standard deviation (SD). Statistical comparisons were undertaken 
using either one way or two ways ANOVA (with a Dunnett correction for multiple 
comparisons) using Stats Direct software version 2.7.9. Differences were considered 




2.3 Results    
2.3.1 Effect of H2O2, pilocarpine, and LPS on cell viability 
This study investigated the effect of H2O2, pilocarpine, and LPS on SH-SY5Y cell 
viability in order to identify a concentration of each oxidative stress inducer that would 
not be highly cytotoxic. Identification of such a concentration was important for the 
study, in order that the expected oxidative stress was not simply attributable to cell 
death. 
Cells exposed to H2O2 (0-1000µM) for 1, 4 and 24 hours showed a decrease in viability 
in a time- and concentration-dependent manner (figure 2.1). At 1 hour, viability was 
maximally reduced to 66.4% of control following exposure to 1000M H2O2 and was 
statistically significant at all concentrations above 10M (p<0.05 at 30M and 100M; 
p<0.001 at 300M and 1000M). At 4 hours, the maximal reduction was 54.6% of 
control with 1000M H2O2 and was again significant at all concentrations above 10M 
(p<0.05 at 30M and 100M; p<0.001 at 300M and 1000M). After exposure for 24 
hours, cell viability was reduced to 33.2% of control with 1000M H2O2 and was once 
more statistically significant at all concentrations above 10M (all p<0.001). 
Cells exposed to pilocarpine (0-1000µM) for 1, 4 and 24 hours also showed a decrease 
in viability in a time- and concentration-dependent manner (figure 2.2). At 1 hour, 
viability was maximally reduced to 72.8% of control following exposure to 1000M 
pilocarpine but the reductions in viability failed to reach statistical significance at any 
concentration. At 4 hours, the maximal reduction was 70.9% of control with 1000M 
pilocarpine, which was the only concentration at which a statistically significant 
difference from control was observed (p<0.05). After exposure for 24 hours, cell 
viability was reduced to 46.7% of control with 1000M pilocarpine, an effect that was 
statistically significant at all concentrations above 10M (all p<0.05). 
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Cells exposed to LPS (0-100µg/ml) for 1, 4 and 24 hours similarly showed a decrease in 
viability in a time- and concentration-dependent manner (figure 2.3). At 1 hour, 
viability was maximally reduced to 82.2% of control following exposure to 100g/ml 
LPS, which was the only concentration at which a statistically significant difference 
from control was observed (p<0.05). At 4 hours, the maximal reduction was 76.0% of 
control with 100g/ml LPS, which was again the only concentration that achieved 
statistical significance (p<0.05). After exposure for 24 hours, cell viability was reduced 
to 57.5% of control with 100g/ml LPS, and was significant at all concentrations above 
1g/ml (p<0.05 at 3g/ml and 10g/ml; p<0.001 at 30g/ml and 100g/ml). 
 
 
Figure 2.1. Effect of 1, 4 and 24 hour exposure to H2O2 (0-1000M) on the viability of 
SH-SY5Y cells as determined by MTT assay. Results (n=3) are expressed as the mean 
(± SD) percentage of the mean control (i.e. 0µM) value in each data series. Statistical 
significance was determined by one-way ANOVA with Dunnett correction for multiple 
comparisons with control within each data series (*p<0.05) and (**p<0.001). 
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Figure 2.2. Effect of 1, 4 and 24 hour exposure to pilocarpine (0-1000M) on the 
viability of SH-SY5Y cells as determined by MTT assay. Results (n=3) are expressed as 
the mean (± SD) percentage of the mean control (i.e. 0µM) value in each data series. 
Statistical significance was determined by one-way ANOVA with Dunnett correction 
for multiple comparisons with control within each data series (*p<0.05) and 
(**p<0.001). 
 
Figure 2.3. Effect of 1, 4 and 24 hour exposure to LPS (0-100g/ml) on the viability of 
SH-SY5Y cells as determined by MTT assay. Results (n=3) are expressed as the mean 
(± SD) percentage of the mean control (i.e. 0µg) value in each data series. Statistical 
significance was determined by one-way ANOVA with Dunnett correction for multiple 
































1st hr 4 hrs 24 hrs
* 































1st hr 4 hrs 24 hrs







































1 hour 4 hours 24 hours
2.3.2 Effect of H2O2 on MDA concentration in SH-SY5Y cells 
SH-SY5Y cells showed no significant changes in MDA concentration after exposure to 
10-100 µM and 10-30 µM H2O2 for 1 and 4 hours, respectively. However, a significant 
increase in MDA concentration (p<0.05) at 100, 300 and 1000 µM H2O2 concentration 
after 4 hours exposure. Furthermore, 10-1000 µM H2O2 showed a significant increase in 




Figure 2.4 Effect of 1, 4 and 24 hour exposure to H2O2 (0-1000µM) on 
malondialdehyde (MDA) concentration in SH-SY5Y cells. Results (n=3) are expressed 
as the mean (± SD) MDA concentration in nmols/µg protein and statistical significance 
was determined by one-way ANOVA with Dunnett correction for multiple comparisons 





2.3.3 Effect of pilocarpine on MDA concentration in SH-SY5Y cells 
Pilocarpine (0-100uM) was without statistically significant effect on MDA 
concentration in SH-SY5Y cells following exposure for 1 hour and 4 hours (figure 2.5). 
In contrast, 24 hour exposure to pilocarpine was associated with a concentration-related 
increase in MDA concentration, which was significantly different from the control 
(0µM) value at 10µM and above (p<0.05).  
 
Figure 2.5 Effect of 1, 4 and 24 hour exposure to pilocarpine (0-100µM) on 
malondialdehyde (MDA) concentration in SH-SY5Y cells. Results (n=3) are expressed 
as the mean (± SD) MDA concentration in nmols/µg protein and statistical significance 
was determined by one-way ANOVA with Dunnett correction for multiple comparisons 
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2.3.4 Effect of LPS on MDA concentration in SH-SY5Y cells 
LPS (0-30uM) was without statistically significant effect on MDA concentration in SH-
SY5Y cells following exposure for 1, 4, and 24 hours (figure 2.6). In contrast, 4 and 24 
hour exposure to LPS was associated with a concentration-related increase in MDA 




Figure 2.6 Effect of 1, 4 and 24 hour exposure to LPS (0-100µg/ml) on 
malondialdehyde (MDA) concentration in SH-SY5Y cells. Results (n=3) are expressed 
as the mean (± SD) MDA concentration in nmols/µg protein and statistical significance 
was determined by one-way ANOVA with Dunnett correction for multiple comparisons 
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2.3.5 Effect of H2O2 on SOD activity in SH-SY5Y cells 
H2O2 (0-30uM) was without statistically significant effect on SOD activity in SH-SY5Y 
cells following exposure for 1, 4, and 24 hours (figure 2.7). In contrast, 1,4, and 24 
hours exposure to H2O2 was associated with a concentration-related increase in MDA 
concentration, which was significantly different from the control (0µM) value at 100µM 
and above (p<0.05). 
 
     
Figure 2.7 Effect of 1, 4 and 24 hour exposure to H2O2 (0-1000µM) on superoxide 
dismutase (SOD) activity in SH-SY5Y cells. Results (n=3) are expressed as the mean (± 
SD) SOD activity in U/µg protein and statistical significance was determined by one-
way ANOVA with Dunnett correction for multiple comparisons with control (0µM) 
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2.3.6 Effect of pilocarpine on SOD activity in SH-SY5Y cells. 
Pilocarpine (0-100uM) was without statistically significant effect on SOD activity in 
SH-SY5Y cells following exposure for 1 hour and 4 hours (figure 2.8). Likewise, 24 
hours exposure to pilocarpine (0-10µM) was without statistically significant effect on 
SOD activity following exposure for 24 hours. In contrast, 24 hour exposure to 
pilocarpine was associated with a concentration-related increase in MDA concentration, 
which was significantly different from the control (0µM) value at 30 and 100 µM 
(p<0.05). 
 
Figure 2.8 Effect of 1, 4 and 24 hour exposure to pilocarpine (0-100µM) on superoxide 
dismutase (SOD) activity in SH-SY5Y cells. Results (n=3) are expressed as the mean (± 
SD) SOD activity in U/µg protein and statistical significance was determined by one-
way ANOVA with Dunnett correction for multiple comparisons with control (0µM) 
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2.3.7 Effect of LPS on SOD activity in SH-SY5Y cells. 
 LPS (0-30uM) was without statistically significant effect on SOD activity in SH-SY5Y 
cells following exposure for 1, 4, and 24 hours (figure 2.9). In contrast, 4 and 24 hour 
exposure to LPS was associated with a concentration-related increase in SOD activity, 
which was significantly different from the control (0µg/ml) value at 100µM (p<0.05). 
      
 
Figure 2.9 Effect of 1, 4 and 24 hour exposure to LPS (0-100µg/ml) on superoxide 
dismutase (SOD) activity in SH-SY5Y cells. Results (n=3) are expressed as the mean (± 
SD) SOD activity in U/µg protein and statistical significance was determined by one-
way ANOVA with Dunnett correction for multiple comparisons with control (0µM) 
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2.3.8 Effect of H2O2 on GSH/GSSG ratio in SH-SY5Y cells. 
H2O2 (0-30uM) was without statistically significant effect on GSH/GSSG ratio in SH-
SY5Y cells following exposure for 1hour and 4 hours (figure 2.10). In contrast, 1,4, and 
24 hours exposure to H2O2 was associated with a concentration-related increase in 
GSH/GSSG ratio, which was significantly different from the control (0µM) value at 
30µM and above and 10 µM after exposure for 24 hours (p<0.05). 
 
Figure 2.10 Effect of 1, 4 and 24 hour exposure to H2O2 (0-1000µM) on reduced to 
oxidised glutathione (GSH/GSSG) ratio in SH-SY5Y cells. Results (n=3) are expressed 
as the mean (± SD) (GSH/GSSG) ratio and statistical significance was determined by 
one-way ANOVA with Dunnett correction for multiple comparisons with control (0µM) 
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2.3.9 Effect of pilocarpine on GSH/GSSG ratio in SH-SY5Y cells. 
Pilocarpine (0-10uM) was without statistically significant effect on GSH/GSSG ratio in 
SH-SY5Y cells following exposure for 1hour and 4 hours (figure 2.11). In contrast, 1,4, 
and 24 hours exposure to pilocarpine was associated with a concentration-related 
increase in GSH/GSSG ratio, which was significantly different from the control (0µM) 
value at 3µM and above (p<0.05).  
 
 Figure 2.11 Effect of 1, 4 and 24 hour exposure to pilocarpine (0-100µM) on reduced 
to oxidised glutathione (GSH/GSSG) ratio in SH-SY5Y cells. Results (n=3) are 
expressed as the mean (± SD) (GSH/GSSG) ratio and statistical significance was 
determined by one-way ANOVA with Dunnett correction for multiple comparisons 
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2.3.10 Effect of LPS on GSH/GSSG ratio in SH-SY5Y cells. 
LPS (0-10ug/ml) was without statistically significant effect on GSH/GSSG ratio in SH-
SY5Y cells following exposure for 1hour and 4 hours (figure 2.12). In contrast, 1,4, and 
24 hours exposure to LPS was associated with a concentration-related increase in 
GSH/GSSG ratio, which was significantly different from the control (0µM) value at 
3µg/ml and above (p<0.05). 
 
 
 Figure 2.12 Effect of 1, 4 and 24 hour exposure to LPS (0-100µg/ml) on reduced to 
oxidised glutathione (GSH/GSSG) ratio in SH-SY5Y cells. Results (n=3) are expressed 
as the mean (± SD) (GSH/GSSG) ratio and statistical significance was determined by 
one-way ANOVA with Dunnett correction for multiple comparisons with control (0µM) 
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2.3.11 Effect of RA on MDA concentration in 100 µM H2O2 treated SH-SY5Y cells 
Exposure to 100µM H2O2 for 1 hour was associated with a statistically significant 
(p<0.05) increase in MDA concentration in both differentiated and undifferentiated SH-
SY5Y cells. However, there were no significant differences between differentiated and 
undifferentiated cells in terms of both basal (un-induced) MDA concentration and 
following induction with 100µM H2O2 (figure 2.13). 
 
Figure 2.13 Effect of differentiation with 10µM retinoic acid on MDA concentration in 
SH-SY5Y cells under basal conditions and following induction of oxidative stress with 
exposure to 100µM H2O2 for 1 hour. Results are expressed as mean (±SEM) MDA 
concentration in nmol/µg protein. (n=4 per group) and statistical significance (*p<0.05) 
was determined by 2-way ANOVA test. n.s: no significant difference.*p: different H2O2 
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2.3.12 Effect of RA on SOD activity in 100 µM H2O2 treated SH-SY5Y cells 
Exposure to 100µM H2O2 for 1 hour was associated with a statistically significant 
(p<0.05) decrease in SOD activity in both differentiated and undifferentiated SH-SY5Y 
cells. However, there were no significant differences between differentiated and 
undifferentiated cells in terms of both basal (un-induced) SOD activity and following 
induction with 100µM H2O2 (figure 2.14). 
 
 
Figure 2.14 Effect of differentiation with 10µM retinoic acid on SOD activity in SH-
SY5Y cells under basal conditions and following induction of oxidative stress with 
exposure to 100µM H2O2 for 1 hour. Results are expressed as mean (±SEM) SOD 
activity in U/µg protein. (n=4 per group) and statistical significance (*p<0.05) was 
determined by 2-way ANOVA test. n.s: no significant difference.*p: different H2O2 
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2.3.13 Effect of RA on GSH / GSSG ratio in 100 µM H2O2 treated SH-SY5Y cells 
Exposure to 100µM H2O2 for 1 hour was associated with a statistically significant 
(p<0.05) decrease in GSH/GSSG ratio in both differentiated and undifferentiated SH-
SY5Y cells. However, there were no significant differences between differentiated and 
undifferentiated cells in terms of both basal (un-induced) GSH/GSSG ratio and 
following induction with 100µM H2O2 (figure 2.15). 
 
Figure 2.15 Effect of differentiation with 10µM retinoic acid on GSH/GSSG ratio in 
SH-SY5Y cells under basal conditions and following induction of oxidative stress with 
exposure to 100µM H2O2 for 1 hour. Results are expressed as mean (±SEM) 
GSH/GSSG ratio. (n=4 per group) and statistical significance (*p<0.05) was determined 
by 2-way ANOVA test. n.s: no significant difference.*p: different H2O2 concentrations 
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2.4 Discussion  
There is a growing body of evidence suggesting that oxidative stress is potentially 
neurotoxic (Sgaravatti et al., 2009). This study has shown that1-100 µM pilocarpine 
produced oxidative stress and decreased SH-SY5Y cells viability, especially at higher 
concentrations, and that 10-1000µM H2O2 and 1-100 µg/ml LPS also induced oxidative 
insult and cell death in a time and concentration dependent manner. 
Many studies have demonstrated that oxidative stress is a major cause of cell death in 
different kinds of human diseases including neurological disorders. Reactive oxygen 
species such as H2O2, O
- and OH- instantly destroy biological molecules, such as lipids, 
proteins and nucleic acids, which can ultimately lead to apoptotic cell death (Bayani et 
al., 2009). Thus, removal of excess reactive oxygen species or suppression of their 
generation by endogenous and/or exogenous antioxidants may be effective in 
preventing oxidative stress and subsequent cell death. In normal basal conditions, there 
is a steady state balance between the production of ROS and their neutralization by the 
cellular antioxidant system.    
The SH-SY5Y neuroblastoma cell line is widely used as an in vitro model for the study 
of different neurological disorders (Agholme et al., 2010; Kovalevich and Langford. 
2013; Krishna et al., 2014). This study showed a non-significant (p<0.05) change in 
MDA concentration, SOD activity and GSH/GSSG ratio between differentiated and 
undifferentiated SH-SY5Y cells after induction of oxidative stress by 100 µM H2O2. 
Thus, undifferentiated SH-SY5Y cells are sensitive to oxidative damage and are a 
suitable in vitro system for these experiments. Furthermore, it was found that cellular 
differentiation has a number of issues that might impact on the interpretation of 
experimental results, such as proteomic changes, cellular proliferation, apoptosis, and 
transcription (Cheung et al., 2009). These authors also suggested that undifferentiated 
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SH-SY5Y cells are more appropriate for studying neurotoxicity and neuroprotection in 
experimental neurological disease research. In addition, it is reported that in studies 
assessing cell stresses, including oxidative stress and metabolic stress, differentiation 
may be undesirable, due to the potential for artefacts in the proteomic data from the 
differentiation process, (Hermann A. 2014).  
H2O2 is one of the most important non-radical ROS produced via metabolism in living 
cells. It is the by-product of enzymatic activity and catecholamine’s oxidation and if not 
metabolised, might generate highly toxic hydroxyl radicals through the Fenton reaction 
(Cho et al., 2009). H2O2 has been extensively used as an inducer of oxidative stress in in 
vitro models (Satoh et al., 1996). Moreover, the exposure of undifferentiated SH-SY5Y 
cells to H2O2 results in an imbalance in energy metabolism because of the harmful 
effects of hydroxyl and peroxyl radicals on membrane lipids and proteins (Satoh et al., 
1996).   
The current study confirmed that cells exposure to H2O2 resulted in a time- and 
concentration-dependent decrease in viability (figure 2.1). This result was consistent 
with previous data reporting a concentration-dependent decrease in cell viability after 
exposure to different concentrations of H2O2 with maintaining cell viability above 80% 
even after 100 µM H2O2 exposure for 24 hours when using SH-SY5Y cells as an in 
vitro model (Webster et al., 2003; Gu  et al., 2013; Kang et al., 2014).  
Undifferentiated SH-SY5Y cells exposure to H2O2 in high concentrations revealed a 
decrease in antioxidant mechanisms (i.e. SOD activity and GSH/GSSG ratio) and an 
increase in MDA concentration, and therefore lipid peroxidation, which reflects the 
strong pro-oxidant activity of H2O2.  These results link to a recently published papers 
reported an increase in MDA concentration and  a decrease in GSH, GPx and SOD and 
CAT activity in various cell lines after exposure to different concentrations of H2O2 
(Wang et al., 2017; Xiaolong. 2017). In addition, previous reports suggested that 
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exogenous added H2O2 induced intracellular ROS generation and affected 
accompanying cellular metabolic responses (Gough and Cotter. 2011; Park et al., 2015). 
The strong pro-oxidant activity of H2O2 has been suggested to be due to its direct 
damaging effect, as it is a highly diffusible ROS that can cross the plasma membrane 
(Forman. 2007). Treatment with H2O2 has been shown to produce more O
- by activation 
of NADPH oxidase and subsequently the formation of peroxunitrite (i.e. ONOO-) 
through superoxide scavenging of nitric oxide (Beckman et al., 1990; Pryor and 
Squadrito. 1995). On the other hand, H2O2 induces lipid peroxidation, which leads to 
lactate dehydrogenase (LDH) release and ultimately cell death by necrosis. Moreover, 
LDH can be involved in membrane and protein damage (Garcimartin et al., 2014).  
LPS has occasionally been used as an experimental inducer of oxidative stress, although 
it is more commonly employed to induce inflammatory or autoimmune responses. In the 
current study, LPS showed a time-dependent decrease in cell viability and an increase in 
oxidative damage in SH-SY5Y cells. These findings are consistent with recently 
published data reporting an increase in MDA concentration and a decrease in GSH level 
and SOD activity in different experimental animals and cell line after exposure to 
various concentrations of LPS (Pourganji et al., 2014; Gou et al., 2015; Frimmel et al., 
2016). It has been found that LPS-induced brain inflammation is accompanied by 
neuronal and glial cell activation resulting in the release of neurotoxic factors such as 
inflammatory cytokines and free radicals (Noworyta et al., 2013). Moreover, cellular 
exposure to LPS may trigger the release of inflammatory mediators, such as tumor 
necrosis factor alpha (TNF-α), which might in turn result in oxidative stress and 
inflammation (Figure 16) (Choudhury et al., 2015; Ruiz-Miyazawa. 2015). To the best 
of our knowledge, no previous reports have used the SH-SY5Y cell line as an in vitro 
model to assess oxidative stress markers after exposure to LPS. However, several 
studies have evaluated the neuroinflammatory effect of LPS on SH-SY5Y cells. 
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Neuroinflammation can contribute to neuronal dysfunction and the development of 
several neurodegenerative diseases, including Parkinson’s diseases, Alzheimer’s 
disease, amyotrophic lateral sclerosis, and multiple sclerosis, at least in part by 
triggering ROS generation and engaging the same TLR pathway that is involved in 
oxidative stress (Glass et al., 2010).      
 
Figure 2.16 LPS-induced inflammation and oxidative stress. LPS activates toll-like 
receptor 4 (TLR4), which leads to activation of nuclear factor kappa B (NF-κB) and 
consequent production of inflammatory cytokines (tumor necrosis factor alpha (TNFα), 
interleukin 1-beta (IL-1β), interleukin 33 (IL-33)), superoxide anion (O2−), nitric oxide 
(NO) and lipid peroxidation (LPO), and diminished levels of reduced glutathione 
(GSH), ferric reducing antioxidant power (FRAP) and to scavenge 2-2-azinobis(3-
ethyllbenzothiazoline-6-sulfonic acid (ABTS) free radicals. Adapted from (Ruiz-
Miyazawa. 2015). 
 
The current results showed an increase in lipid peroxidation by-product (i.e. MDA) and 
a decrease in SOD activity and GSH/GSSG ratio in a time- and concentration-
dependent manner after exposure to different concentrations of pilocarpine. Pilocarpine 
is widely used to induce seizures-related oxidative stress in several experimental models 
(Freitas et al., 2004; Tome et al., 2010; Hermann. 2014). The results reported here are 
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agreed with previous studies which reported that treatment of various experimental 
animals with different pilocarpine concentrations induced lipid peroxidation, decrease 
GSH level and SOD activity in addition to increased nitric oxide, TNF-α, and IL-6 
which play an important role in inflammation and oxidative stress as well (Freitas et al., 
2004; Santos et al., 2011; Kabel. 2014; Noor et al., 2015). Moreover, it has been 
reported that pilocarpine binding to M1 activates the phospholipase C and therefore 
produces diacylglycerol (DG) and inositol triphosphate (IP3), which results in alteration 
in Ca++ and K+ current and increases the excitability of the brain. The high 
concentration of Ca++ promotes the high release of glutamate, which induces the status 
epilepticus (SE). The tissue excitability and/or SE increase the utilization rate of 
catecholamine’s which are degraded by MAO and COMT and, during these processes, 
free radicals can be formed. These free radicals are also generated during glucose 
metabolism and mitochondrial transport chain, which is over activated during SE. In 
addition, the SOD presented a decreased activity during seizures, associated to an 
increased MDA concentration and tissue damage in the hippocampus of epileptic 
animals (Scorza, F. A. et al., 2009). 
 
2.4.1 Conclusions 
 The present study revealed that H2O2, LPS and pilocarpine can attenuate basal 
antioxidant mechanisms and decrease cell viability in a time and concentration-
dependent manner in human SH-SY5Y cells. In addition, this study demonstrated that 
100 µM H2O2 was the ideal pro-oxidant because of efficient induction of oxidative 
stress with minimum time exposure (i.e. 4 hours) and minimum cell death (less than 
20%) in comparison to other suggested H2O2, LPS, and pilocarpine concentrations used 
in this experiment. Moreover, in terms of oxidative stress indicators, no significant 
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changes have been found between differentiated and undifferentiated SH-SY5Y cells 
after exposure to 100µM H2O2. So, according to these findings and others from previous 
reports mentioned many issues and undesirability in using differentiated SH-SY5Y cells 
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Oxidative stress is an imbalance between pro-oxidants and anti-oxidants in favourite of 
pro-oxidants. Free radicals are involved in pathogenesis of various diseases including 
atherosclerosis, diabetes, stroke, inflammatory bowel diseases and lung cancer 
(Sundstrom et al., 1984; Plachta et al., 1992). Awareness of the important role of 
oxidative damage by ROS and/or RNS in seizure disorders has arisen in the last two 
decades (Cengis et al., 2000; Ercegovac et al., 2010).  
The brain is particularly susceptible to oxidative damage because of high oxygen 
consumption, production of large amounts of ROS and RNS, susceptibility to lipid 
peroxidation, richness in iron content, and lack of important antioxidant enzymes (i.e. 
catalase) (Shin et al., 2011; Naziroglu 2012). Therefore, any pathological brain condition 
requires an increase in energy consumption which might eventually make the brain most 
sensitive to oxidative insult. (Naziroglu 2007; Ozmen et al., 2007; Uttara et al., 2009). 
However, the role of oxidative stress in epilepsies has only recently started to be 
recognized (Ashrafi et al., 2007). Still, the question of whether oxidative stress is a cause 
or a consequence of seizures remains unanswered.  
It has been reported that increased generation of free radicals or reduced activity of anti-
oxidative defence mechanisms can cause some forms of epilepsy and, in addition, 
increase the risk of seizure recurrence (Ashrafi et al., 2007). Moreover, free radicals may 
also exacerbate some forms of seizures (Menon et al., 2012) and there are several 
experimental and clinical studies revealing that seizures can result directly from free 
radical production and oxidative damage to proteins, lipids and DNA molecules 
(Wagner et al., 2004). In addition, animal studies in which exogenous antioxidants were 
used together with AEDs showed a decrease in oxidative insults and a reduction in 
seizure frequency (Willmore et al., 1981; Patsoukis et al., 2004). The sophisticated 
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mechanism of epileptogenesis remains elusive but neuronal cell death mediated by 
oxidative damage is one of the important factors that might affect the evolution of 
epilepsy through mitochondrial dysfunction (Menon et al., 2012). 
The pro-oxidant/antioxidant balance in epilepsy is not only modulated by seizures 
intrinsically, but also by AEDs (Verrotti 2002; Johannesson et al., 2009). Most of the 
commonly used AEDs, including CBZ and VPA, are metabolized to generate reactive 
metabolites with the capability of covalent binding to macromolecules, such as proteins, 
lipids or other vital biomolecules, and thus provoking systemic toxicity (Yuksil et al., 
2000; Hamed et al., 2004). Furthermore, it has been found that long-term use of AEDs, 
such as CBZ, VPA or phenobarbital (PB), increases free radical formation and causes 
oxidative damage to vital biomolecules within neuronal cells (Maertens et al., 1995; 
Cengis et al., 2000). However, it remains uncertain whether the use of AEDs is 
associated with a significant pro-oxidant effect, since major antioxidant enzyme 
activities, including SOD and Gpx, have been reported to be increased, unchanged or 
decreased following AED exposure (Cengis et al., 2000; Yuksil et al., 2000; Hamed et 
al., 2004). 
CBZ, VPA, LEV and LTG are amongst the most commonly prescribed AEDs in 
epilepsy (Chadwick et al., 2008; Johannesson et al., 2009). These drugs are considered 
the first-line and the most effective AEDs for common types of seizure (Marson et al., 
2007). As with other conventional anticonvulsants, they reduce neuronal excitability 
through effects on ion channels and synaptic function (Stafstorm et al., 2009). 
Studies exploring the effect of AEDs on pro-oxidant/antioxidant balance have, so far, 
mainly focused on VPA and CBZ and their effect on lipid peroxidation and enzymatic 
antioxidant defence mechanisms (Martinez-Ballestros et al., 2004; Sobaniec et al., 
2006). The extent of protein oxidative damage with AEDs has not been fully evaluated, 
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while DNA oxidative damage has only been examined in children receiving VPA 
therapy and recently, in one study, on adult patients receiving VPA, CBZ and LEV 
(Schulpis et al., 2006; Varoglu et al., 2010). It is suggested that VPA impairs the liver 
function resulting in free radicals production in children and VPA, LEV, and CBZ 
increased oxidative stress in adults after two months of treatment.  Furthermore, data on 
LTG effects on oxidative stress in patients with epilepsy are very limited. Unfortunately, 
at this time, little is known about the clinical pro-oxidant or antioxidant effects of AEDs 
since the presence of seizure activity is associated with changes in the intracellular levels 
of antioxidants and pro-oxidants, potentially confounding the results of drug studies 
(Martinc et al., 2012). 
3.1.1 Aims and objectives 
The aims of the present study were to: 
1- Explore the effects of CBZ, VPA, LEV and LTG on MDA concentration, as a 
marker of lipid peroxidation, in the SH-SY5Y cell line under basal conditions 
and following induction of oxidative stress by H2O2. 
2- Explore the effects of CBZ, VPA, LEV and LTG on SOD activity, as a marker of 
antioxidant enzyme activity, in the SH-SY5Y cell line under basal conditions and 
following induction of oxidative stress by H2O2. 
3- Explore the effects of CBZ, VPA, LEV and LTG on the GSH/GSSG ratio, as a 
marker of the antioxidant defence system, in the SH-SY5Y cell line under basal 






3.2. Materials and Methods 
3.2.1 Chemicals 
Dimethylsulfide (DMSO), CBZ, LEV, LTG and VPA were purchased from Thermo 
Fisher Scientific, Loughborough, UK.  Other chemicals were sourced as described in 
chapter 2, section 2.2.1. 
3.2.2 Cell culture 
SH-SY5Y cells were cultured as described in chapter 2, section 2.2.2. 
3.2.3 AED effects on cell viability 
SH-SY5Y cells were seeded in 96-well plates at a density of 0.4 x 104 cells / well in 0.1 
ml culture medium (see section 2.2.2) and placed in an incubator containing humidified 
95% air and 5% CO2 at 37
oC for 2-3 days until they reached 80-90% confluence. Cells 
were then treated with CBZ (0, 1, 3, 10, 30 and 100 µM), VPA (0, 10, 30, 100, 300 and 
1000 µM), LTG (0, 1, 3, 10, 30 and 100 µM) or LEV (0, 3, 10, 30, 100 and 300 µM) for 
1, 4 or 24 hours and an MTT assay was performed as described in chapter 2, section 
2.2.9.   
3.2.4 AED effects on oxidative stress 
SH-SY5Y cells were seeded in 24-well plates at a density of 1.88 x 104 cells / well in 
0.5 ml culture medium (see section 2.2.2) and placed in an incubator containing 
humidified 95% air and 5% CO2 at 37
oC for 2-3 days until they reached 80-90% 
confluence.  
In the first series of experiments, cells were treated with either CBZ (0, 10, 30, 100, 300 
and 1000µM), VPA (0, 10, 30, 100, 300 and 1000µM), LTG (0, 1, 3, 10, 30 and 
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100µM) or LEV (0, 3, 10, 30, 100 and 300µM) for 24 hours. VPA and LTG were 
dissolved in serum-free medium (SFM; see chapter 2, section 2.2.4) whereas CBZ and 
LEV were dissolved in SFM containing 0.2% DMSO. Thereafter, cells were exposed to 
100 M H2O2 for 4 hours to induce oxidative stress, with an equivalent number of wells 
left untreated as non-oxidative stress controls (working volumes; see-chapter2-table2.1). 
Existing culture medium was then aspirated; cells washed three times with 0.5ml PBS, 
and scraped in 1 ml PBS prior to analysis of oxidative stress markers. 
In a second series of experiments, cells were initially treated with H2O2 (0, 10, 30, 100, 
300 and 1000 µM) in SFM for 4 hours. Thereafter, cells were exposed to single 
concentrations of either CBZ (10 M), VPA (100 M), LEV (30 M) or LTG (10 M) 
for a further 4 hours, with an equivalent number of wells left untreated in each case as 
non-AED controls. Existing culture medium was then aspirated; cells washed three 
times with 1ml PBS, and scraped in 1 ml PBS prior to analysis of oxidative stress 
markers.  
3.2.5 Protein  quantitation 
Protein in cell lysates was quantified by BCA Protein Assay Kit as described in chapter 
2, section 2.2.8. 
3.2.6 Oxidative stress markers 
MDA concentration, GSH/GSSG ratio, and SOD activity were determined as described 
in chapter 2, sections 2.2.5, 2.2.6 and 2.2.7, respectively. 
3.2.7 Statistical analysis 
All experiments were performed using two technical replicates (i.e. analyses of all 
samples performed in duplicate) and three biological replicates (i.e. n=3 per group). 
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Results were reported as mean ± standard deviation (SD). Statistical comparisons were 
undertaken using either one way or two way ANOVA as appropriate, and with a 
Dunnett correction for multiple comparisons, using Stats Direct software version 2.7.9. 
Differences were considered significant at p≤0.05. 
3.3 Results 
3.3.1 Effect of CBZ, VPA, LEV and LTG on cell viability 
Cells exposed to CBZ (0-100 µM) for 1, 4 and 24 hours showed a decrease in viability in 
a time- and concentration-dependent manner (figure 3.1). At 1 hour, viability was 
maximally reduced to 77.6% of control following exposure to 100 M CBZ and was 
statistically significant at the same concentration (p<0.05 at 100 M). At 4 hours, the 
maximal reduction was 69.7% of control with 100 M CBZ and was significant at 10 
M CBZ and above (all p<0.05). After exposure for 24 hours, cell viability was reduced 
to 64.4% of control with 100 M CBZ and was statistically significant at all 
concentrations tested (p<0.05 at 1 to 30 M CBZ; p<0.001 at 100 M CBZ). 
Cells exposed to VPA (0-1000 µM) for 1, 4 and 24 hours also showed a decrease in 
viability in a time- and concentration-dependent manner (figure 3.2). At 1 hour, viability 
was maximally reduced to 76.2% of control following exposure to 1000M VPA and 
was statistically significant at 300M VPA and above (p<0.05). At 4 hours, the maximal 
reduction was 61.9% of control with 1000M VPA and was statistically significant at 
30M VPA and above (p<0.05). After exposure for 24 hours, cell viability was reduced 
to 57.1% of control with 1000M VPA and was statistically significant at all 
concentrations tested (p<0.05 at 10 to 300 M VPA; p<0.001 at 1000 M VPA). 
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Cells exposed to LEV (0-300 µM) for 1, 4 and 24 hours similarly showed a decrease in 
viability in a time- and concentration-dependent manner (figure 3.3). At 1 hour, viability 
was maximally reduced to 87.0% of control following exposure to 300 M LEV but was 
not significantly different from control at any concentration (p>0.05). At 4 hours, the 
maximal reduction was 78.0% of control with 300 M LEV, which was statistically 
significant at 3 M LEV and above (p<0.05). After exposure for 24 hours, cell viability 
was reduced to 64.0% of control with 300 M LEV, and was significant at 
concentrations of 10M LEV and above (p<0.05 at 10 to 100 M LEV; p<0.001 at 300 
M LEV). 
Cells exposed to LTG (0-100 µM) for 1, 4 and 24 hours showed a decrease in viability in 
a time- and concentration-dependent manner (figure 3.4). At 1 hour, viability was 
maximally reduced to 85.0% of control following exposure to 100 M LTG but was not 
significantly different from control at any concentration (p>0.05). At 4 hours, the 
maximal reduction was 82.0% of control with 100 M LTG and was statistically 
significant at the same concentration (p<0.05 at 100 M LTG). After exposure for 24 
hours, cell viability was reduced to 74.0% of control with 100 M LTG and was 
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Figure 3.1 Effect of 1, 4 and 24 hour exposure to CBZ (0-100 M) on the viability of 
SH-SY5Y cells as determined by MTT assay. Results (n=3) are expressed as the mean 
(± SD) percentage of the mean control (i.e. 0 µM) value in each data series. Statistical 
significance was determined by one-way ANOVA with Dunnett correction for multiple 
comparisons (*p<0.05; **p<0.001) with control (0µM) within each data series  
 Figure 3.2 Effect of 1, 4 and 24 hour exposure to VPA (0-1000 M) on the viability of 
SH-SY5Y cells as determined by MTT assay. Results (n=3) are expressed as the mean 
(± SD) percentage of the mean control (i.e. 0 µM) value in each data series. Statistical 
significance was determined by one-way ANOVA with Dunnett correction for multiple 
comparisons (*p<0.05; **p<0.001) with control (0µM) within each data series.  
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Figure 3.3 Effect of 1, 4 and 24 hour exposure to LEV (0-300 M) on the viability of 
SH-SY5Y cells as determined by MTT assay. Results (n=3) are expressed as the mean 
(± SD) percentage of the mean control (i.e. 0 µM) value in in each data series. Statistical 
significance was determined by one-way ANOVA with Dunnett correction for multiple 
comparisons (*p<0.05; **p<0.001) with control (0µM) within each data series. 
Figure 3.4 Effect of 1, 4 and 24 hour exposure to LTG (0-100 M) on the   viability of 
SH-SY5Y cells as determined by MTT assay. Results (n=3) are expressed as the mean 
(± SD) percentage of the mean control (i.e. 0 µM) value in in each data series. Statistical 
significance was determined by one- -way ANOVA with Dunnett correction for 
multiple comparisons (*p<0.05) with control (0µM) within each data series. 
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3.3.2 Effect of 1 hour exposure to CBZ, VPA, LEV, and LTG on basal and induced 
MDA concentrations in SH-SY5Y cells  
One hour exposure to CBZ (0-100 M) was associated with a concentration-dependent 
increase in MDA levels in SH-SY5Y cells, an effect that was statistically significant at 
concentrations of 30 and 100 M CBZ (p<0.001). Subsequent exposure of CBZ-treated 
cells to 100 µM H2O2 for 4 hours enhanced its action on MDA concentrations, with 
significant differences from control observed at all CBZ pre-treatment concentrations 
(p<0.05 at 1 and 3 M CBZ; p<0.001 at 10 to 100 M CBZ; figure 3.5A). 
One hour exposure to VPA (0-1000 M) was associated with a concentration-dependent 
increase in MDA levels in SH-SY5Y cells, an effect that was significantly different from 
control at concentrations of 100 M VPA and above (p<0.05 at 100 M VPA; p<0.001 
at 300 and 1000 M VPA). Subsequent exposure of VPA-treated cells to 100 µM H2O2 
for 4 hours appeared to augment its effect on MDA concentrations but the pattern of 
statistical significance was unchanged (p<0.05 at 100 M VPA; p<0.001 at 300 and 
1000 M VPA; figure 3.5B).  
One hour exposure to LEV (0-300 M) was associated with a concentration-dependent 
increase in MDA levels in SH-SY5Y cells, an effect that was statistically significant at 
concentrations of 30 M LEV and above (p<0.05 at 30 M LEV; p<0.001 at 100 and 
300 M LEV). Subsequent exposure of LEV-treated cells to 100 µM H2O2 for 4 hours 
enhanced its action on MDA concentrations, with significant differences from control 




One hour exposure to LTG (0-100 M) was associated with a concentration-dependent 
increase in MDA levels in SH-SY5Y cells, an effect that was significantly different from 
control at concentrations of 30 and 100 M LTG (both p<0.001). Subsequent exposure 
of LTG-treated cells to 100 µM H2O2 for 4 hours enhanced its effect on MDA 
concentrations, with statistical significance observed at LTG pre-treatment 
concentrations of 3 M and above (p<0.05 at 3 and 10 M LTG; p<0.001 at 30 and 100 
M LTG; figure 3.5D). 
3.3.3 Effect of 4 hours exposure to CBZ, VPA, LEV, and LTG on basal and 
induced MDA concentrations in SH-SY5Y cells  
Four hours exposure to CBZ (0-100 M) was associated with a concentration-dependent 
increase in MDA levels in SH-SY5Y cells, an effect that was statistically significant at 
concentrations of 30 and 100 M CBZ (p<0.001). Subsequent exposure of CBZ-treated 
cells to 100 µM H2O2 for 4 hours enhanced its action on MDA concentrations, with 
significant differences from control observed at all CBZ pre-treatment concentrations 
(p<0.05 at 10M CBZ; p<0.001 at 30 to 100 M CBZ; figure 3.6A). 
Four hours  exposure to VPA (0-1000 M) was associated with a concentration-
dependent increase in MDA levels in SH-SY5Y cells, an effect that was significantly 
different from control at concentrations of 100 M VPA and above (p<0.05 at 100 to 
1000M VPA). Subsequent exposure of VPA-treated cells to 100 µM H2O2 for 4 hours 
appeared to augment its effect on MDA concentrations but the pattern of statistical 
significance was unchanged (p<0.05 at 100 M VPA; p<0.001 at 300 and 1000 M 
VPA; figure 3.6B).  
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Four hours exposure to LEV (0-300 M) was associated with a concentration-dependent 
increase in MDA levels in SH-SY5Y cells, an effect that was statistically significant at 
concentrations of 30 M LEV and above (p<0.05 at 10 to 30M LEV; p<0.001 at 100 
and 300 M LEV). Subsequent exposure of LEV-treated cells to 100 µM H2O2 for 4 
hours enhanced its action on MDA concentrations, with significant differences from 
control observed at LEV pre-treatment concentrations of 10 M and above (p<0.05 at 10 
to 30M LEV; p<0.001 at 100 and 300 M LEV figure 3.6C).   
Four hours exposure to LTG (0-100 M) was associated with a concentration-dependent 
increase in MDA levels in SH-SY5Y cells, an effect that was significantly different from 
control at concentrations of 30 and above (p<0.05 at 10M LTG; p<0.001 at 30 and 100 
M LTG). Subsequent exposure of LTG-treated cells to 100 µM H2O2 for 4 hours 
enhanced its effect on MDA concentrations, with statistical significance observed at 
LTG pre-treatment concentrations of 10M and above (p<0.05 at 10M LTG; p<0.001 
at 30 and 100 M LTG; figure 3.6D). 
3.3.4 Effect of 24 hours exposure to CBZ, VPA, LEV, and LTG on basal and 
induced MDA concentrations in SH-SY5Y cells  
Twenty four hours exposure to CBZ (0-100 M) was associated with a concentration-
dependent increase in MDA levels in SH-SY5Y cells, an effect that was statistically 
significant at concentrations of 10 and 100 M CBZ (p<0.05 at 10µM CBZ; p<0.001 at 
30µM and 100µM CBZ). Subsequent exposure of CBZ-treated cells to 100 µM H2O2 for 
4 hours enhanced its action on MDA concentrations, with significant differences from 
control observed at all CBZ pre-treatment concentrations (P<0.05 at 10µM CBZ; 
p<0.001 at 300µM and 1000µM CBZ; figure 3.7A). 
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Twenty four hours exposure to VPA (0-1000 M) was associated with a concentration-
dependent increase in MDA levels in SH-SY5Y cells, an effect that was significantly 
different from control at concentrations of 100 M VPA and above (p<0.05 at 
100MVPA;  p<0.001 at 300µM and 1000µM VPA). Subsequent exposure of VPA-
treated cells to 100 µM H2O2 for 4 hours appeared to augment its effect on MDA 
concentrations but the pattern of statistical significance was unchanged (p<0.05 at 100 
M VPA; p<0.001 at 300 and 1000 M VPA; figure 3.7B).  
Twenty four hours exposure to LEV (0-300 M) was associated with a concentration-
dependent increase in MDA levels in SH-SY5Y cells, an effect that was statistically 
significant at concentrations of 30 M LEV and above (p<0.001 at 30M and 300 M 
LEV). Subsequent exposure of LEV-treated cells to 100 µM H2O2 for 4 hours enhanced 
its action on MDA concentrations, with significant differences from control observed at 
LEV pre-treatment concentrations of 10 M and above (p<0.001 at 30M and 300 M 
LEV figure 3.7C).   
Twenty four hours exposure to LTG (0-100 M) was associated with a concentration-
dependent increase in MDA levels in SH-SY5Y cells, an effect that was significantly 
different from control at concentrations of 30 and above (p<0.05 at 3M and10M LTG; 
p<0.001 at 30M and 100 M LTG). Subsequent exposure of LTG-treated cells to 100 
µM H2O2 for 4 hours enhanced its effect on MDA concentrations, with statistical 
significance observed at LTG pre-treatment concentrations of 10M and above (p<0.05 
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Figure 3.5 Effect of 1 hour exposure to (A) carbamazepine (CBZ; 0-100 µM), (B) 
sodium valproate (VPA; 0-1000 µM), (C) levetiracetam (LEV; 0-300 µM) and (D) 
lamotrigine (LTG; 0-100 M), with and without subsequent exposure to 100 M H2O2 
for 4 hours, on malondialdehyde (MDA) concentration in SH-SY5Y cells. Results (n=3) 
are expressed as the mean (± SD) MDA concentration (nmol/mg protein) and statistical 
significance was determined by one-way ANOVA with Dunnett correction for multiple 
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Figure 3.6 Effect of 4 hours exposure to (A) carbamazepine (CBZ; 0-100 µM), (B) 
sodium valproate (VPA; 0-1000 µM), (C) levetiracetam (LEV; 0-300 µM) and (D) 
lamotrigine (LTG; 0-100 M), with and without subsequent exposure to 100 M H2O2 
for 4 hours, on malondialdehyde (MDA) concentration in SH-SY5Y cells. Results (n=3) 
are expressed as the mean (± SD) MDA concentration (nmol/mg protein) and statistical 
significance was determined by one-way ANOVA with Dunnett correction for multiple 
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Figure 3.7 Effect of 24 hours exposure to (A) carbamazepine (CBZ; 0-100 µM), (B) 
sodium valproate (VPA; 0-1000 µM), (C) levetiracetam (LEV; 0-300 µM) and (D) 
lamotrigine (LTG; 0-100 M), with and without subsequent exposure to 100 M H2O2 
for 4 hours, on malondialdehyde (MDA) concentration in SH-SY5Y cells. Results (n=3) 
are expressed as the mean (± SD) MDA concentration (nmol/mg protein) and statistical 
significance was determined by one-way ANOVA with Dunnett correction for multiple 
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3.3.5 Effect of 1 hour exposure to CBZ, VPA, LEV, and LTG on basal and induced 
SOD activity in SH-SY5Y cells  
One hour exposure to CBZ (0-100 M) was associated with a concentration-dependent 
decrease in SOD activity in SH-SY5Y cells, an effect that was statistically significant at 
concentrations of 10 and 100 M CBZ (p<0.05 at 10µM to 100µM CBZ). Subsequent 
exposure of CBZ-treated cells to 100 µM H2O2 for 4 hours enhanced its action on SOD 
activity with significant differences from control observed at all CBZ pre-treatment 
concentrations (P<0.01 at 10µM to 100µM CBZ; figure 3.8A). 
One hour exposure to VPA (0-1000 M) was associated with a concentration-dependent 
decrease in SOD activity in SH-SY5Y cells, an effect that was significantly different 
from control at concentrations of 100 M VPA and above (p<0.01 at 100M to 1000µM 
VPA). Subsequent exposure of VPA-treated cells to 100 µM H2O2 for 4 hours appeared 
to augment its effect on SOD activity but the pattern of statistical significance was 
unchanged (p<0.01 at 100 M to 1000 M VPA; figure 3.8B).  
One four hours exposure to LEV (0-300 M) was associated with a concentration-
dependent decrease in SOD activity in SH-SY5Y cells, an effect that was statistically 
significant at concentrations of 30 M LEV and above (p<0.05 at 30M and 100 M 
LEV; p<0.01 at 300 µM VPA). Subsequent exposure of LEV-treated cells to 100 µM 
H2O2 for 4 hours enhanced its action on SOD activity, with significant differences from 
control observed at LEV pre-treatment concentrations of 10 M and above (p<0.05 at 
30M and 100M LEV; p<0.01 at 300µM LEV; figure 3.8C).   
One hour exposure to LTG (0-100 M) was associated with a concentration-dependent 
decrease in SOD activity in SH-SY5Y cells, an effect that was significantly different 
from control at concentrations of 30µM LTG and above (p<0.05 at 30M and100M 
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LTG). Subsequent exposure of LTG-treated cells to 100 µM H2O2 for 4 hours enhanced 
its effect on SOD activity, with statistical significance observed at LTG pre-treatment 
concentrations of 30M and above (p<0.05 at 30M  and 100M LTG; figure 3.8D). 
3.3.6 Effect of 4 hours exposure to CBZ, VPA, LEV, and LTG on basal and 
induced SOD activity in SH-SY5Y cells  
Four hours exposure to CBZ (0-100 M) was associated with a concentration-dependent 
decrease in SOD activity in SH-SY5Y cells, an effect that was not statistically 
significant at all concentrations CBZ. Subsequent exposure of CBZ-treated cells to 100 
µM H2O2 for 4 hours enhanced its action on SOD activity with significant differences 
from control observed at all CBZ pre-treatment concentrations (p<0.05 at 10µM to 
100µM CBZ; figure 3.9A). 
Four hours exposure to VPA (0-1000 M) was associated with a concentration-
dependent decrease in SOD activity in SH-SY5Y cells, an effect that was significantly 
different from control at concentrations of 300 M VPA and above (p<0.05 at 300M to 
1000µM VPA). Subsequent exposure of VPA-treated cells to 100 µM H2O2 for 4 hours 
appeared to augment its effect on SOD activity but the pattern of statistical significance 
was unchanged (p<0.05 at 300 M to 1000 M VPA; figure 3.9B).  
Four hours exposure to LEV (0-300 M) was associated with a concentration-dependent 
decrease in SOD activity in SH-SY5Y cells, an effect that was statistically significant at 
concentrations of 10 M LEV and above (p<0.05 at 10M to 300 M LEV). Subsequent 
exposure of LEV-treated cells to 100 µM H2O2 for 4 hours enhanced its action on SOD 
activity, with significant differences from control observed at LEV pre-treatment 
concentrations of 10 M and above (p<0.05 at 30M to 300M LEV; figure 3.9C).   
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Four hours exposure to LTG (0-100 M) was associated with a concentration-dependent 
decrease in SOD activity in SH-SY5Y cells, an effect that was significantly different 
from control at concentrations of 30µM LTG and above (p<0.05 at 10M to 100M 
LTG). Subsequent exposure of LTG-treated cells to 100 µM H2O2 for 4 hours enhanced 
its effect on SOD activity, with statistical significance observed at LTG pre-treatment 
concentrations of 10M and above (p<0.05 at 10M  to 100M LTG; figure 3.9D). 
3.3.7 Effect of 24 hours exposure to CBZ, VPA, LEV, and LTG on basal and 
induced SOD activity in SH-SY5Y cells  
Twenty four hours exposure to CBZ (0-100 M) was associated with a concentration-
dependent decrease in SOD activity in SH-SY5Y cells, an effect that was significantly 
different from control at concentrations of 30M CBZ and above(p<0.05 at 30M and 
100µM CBZ) . Subsequent exposure of CBZ-treated cells to 100 µM H2O2 for 4 hours 
enhanced its action on SOD activity with significant differences from control observed 
at all CBZ pre-treatment concentrations (p<0.05 at 1µM to 100µM CBZ; figure 3.10A). 
Twenty four hours exposure to VPA (0-1000 M) was associated with a concentration-
dependent decrease in SOD activity in SH-SY5Y cells, an effect that was significantly 
different from control at concentrations of 30 M VPA and above (p<0.01 at 30M to 
1000µM VPA). Subsequent exposure of VPA-treated cells to 100 µM H2O2 for 4 hours 
appeared to augment its effect on SOD activity but the pattern of statistical significance 
was unchanged (p<0.01 at 30 M to 1000 M VPA; figure 3.10B).  
Twenty four hours exposure to LEV (0-300 M) was associated with a concentration-
dependent decrease in SOD activity in SH-SY5Y cells, an effect that was statistically 
significant at concentrations of 10 M LEV and above (p<0.01 at 10M to 300M 
LEV). Subsequent exposure of LEV-treated cells to 100 µM H2O2 for 4 hours enhanced 
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its action on SOD activity, with significant differences from control observed at LEV 
pre-treatment concentrations of 10 M and above (p<0.01 at 10M to 300M LEV; 
figure 3.10C).   
Twenty four hours exposure to LTG (0-100 M) was associated with a concentration-
dependent decrease in SOD activity in SH-SY5Y cells, an effect that was significantly 
different from control at concentrations of 30µM LTG and above (p<0.05 at 30M and 
100M LTG). Subsequent exposure of LTG-treated cells to 100 µM H2O2 for 4 hours 
enhanced its effect on SOD activity, with statistical significance observed at LTG pre-








Figure 3.8 Effect of 1 hour exposure to (A) carbamazepine (CBZ; 0-100 µM), (B) 
sodium valproate (VPA; 0-1000 µM), (C) levetiracetam (LEV; 0-300 µM) and (D) 
lamotrigine (LTG; 0-100 M), with and without subsequent exposure to 100 M H2O2 
for 4 hours, on SOD activity in SH-SY5Y cells. Results (n=3) are expressed as the mean 
(± SD) SOD activity (U/mg protein) and statistical significance was determined by one-
way ANOVA with Dunnett correction for multiple comparisons (*p<0.05; **p<0.001) 


























































































































































Figure 3.9 Effect of 4 hours exposure to (A) carbamazepine (CBZ; 0-100 µM), (B) 
sodium valproate (VPA; 0-1000 µM), (C) levetiracetam (LEV; 0-300 µM) and (D) 
lamotrigine (LTG; 0-100 M), with and without subsequent exposure to 100 M H2O2 
for 4 hours, on SOD activity in SH-SY5Y cells. Results (n=3) are expressed as the mean 
(± SD) SOD activity (U/mg protein) and statistical significance was determined by one-
way ANOVA with Dunnett correction for multiple comparisons (*p<0.05; **p<0.001) 
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Figure 3.10 Effect of 24 hours exposure to (A) carbamazepine (CBZ; 0-100 µM), (B) 
sodium valproate (VPA; 0-1000 µM), (C) levetiracetam (LEV; 0-300 µM) and (D) 
lamotrigine (LTG; 0-100 M), with and without subsequent exposure to 100 M H2O2 
for 4 hours, on SOD activity in SH-SY5Y cells. Results (n=3) are expressed as the mean 
(± SD) SOD activity (U/mg protein) and statistical significance was determined by one-
way ANOVA with Dunnett correction for multiple comparisons (*p<0.05; **p<0.001) 
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3.3.8 Effect of 1 hour exposure to CBZ, VPA, LEV, and LTG on basal and induced 
GSH/GSSG ratio in SH-SY5Y cells  
One hour exposure to CBZ (0-100 M) was associated with a concentration-dependent 
decrease in GSH/GSSG ratio in SH-SY5Y cells, an effect that was significantly different 
from control at concentrations of 1M CBZ and above(p<0.01 at 1M to 100µM CBZ) . 
Subsequent exposure of CBZ-treated cells to 100 µM H2O2 for 4 hours enhanced its 
action on GSH/GSSG ratio with significant differences from control observed at all CBZ 
pre-treatment concentrations (p<0.01 at 1µM to 100µM CBZ; figure 3.11A). 
One hour exposure to VPA (0-1000 M) was associated with a concentration-dependent 
decrease in GSH/GSSG ratio in SH-SY5Y cells, an effect that was significantly different 
from control at concentrations of 100 M VPA and above (p<0.05 at 100M to 1000µM 
VPA). Subsequent exposure of VPA-treated cells to 100 µM H2O2 for 4 hours appeared 
to augment its effect on GSH/GSSG ratio but the pattern of statistical significance was 
unchanged (p<0.05 at 10M VPA; p<0.01 at 30M to 1000 M VPA; figure 3.11B).  
One hour exposure to LEV (0-300 M) was associated with a concentration-dependent 
decrease in GSH/GSSG ratio in SH-SY5Y cells, an effect that was statistically 
significant at concentrations of 10 M LEV and above (p<0.05 at 10M and 30M 
LEV; p<0.01 at 100M and 300M LEV). Subsequent exposure of LEV-treated cells to 
100 µM H2O2 for 4 hours enhanced its action on GSH/GSSG ratio with significant 
differences from control observed at LEV pre-treatment concentrations of 10 M and 
above (p<0.05 at 10M ; p<0.01 at 30M to 300M LEV; figure 3.11C).   
One hour exposure to LTG (0-100 M) was associated with a concentration-dependent 
decrease in GSH/GSSG ratio in SH-SY5Y cells, an effect that was significantly different  
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from control at concentrations of 30µM LTG and above (p<0.05 at 30M; p<0.01 at 
100M LTG). Subsequent exposure of LTG-treated cells to 100 µM H2O2 for 4 hours 
enhanced its effect on GSH/GSSG ratio, with statistical significance observed at LTG 
pre-treatment concentrations of 30M and above (p<0.05 at 30M; p<0.01 at 100M 
LTG; figure 3.11D). 
3.3.9 Effect of CBZ, VPA, LEV, and LTG and H2O2 on GSH/GSSG ratio after 4 
hours exposure in SH-SY5Y cells 
Four hours exposure to CBZ (0-100 M) was associated with a concentration-dependent 
decrease in GSH/GSSG ratio in SH-SY5Y cells, an effect that was significantly different 
from control at concentrations of 1M CBZ and above(p<0.05 at 30M and 100µM 
CBZ) . Subsequent exposure of CBZ-treated cells to 100 µM H2O2 for 4 hours enhanced 
its action on GSH/GSSG ratio with significant differences from control observed at all 
CBZ pre-treatment concentrations (p<0.05 at 1µM to 100µM CBZ; figure 3.12A). 
Four hours exposure to VPA (0-1000 M) was associated with a concentration-
dependent decrease in GSH/GSSG ratio in SH-SY5Y cells, an effect that was 
significantly different from control at concentrations of 30 M VPA and above (p<0.01 
at 30M to 1000µM VPA). Subsequent exposure of VPA-treated cells to 100 µM H2O2 
for 4 hours appeared to augment its effect on GSH/GSSG ratio but the pattern of 
statistical significance was unchanged (p<0.01 at 10M to 1000 M VPA; figure 
3.12B).  
Four hours exposure to LEV (0-300 M) was associated with a concentration-dependent 
decrease in GSH/GSSG ratio in SH-SY5Y cells, an effect that was statistically 
significant at concentrations of 10 M LEV and above (p<0.01 at 10M to 300M 
LEV). Subsequent exposure of LEV-treated cells to 100 µM H2O2 for 4 hours enhanced 
132 
 
its action on GSH/GSSG ratio with significant differences from control observed at LEV 
pre-treatment concentrations of 10 M and above (p<0.01 at 10M to 300M LEV; 
figure 3.12C).   
Four hours exposure to LTG (0-100 M) was associated with a concentration-dependent 
decrease in GSH/GSSG ratio in SH-SY5Y cells, an effect that was significantly different 
from control at concentrations of 10µM LTG and above (p<0.05 at 10M; p<0.01 at 
30M and 100M LTG). Subsequent exposure of LTG-treated cells to 100 µM H2O2 for 
4 hours enhanced its effect on GSH/GSSG ratio, with statistical significance observed at 
LTG pre-treatment concentrations of 10M and above (p<0.05 at 10M; p<0.01 at 
30M and 100M LTG; figure 3.12D). 
3.3.10 Effect of CBZ, VPA, LEV, and LTG and H2O2 on GSH/GSSG ratio after 24 
hours exposure in SH-SY5Y cells 
Twenty four hours exposure to CBZ (0-100 M) was associated with a concentration-
dependent decrease in GSH/GSSG ratio in SH-SY5Y cells, an effect that was 
significantly different from control at concentrations of 1M CBZ and above(p<0.01 at 
1M to 100µM CBZ) . Subsequent exposure of CBZ-treated cells to 100 µM H2O2 for 4 
hours enhanced its action on GSH/GSSG ratio with significant differences from control 
observed at all CBZ pre-treatment concentrations (p<0.01 at 1µM to 100µM CBZ; 
figure 3.13A). 
Twenty four hours exposure to VPA (0-1000 M) was associated with a concentration-
dependent decrease in GSH/GSSG ratio in SH-SY5Y cells, an effect that was 
significantly different from control at concentrations of 10 M VPA and above (p<0.01 
at 10M to 1000µM VPA). Subsequent exposure of VPA-treated cells to 100 µM H2O2 
133 
 
for 4 hours appeared to augment its effect on GSH/GSSG ratio but the pattern of 
statistical significance was unchanged (p<0.01 at 10M to 1000 M VPA; figure 
3.13B).  
Twenty four hours exposure to LEV (0-300 M) was associated with a concentration-
dependent decrease in GSH/GSSG ratio in SH-SY5Y cells, an effect that was 
statistically significant at concentrations of 10M LEV and above (p<0.05 at 10M and 
30M LEV; p<0.01 at 100M and 300M LEV). Subsequent exposure of LEV-treated 
cells to 100 µM H2O2 for 4 hours enhanced its action on GSH/GSSG ratio with 
significant differences from control observed at LEV pre-treatment concentrations of 10 
M and above (p<0.05 at 3M LTG; p<0.01 at 10M to 300M LEV; figure 3.13C).   
Twenty four hours exposure to LTG (0-100 M) was associated with a concentration-
dependent decrease in GSH/GSSG ratio in SH-SY5Y cells, an effect that was 
significantly different from control at concentrations of 10µM LTG and above (p<0.01 
at 10M to100M LTG). Subsequent exposure of LTG-treated cells to 100 µM H2O2 for 
4 hours enhanced its effect on GSH/GSSG ratio, with statistical significance observed at 
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Figure 3.11 Effect of 1 hour exposure to (A) carbamazepine (CBZ; 0-100 µM), (B) 
sodium valproate (VPA; 0-1000 µM), (C) levetiracetam (LEV; 0-300 µM) and (D) 
lamotrigine (LTG; 0-100 M), with and without subsequent exposure to 100 M H2O2 
for 4 hours, on GSH/GSSG ratio in SH-SY5Y cells. Results (n=3) are expressed as the 
mean (± SD) GSH/GSSG ratio and statistical significance was determined by one-way 
ANOVA with Dunnett correction for multiple comparisons (*p<0.05; **p<0.001) with 
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Figure 3.12 Effect of 4 hours exposure to (A) carbamazepine (CBZ; 0-100 µM), (B) 
sodium valproate (VPA; 0-1000 µM), (C) levetiracetam (LEV; 0-300 µM) and (D) 
lamotrigine (LTG; 0-100 M), with and without subsequent exposure to 100 M H2O2 
for 4 hours, on GSH/GSSG ratio in SH-SY5Y cells. Results (n=3) are expressed as the 
mean (± SD) GSH/GSSG ratio and statistical significance was determined by one-way 
ANOVA with Dunnett correction for multiple comparisons (*p<0.05; **p<0.001) with 
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Figure 3.13 Effect of 24 hours exposure to (A) carbamazepine (CBZ; 0-100 µM), (B) 
sodium valproate (VPA; 0-1000 µM), (C) levetiracetam (LEV; 0-300 µM) and (D) 
lamotrigine (LTG; 0-100 M), with and without subsequent exposure to 100 M H2O2 
for 4 hours, on GSH/GSSG ratio in SH-SY5Y cells. Results (n=3) are expressed as the 
mean (± SD) GSH/GSSG ratio and statistical significance was determined by one-way 
ANOVA with Dunnett correction for multiple comparisons (*p<0.05; **p<0.001) with 
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3.3.11 Effect of selected AEDs on MDA concentrations in SH-SY5Y cells following 
4-hour pre-treatment with H2O2  
Four hour exposure of SH-SY5Y cells to H2O2 (0-1000 M) was associated with a 
concentration-related increase in MDA levels that was significantly different from 
control at 100M H2O2 and above (p<0.05 at 100 M H2O2; p<0.001 at 300 and 1000 
M H2O2; figure 3.14). Subsequent 1 hour exposures to either 10 M CBZ or 100 M 
VPA enhanced the effect of H2O2, with statistical significance observed in the CBZ 
group at H2O2 concentrations of 30 M and above (p<0.05 at 30 and 100 M H2O2; 
p<0.001 at 300 and 1000 M H2O2; figure 3.14) and, likewise, in the VPA group at 
H2O2 concentrations of 30 M and above (p<0.05 at 30 M H2O2; p<0.001 at 100 to 
1000 M H2O2; figure 3.14). 
Four hour exposure of SH-SY5Y cells to H2O2 (0-1000 M) was associated with a 
concentration-related increase in MDA levels that was significantly different from 
control at 100M H2O2 and above (p<0.05 at 100 and 300 M H2O2; p<0.001 at 1000 
M H2O2; figure 3.15). Subsequent 1 hour exposures to either 30 M LEV or 10 M 
LTG enhanced the effect of H2O2, with statistical significance observed in the LEV 
group at H2O2 concentrations of 30 M and above (p<0.05 at 30 to 300 M H2O2; 
p<0.001 at 1000 M H2O2; figure 3.15) and, likewise, in the LTG group at H2O2 
concentrations of 30 M and above (p<0.05 at 30 M H2O2; p<0.001 at 100 to 1000 M 







Figure 3.14 Effect of 4 hour exposure to 0-1000 M H2O2, with or without subsequent 
1 hour exposures to either 10 M carbamazepine (CBZ; red bars) or 100 M sodium 
valproate (VPA; green bars), on malondialdehyde (MDA) concentration in SH-SY5Y 
cells. Results (n=3) are expressed as the mean (± SD) MDA concentration (in nmol/mg 
protein) and statistical significance was determined by one-way ANOVA with Dunnett 
correction for multiple comparisons (*p<0.05; **p<0.001) with control (0µM) within 
each data series. 
 
Figure 3.15 Effect of 4 hour exposure to 0-1000 M H2O2, with or without subsequent 
1 hour exposures to either 30 M levetiracetam (LEV; red bars) or 10 M lamotrigine 
(LTG; green bars), on malondialdehyde (MDA) concentration in SH-SY5Y cells. 
Results (n=3) are expressed as the mean (± SD) MDA concentrations (in nmol/mg 
protein) and statistical significance was determined by one-way ANOVA with Dunnett 
correction for multiple comparisons (*p<0.05; **p<0.001) with control (0µM) within 
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3.3.12 Effect of H2O2 and fixed concentrations of CBZ and VPA on SOD activity 
after 4 hours exposure in SH-SY5Y cells 
Four hour exposure of SH-SY5Y cells to H2O2 (0-1000 M) was associated with a 
concentration-related decrease in SOD activity that was significantly different from 
control at 100M H2O2 and above (p<0.05 at 100 M H2O2; p<0.001 at 300 and 1000 
M H2O2; figure 3.16). Subsequent 1 hour exposures to either 10 M CBZ or 100 M 
VPA enhanced the effect of H2O2, with statistical significance observed in the CBZ 
group at H2O2 concentrations of 30 M and above (p<0.001 at 10 to 1000 M H2O2; 
figure 3.16) and, likewise, in the VPA group at H2O2 concentrations of 100 M and 
above (p<0.001 at 100 to 1000 M H2O2; figure 3.16). 
Four hour exposure of SH-SY5Y cells to H2O2 (0-1000 M) was associated with a 
concentration-related decrease in SOD activity that was significantly different from 
control at 100M H2O2 and above (p<0.05 at 100 and 300 M H2O2; p<0.001 at 1000 
M H2O2; figure 3.17). Subsequent 1 hour exposures to either 30 M LTG or 300 M 
LEV enhanced the effect of H2O2, with statistical significance observed in the LEV 
group at H2O2 concentrations of 300 M and above (p<0.001 at 300M and above H2O2; 
figure 3.17) and, likewise, in the LTG group at H2O2 concentrations of 30 M and above 









Figure 3.16 Effect of 4 hours exposure to 0-1000 M H2O2, with or without subsequent 
1 hour exposures to either 10 M carbamazepine (CBZ; red bars) or 100 M sodium 
valproate (VPA; green bars), on SOD activity in SH-SY5Y cells. Results (n=3) are 
expressed as the mean (± SD) SOD activity (U/mg protein) and statistical significance 
was determined by one-way ANOVA with Dunnett correction for multiple comparisons 
(*p<0.05; **p<0.001) with control (0µM) within each data series. 
 
 
Figure 3.17 Effect of 4 hour exposure to 0-1000 M H2O2, with or without subsequent 
1 hour exposures to either 30 M levetiracetam (LEV; red bars) or 10 M lamotrigine 
(LTG; green bars), on SOD activity in SH-SY5Y cells. Results (n=3) are expressed as 
the mean (± SD) SOD activity (U/mg protein) and statistical significance was 
determined by one-way ANOVA with Dunnett correction for multiple comparisons 
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3.3.13 Effect of H2O2 and fixed concentrations of CBZ and VPA on GSH/GSSG 
ratio after 4 hours exposure in SH-SY5Y cells 
Four hour exposure of SH-SY5Y cells to H2O2 (0-1000 M) was associated with a 
concentration-related decrease in GSH/GSSG ratio that was significantly different from 
control at 100M H2O2 and above (p<0.05 at 10 M H2O2; p<0.001 at 30 and 1000 M 
H2O2; figure 3.18). Subsequent 1 hour exposures to either 10 M CBZ or 100 M VPA 
enhanced the effect of H2O2, with statistical significance observed in the CBZ group at 
H2O2 concentrations of 10 M and above (p<0.001 at 10 to 1000 M H2O2; figure 3.18) 
and, likewise, in the VPA group at H2O2 concentrations of 100 M and above (p<0.001 
at 10 to 1000 M H2O2; figure 3.18). 
Four hour exposure of SH-SY5Y cells to H2O2 (0-1000 M) was associated with a 
concentration-related decrease in GSH/GSSG ratio that was significantly different from 
control at 100M H2O2 and above (p<0.05 at 100 and 300 M H2O2; p<0.001 at 1000 
M H2O2; figure 3.19). Subsequent 1 hour exposures to either 30 M LTG or 300 M 
LEV enhanced the effect of H2O2, with statistical significance observed in the LEV 
group at H2O2 concentrations of 10 M and above (p<0.001 at 10M and above H2O2; 
figure 3.19) and, likewise, in the LTG group at H2O2 concentrations of 30 M and above 









Figure 3.18 Effect of 4 hours exposure to 0-1000 M H2O2, with or without subsequent 
1 hour exposures to either 10 M carbamazepine (CBZ; red bars) or 100 M sodium 
valproate (VPA; green bars), on GSH/GSSG ratio in SH-SY5Y cells. Results (n=3) are 
expressed as the mean (± SD) GSH/GSSG ratio and statistical significance was 
determined by one-way ANOVA with Dunnett correction for multiple comparisons 
(*p<0.05; **p<0.001) with control (0µM) within each data series. 
 
Figure 3.19 Effect of 4 hour exposure to 0-1000 M H2O2, with or without subsequent 
1 hour exposures to either 30 M levetiracetam (LEV; red bars) or 10 M lamotrigine 
(LTG; green bars), on GSH/GSSG ratio in SH-SY5Y cells. Results (n=3) are expressed 
as the mean (± SD) GSH/GSSG ratio and statistical significance was determined by 
one-way ANOVA with Dunnett correction for multiple comparisons (*p<0.05; 
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Oxidative damage to the brain can be initiated by exposure to specific chemicals and is 
associated with a number of CNS diseases. It has been reported that the increase in 
ROS and/or RNS or any drop in basal antioxidant activity may increase the frequency 
of seizures (Willmore et al., 1981; Jesberger et al., 1991). An increase in free radicals 
may similarly cause neuronal damage as a result of membrane lipid peroxidation, 
decreased GSH levels and a reduction in the expression and/or activity of antioxidant 
enzymes.  
The current study revealed that incubation of SH-SY5Y cells with different 
concentrations of CBZ, VPA, LEV and LTG for 1, 4, and 24 hours had a negative 
effect on cell viability and on the pro-oxidant/antioxidant balance. Subsequent addition 
of 100 µM H2O2 for 4 hours worsened this oxidative damage. Moreover, exposure of 
SH-SY5Y cells to various concentrations of H2O2 caused expected oxidative stress 
changes which were exacerbated following subsequent exposure to fixed concentrations 
of the selected AEDs. 
Oxidative stress has been defined as an imbalance of oxidantsand antioxidants in favor 
of the oxidants, potentially leading tocell damage (van der Schalie et al., 2004; Li et al., 
2010a). In order to cope with the oxidative damage, organisms have evolved multiple 
systems of antioxidant defense. Endogenous enzymatic and nonenzymatic antioxidants 
are essential for the conversion of ROS to harmless substances and for maintenance of 
cellular metabolism and function (Zhang et al., 2008). The brainis a target for different 
stressors because of its high sensitiveness to stress-induced degenerative conditions (Li 
et al., 2010). 
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Oxidative stress has been suggested as a possible mechanism implicated in the 
pathogenesis of epilepsy (Chang and Yu, 2010). Various clinical and experimental 
studies have reported that homeostasis of trace elements (i.e. zinc and copper), 
membrane lipid peroxidation, and antioxidants are critical for brain function, and are 
directly or indirectly involved in the pathophysiology of neuronal excitability, neuronal 
excitotoxicity, seizure recurrence and in the resistance of seizures to treatment with 
commonly used AEDs (Hamed et al., 2004). In addition, AEDs themselves can alter the 
homeostasis of trace elements and critically increase by-products of MDA at the 
expense of protective antioxidant mechanisms, which might lead to an increase in the 
resistance to drugs, seizure recurrence and unwanted side effects of treatment (Hamed 
et al., 2004).  
Potential benefits of antioxidants, used as add-on therapy, were extensively studied in 
different in vitro or in vivo animal models of seizures and epilepsy and in patients with 
epilepsy (Martinc et al., 2014). It is found that endogenous antioxidants (α-lipoic acid, 
melatonin, and ubiquinone) play an important role in decreasing nitrite content and lipid 
peroxidation level, while increased SOD, CAT, and GPx activities, direct scavenging of 
hydroxyl and other free radicals, by inhibiting NO synthase (Martinc et al., 2014). 
Further support for the role of free radicals in seizures came from the successful use of 
exogenously administered antioxidants, as vitamin C and vitamin E, to protect the brain 
against seizure-induced damage (Ueda et al., 1997; Murashima 1998; Barros et al., 
2007; Santos et al., 2009). 
The current study confirmed that exposure of cells to different concentrations of 
selected AEDs resulted in a time and concentration-dependent decrease in viability. 
Therapeutic concentrations which are considered to be 15-50µM for CBZ (Ching, 
2016), 350-700µM for VPA (Brunton et al., 2011), 15-40µM for LTG (Wolf, 1992) and 
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45-180M for LEV (Martinc et al., 2012) were included in this study. The average 
undifferentiated SH-SY5Y cells viability was 65-70% at the selected AEDs therapeutic 
concentrations. Comparison of the findings with those of other studies confirms that 
CBZ (2.5µM, 5µM, and 10µM) and valproic acid (1.25mM, 2.5mM, and 5mM) 
exposure to SW480 colon cancer cell lines for 24, 48, and 72 days decreased cells 
viability in a time-and-concentration dependent manner and less than 40% at their 
highest concentrations (Akbarzadeh et al., 2016). This also accords with earlier 
observations, which showed that CBZ decreased astrocyte cell viability by 50% at 
850µM after 48 hours exposure (Pavone and Cardile. 2003). These results are in 
agreement with (Stockhausen et al., 2005) findings which showed   that SH-SY5Y cells 
exposure to 1-4mM VPA resulted in decteasing cells viability by less than 50% at its 
highest concentration.  
Another important finding was that LEV and LTG decreased the undifferentiated SH-
SY5Y cells viability in a-time and-concentration dependent manner. These results did 
not match those observed in earlier studies which indicated a slight decrease, i.e. about 
10%, in astrocyte cells viability after exposure to 300µM LEV and 100µM for 48 hours 
(Pavone and Cardile, 2003). A possible explanation for this might be that astrocyte cells 
are more resistant to apoptotic damage than the undifferentiated SH-SY5Y cells 
(Yasmeen et al., 2015). To the best of our knowledge, there was no previous data about 
the LTG and LEV viability test done on SH-SY5Y cells.  
This study also showed that exposure of undifferentiated SH-SY5Y cells to different 
concentrations of CBZ, VPA, LEV and LTG for 1, 4 and 24 hours was associated with 
oxidative stress changes in terms of increased MDA concentration, decreased SOD 
activity, and decreased GSH/GSSG ratio in a time-and-concentration dependent-
manner. These changes were exacerbated by further exposure to H2O2 for 4 hours. 
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These findings corroborate the ideas of (Li et al., 2010), who suggested the antioxidant 
defense system in brain homogenates was affected under the oxidative stress induced by 
CBZ. In antioxidant enzymes, SOD is always considered as the first line of defense 
against ROS due to the inhibitory effects on oxyradical formation (Firat et al., 2009). 
They found that SOD activities were strongly inhibited along with increased CBZ 
concentration and prolonged incubation period, which could be due to the flux of 
superoxide radicals, resulting in H2O2 increase in the cell (Zhang et al., 2008). These 
results reflect those of (Hamed et al., 2004; Shin et al., 2011) who also found that in 
CBZ treated patients there was a significant increase in MDA level and a decrease in 
total antioxidant activity. This study supports evidence from previous observations 
indicate that VPA increases plasma and hepatic levels of 15-F2-IsoP, TBARs level, and 
lipid hydroperoxide , a marker for oxidative stress, in rats (Vincent et al., 2005). 
Similarly, in another study it has been suggested that patients on VPA therapy may be 
at risk of developing oxidative stress resulting in DNA oxidation as shown by the 
remarkably high 8- hydroxydeoxyguanosine (8-OHdG) levels, as a marker of oxidative 
stress, evaluated in their sera (Schulpis et al., 2006). In another study, these results are 
in agreement with (Cengis et al., 2000) findings which evaluated the effects of VPA 
and CBZ therapy on erythrocyte GSH, GSH-Px, SOD, and lipid peroxidation in 
epileptic children. They found that GSH levels were reduced and may result in an 
increase of organic hydroperoxides (Cengiz et al., 2000). 
The pro-oxidant effects of the newer AEDs, LEV and LTG, are less widely reported. To 
the best of our knowledge, there is just one previous report that investigated the effect 
of LEV on oxidative stress markers. LEV was shown to cause oxidative stress in 
epilepsy patients by increasing urinary 15F-2t-isoprostane level which is a highly 
reliable marker of oxidative damage (Ozden et al., 2010). Likewise, these results 
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supports evidence from previous observations by (Varoglu et al., 2010) which 
suggested an increase in serum 8-OHdG by 3 fold with LEV, and by 4 fold with CBZ 
and VPA treatment for 2 months. In respect of LTG, there is again, to the best of our 
knowledge, just one report that assessed the effect of LTG on oxidative insults. It was 
found that LTG increased MDA concentration 2-fold and decreased catalase activity 3-
fold in comparison to control, using a rat liver tissue model (Poorrostami A. et al., 
2014). The mechanism behind LTG-induced liver injury is not clearly explained. Some 
reports have suggested this may be caused by an immune reaction to the arene oxide 
metabolite of LTG, leading to an inflammatory process and oxidative stress (Mecarelli 
et al., 2005).  Another important finding was that incubation of SH-SY5Y cells with 
fixed concentrations of AEDs exacerbated the expected oxidative stress changes H2O2 . 
These results support previous findings in present study which proved the pro-oxidant 
behaveour of the selected AEDs. 
The methods have been used in this experiment are considered reliable as they have 
been used by many researchers previously. SH-SY5Y cells are widely used as a suitable 
model to investigate neurononal disorders and to induce oxidative stress (Akki et al., 
2018). Nevertheless, the findings of the current study are limited because of low n-
numbers, lack of independent validation of findings, and potentially by the use of cell 
lines at a variable passage number, particularly with respect to comparison between 
these results and those in previous chapters. It is well known that passage number has 
an impact on growth rates and on physiological and chemical characteristics of 
immortalised cell lines. It should also be recognized that a weakness of in vitro cell 
cultures is that they are studied in isolation and in the absence of their normal 
environment, which includes interactions with other cell types that might be critical to 
the process being tested. In such cases, in vivo testing is often preferred because it is 
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better suited for observing the overall effects of experiment conditions or an 
intervention on a living subject.  
3.4.1 Conclusions  
In conclusion, the current study revealed negative effects of the selected AEDs on the 
pro-oxidant / anti-oxidant balance which were both time- and concentration-dependent 
and which were excacerbated by subsequent exposure of cells to H2O2. The reverse was 
also true, in that the expected expected oxidative stress observed with H2O2 was 
boosted, rather than attenuated, by subsequent exposure to AEDs. This pro-oxidant 
behaviour of AEDs that was observed throughout these experiments was unexpected 
but may be related to covalent binding of their toxic metabolites, resulting in cell stress 
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Oxidative damage and mitochondrial dysfunction are currently accepted as key 
hallmarks of classic inflammatory, degenerative, systemic, and neuronal diseases (Floyd 
and Carney, 1992; Valko et al., 2006). ROS perform diverse physiological functions 
and play important roles in host defence, cell signalling, regulation of gene expression, 
and cell differentiation. ROS levels are tightly regulated in the CNS because the brain is 
particularly sensitive to oxidative stress (Halliwell and Gutteridge, 1985; Valko et al., 
2004). When CNS ROS levels increase as a result of pathological conditions, the 
cellular antioxidant capacity is overwhelmed and this results in oxidative stress and 
damage to essential cellular structures (Wood-Kaczmar et al., 2006; Henchcliffe and 
Beal., 2008). To counteract the detrimental effects of ROS and to restore the delicate 
redox balance in the CNS, cells are equipped with endogenous antioxidant defence 
mechanisms that comprise several antioxidant enzymes (Aparicio et al., 2015).  
Antioxidants can be divided into direct and indirect varieties depending on the 
mechanism by which protection against oxidative stress is delivered (Aparicio et al., 
2015). Direct antioxidants modify reactive oxygen and nitrogen radicals by donating 
hydrogen ions or electrons, while indirect anti-oxidants exert effects via upregulation of 
phase II detoxification and anti-oxidant enzymes through activation of Nrf2 (Nguyen et 
al., 2003; Nguyen et al., 2004).  
Nrf2 has been described as the master regulator of the anti-oxidant response. Under 
homeostatic conditions, Nrf2 transcription is repressed by its negative regulator, Kelch-
like ECH-associated protein 1 (Keap1) (Itoh et al, 2003). Following exposure to ROS, 
Nrf2 dissociates from cytosolic Keap1 and translocates to the nucleus. It subsequently 
binds to antioxidant response elements (ARE) in the promoter region of hundreds of 
genes that are involved in antioxidant protection and detoxification, including those 
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encoding heme oxygenase-1 (HO-1), NAD(P)H quinone oxidoreductase 1 (NQO-1), 
microsomal glutathione S-transferase (mGST), glutathione peroxidase (Gpx), and 
superoxide dismutase (SOD) (Li et al., 1992; Long et al., 2000). 
Many studies have demonstrated that activation of the Nrf2/ARE pathway occurs in 
response to an excess of ROS such as H2O2 (Purdom-Dickinson et al., 2007), 
inflammation and infection through activation of Toll-like receptors (TLRs) by LPS 
(Vijayan et al., 2011; Birgisdottir et al., 2013), and activation of M1 neuronal receptors 
by cholinomimetic compounds such as carbachol and pilocarpine (Espada et al., 2009). 
Further evidence suggests that the Nrf2-Keap1 system contributes to protection against 
various disorders, such as cancer, liver toxicity and inflammation (Fainstein 2007), and 
has relevance in the pathophysiology of various neurological conditions, such as 
Alzheimer’s disease (Yehiely et al., 1997), Parkinson’s disease (Clements et al., 2006), 
multiple sclerosis (Schreibelt et al., 2007), amyotrophic lateral sclerosis (Pehar et al., 
2005), Huntington’s disease (Van Roon-Mom  et al., 2008), and epilepsy (Kraft et al., 
2006). 
Currently, it is believed that sustained neuronal hyperactivity and seizures can lead to 
neuronal injury and death as a result of underlying biochemical mechanisms, including 
the formation of excessive ROS (Mariani et al., 2005), and subsequently induced 
abnormal structural alterations to cellular proteins, membrane lipids, DNA, and RNA. 
A strong line of evidence supports the hypothesis that oxidative stress is an underlying 
mechanism in the initiation and progression of epilepsy and also contributes to neuronal 
degeneration in the epileptic focus (Shin et al., 2011). Nrf2 and its related gene cascade, 
which includes as HO-1 and NQO-1, have been suggested as neuroprotective 
therapeutic strategies for the treatment of epilepsy (Aparicio et al., 2015). 
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The aim of treatment of epilepsy is to control seizures with the most appropriate AED 
without causing any significant side effects. The commonly used AEDs such as CBZ, 
VPA, LTG, and LEV are intended to provide symptomatic relief by inhibiting seizure 
generation by targeting neuronal hyper-excitability. However, it is unclear whether they 
are able to modulate or prevent the underlying epileptogenic process in high risk 
patients. Currently, there is no available treatment known to inhibit the process of 
epileptogenesis (Choi 1993; Aparicio et al, 2015). 
Until now, the majority of research exploring the relationship between AEDs and 
oxidative stress has been either clinical or has involved in vivo models of epilepsy 
(Cengiz et al., 2000; Arora et al., 2010). One of the few in vitro studies to be published 
used rat primary astrocyte cell cultures which have higher concentration of reduced 
glutathione and higher levels of antioxidant enzymes than cells from a neuronal lineage 
(Cardile et al., 2000).  
4.1.1 Aims and objectives 
The present study aimed to: 
1- Investigate the effects of LPS, H2O2 and pilocarpine on Nrf2, HO-1, and NQO-1 
gene expression as a marker of phase II detoxification antioxidant response in 
the SH-SY5Y neuroblastoma cell line.   
2- Choose optimum conditions (inducer, concentration of inducer, duration of 
exposure) for induction of oxidative stress in SH-SY5Y cells to be employed in 
further investigations. 
3- Explore the effects of carbamazepine (CBZ), valproic acid (VPA), levetiracetam 
(LEV), and lamotrigine (LTG) on the expression of Nrf2, HO-1 and NQO-1 
genes in the SH-SY5Y cell line.   
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4.2 Materials and methods 
4.2.1 Chemicals 
Reverse transcription kit, trizole reagent solution for RNA extraction, FAM labelled 
Nrf2, HO-1, NQO-1, and VIC labelled GAPDH Taqman gene expression assays, 
Taqman gene expression master mix, isopropanol (IPA), chloroform, and ethyl alcohol  
were purchased from Thermo Fisher Scientific, Loughborough, UK. Other chemicals 
were sourced as described in chapter 2, section 2.2.1 and chapter 3, section 3.2.1. 
4.2.2 Cell culture 
SH-SY5Y cells were cultured as described in chapter 2, section 2.2.2. 
4.2.3 Induction of oxidative stress 
SH-SY5Y cells were seeded in 12-well plates at a density of 4 x 104 cells / well in 1ml 
culture medium and placed in an incubator containing humidified 95% air and 5% CO2 
at 37oC for 3 days until they reached 80-90% confluence. Thereafter, the existing 
medium was aspirated and the cells treated with H2O2 (0, 10, 30, 100, 300 and 
1000µM), pilocarpine (0, 1, 3, 10, 30 and 100µM) or LPS (0, 1, 3, 10, 30 and 
100µg/ml) in serum free medium for 1, 4 or 24 hours. In each case, activation of the 
phase II detoxification antioxidant response was determined by fold-changes in the 
expression of Nrf2, HO-1 and NQO-1 genes by reverse-transcription polymerase chain 
reaction (RT-PCR), as described below. 
4.2.4 Cell treatment with AEDs 
SH-SY5Y cells were seeded in 12-well plates at a seeding density of 4 x 104 cells / well 
in 1 ml culture medium and placed in an incubator containing humidified 95% air and 
5% CO2 at 37
oC for 2-3 days until they reached 80-90% confluence. Then, cells were 
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treated with either CBZ (0, 10, 30, 100, 300 and 1000µM), VPA (0, 10, 30, 100, 300 
and 1000µM), LTG (0, 1, 3, 10, 30 and 100µM) or LEV (0, 3, 10, 30, 100 and 300µM) 
for 24 hours. VPA and LTG were dissolved in serum-free medium (SFM; see chapter 3, 
section 3.2.3) whereas CBZ and LEV were dissolved in SFM containing 0.2% DMSO. 
A further batch of SH-SY5Y cells was treated with the same AEDs at the same range of 
concentrations but was subsequently exposed to 100µM H2O2 for an additional 4 hours. 
Following treatment with AEDs (with or without additional exposure to H2O2), total 
mRNA was isolated and the expression of Nrf2, HO-1 and NQO-1 quantified by RT-
PCR.  
4.2.5 Isolation of mRNA  
After aspirating the medium, SH-SY5Y cells were washed twice with 1ml PBS. Cells 
were lysed by adding 500μl of trizole reagent to each well. The lysates were transferred 
to autoclaved Eppendorf tubes, mixed with 100μl of 100% chloroform, shaken 
vigorously for 15 seconds to obtain a homogenised mixture, and then incubated at room 
temperature for 10 minutes. Thereafter, lysates were centrifuged at 14000xg for 15 
minutes at 4°C which resulted in separation into three distinct phases; a lower, red-
coloured phenol-chloroform phase, an interphase (containing DNA), and a colourless 
upper aqueous phase (containing RNA). The aqueous phase containing RNA was 
transferred carefully to a fresh Eppendorf tube and the remaining solution discarded. 
Thereafter, 250μl of 100% isopropanol was added to each tube and samples were mixed 
by vortexing, incubated at room temperature for 10 minutes, and centrifuged at 
14000xgfor 10 minutes at 4°C. This caused the RNA to precipitate in the form of a 
white pellet at the bottom of the tube. The supernatant was carefully aspirated without 
disturbing pellet, 100μl of 75% ethanol was added and all samples again centrifuged at 
14000 xg for 10 minutes at 4°C. Thereafter, the supernatant was again discarded 
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without disturbing the resulting pellet. The RNA pellet was then air-dried for 15 
minutes to allow evaporation of any remaining ethanol, 15μl of RNAase/DNAase free 
water was added, and samples were mixed gently by pipetting up and down. The quality 
and quantity of extracted RNA were determined using a Nanodrop 8000 
Spectrophotometer (Thermo Fisher Scientific, TX, USA). All samples were stored at -
20°C until required for reverse transcription. 
4.2.6 Reverse transcription of total RNA 
A volume equivalent to 2μg of total RNA for each sample was added to reverse 
transcription reagents as shown in table 2.1. 
Component Volume in 20μl reaction Final concentration 
DEPC-treated water Up to 20μl - 
10X RT buffer 2.0μl 1X 
25mM MgCl2 1.4μl 1.75mM 
10mM dNTP mix (2.5mM each) 4.0μl 0.5mM each 
RNase inhibitor (20U/μL) 1.0μl 1.0U/μl 
MultiScribe™ RT (50U/μL) 1.0μl 2.5U/μl 
Random hexamers (50μM) 1.0μl 2.5μM 
Template RNA Dependent on concentration   2μg per reaction  
 
Table 4.1 Reverse transcription reaction components. DEPC= diethyl pyrocarbonate, 
RT=reverse transcriptase, MgCl2=magnesium chloride, dNTP=  deoxyribonucleotide 
triphosphate. 
Samples were mixed gently and then placed on the heating block of a 96-well Veriti 
thermal cycler (Applied Biosystems, Warrington, UK). The thermal cycler was 
programmed to the following reaction cycling parameters; 25oC for 10 mins, 37oC for 30 
mins, 95oC for 5 mins, and soak at 4oC indefinitely. On completion of the reaction 
cycle, samples were again mixed by vortex and briefly centrifuged at high speed for a 
few seconds. Thereafter, the quality and quantity of the resulting cDNA was determined 
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using a Nanodrop 8000 Spectrophotometer and  cDNA normalised to a concentration of 
20ng/μl by dilution with RNAase/DNAase free water. 
4.2.7 Gene expression by real-time PCR  
Gene expression analysis was carried out using a 7900HT Fast Real-Time PCR system 
(Applied Biosystems, CA, USA). Taqman gene expression assays (FAM-labelled target 
gene; VIC-labelled endogenous control) and Taqman gene expression master mix were 
used to perform duplex real-time PCR reactions to assess the levels of mRNA of target 
genes relative to mRNA levels of GAPDH (housekeeping gene). Composition of the 
real-time PCR reaction mix is described in Table 2.3. All reactions were performed in a 
384-well PCR plate (Thermo Fisher Scientific, TX, USA) using the cycling parameters 
outlined in in section 4.2.6 above. After cycling, plates were sealed, mixed by vortex for 
2 minutes, centrifuged at 2000xg for 5 minutes at 40C, and finally loaded into the 
Taqman Real Time PCR machine. mRNA expression was calculated using the 
comparative CT method according to the manufacturer’s protocol. Fold-changes in 
expression of target genes relative to the housekeeping gene was reported as 2^(-
ΔΔCT). 
Table 4.2 Reaction components for real-time PCR 
 
 
For each sample Volume per reaction (µl) 
TaqMan Gene Expression Assay (target) 
(20X FAM dye-labelled) 
1 
TaqMan Gene Expression Assay (housekeeping) 
(20X VIC dye-labelled, primer-limited) 
1 
TaqMan Gene Expression Master Mix (2X) 10 
RNAse-free water 4 




4.2.8 Statistical analysis 
All experiments were performed using two technical replicates (i.e. analyses of all 
samples performed in duplicate) and four biological replicates (i.e. n=4 per group). 
Results were reported as the mean (± SD) 2^(-∆∆CT) Statistical comparisons were 
undertaken using either one way or two way ANOVA as appropriate, and with a 
Dunnett correction for multiple comparisons, using Stats Direct software version 2.7.9. 
Differences were considered statistically significant at p≤0.05. 
4.3 Results 
4.3.1 Effect of H2O2, pilocarpine, and LPS on selected gene expression in SH-SY5Y 
cells 
Cells exposed to H2O2 (0-1000µM) for 1, 4 and 24 hours showed an increase in gene 
expression in a time- and concentration dependent-manner. At 1 hour, Nrf2 expression 
was maximally increased by 7.2 fold in comparison to that of GAPDH (housekeeping 
gene) following exposure to 1000M H2O2 and was statistically significant (p<0.001) at 
H2O2 concentrations of both 300M and 1000µM in comparison to control (0µM; figure 
4.1). At 4 and 24 hours, the maximal increases in Nrf2 expression were 11.9-fold and 
15.2-fold, respectively, after exposure to 1000M H2O2 and were significant (p<0.001) 
at all H2O2 concentrations above 30M when compared with control (0µM; figure 4.1). 
At 1, 4 and 24 hours, HO-1 expression was maximally increased to 3.7-fold, 5.7-fold, 
and 12.6-fold, relative to the expression of GAPDH, following exposure to 1000M 
H2O2 and was statistically significant (p<0.05) at H2O2 concentrations of 300M and 
1000µM compared to control  (0µM; figure 4.2). At 1 hour, NQO-1 expression was 
maximally increased to 3.2-fold relative to GAPDH following exposure to 1000M 
H2O2 and was statistically significant (p<0.05) at 1000M H2O2 when compared to 
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control (0µM; figure 4.3). At 4 and 24 hours, the maximal increases in NQO-1 
expression were 2.9-fold and 16.1-fold, respectively, after 1000M H2O2 exposure and 
was statistically significant at all concentrations above 100M (p<0.05 at 300M H2O2; 
p<0.001 at 1000M H2O2) in comparison to NQO-1 expression in control (0µM) 
samples. 
Cells exposed to pilocarpine (0-100µM) for 1, 4 and 24 hours also showed time- and 
concentration-dependent increases in gene expression. At 1, 4, and 24 hours, Nrf2 
expression was increased by a factor of 1.4, 1.2, and 1.9, respectively, following 
exposure to 100M pilocarpine but the elevation in expression was only statistically 
significant (p<0.05) in those cells exposed to 100M pilocarpine for 24 hours when 
compared to the corresponding controls (0µM; figure 4.4). At 1 hour exposure to the 
highest concentration of pilocarpine (i.e. 100M), HO-1 expression relative to that of 
GAPDH was unchanged (1.0-fold), while at 4 and 24 hours, expression was elevated by 
a factor of 1.5 and 2.2, respectively (figure 4.5). When compared to control samples 
(0M), the effects of pilocarpine on HO-1 expression were only statistically significant 
(p<0.05) following 24 hour exposure to pilocarpine concentrations of 30M and 100M 
(figure 4.5). At 1, 4 and 24 hours, NQO-1 expression relative to that of GAPDH was 
increased by 1.9-fold, 2.0-fold and 2.2-fold, respectively, after exposure to 100M 
pilocarpine, achieving statistical significance (p<0.05) following 4 and 24 hour 
exposures to 100M pilocarpine only (figure 4.6). 
Cells exposed to LPS (0-100µg/ml) for 1, 4 and 24 hours again showed an increase in 
gene expression that was time- and concentration-dependent. At 1 hour, Nrf2 expression 
was increased up to 2.3-fold in relation to GAPDH expression but failed to reach 
statistical significance at any concentration of LPS in comparison to control (0µM) 
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value (figure 4.7). At 4 hours, there was a 4.8-fold increase in Nrf2 expression at the 
highest LPS concentration (100g/ml) with significant (p<0.05) differences from 
control (0M) observed at LPS concentrations above 10M (figure 4.7). At 24 hours, 
the maximal increase in Nrf2 expression relative to GAPDH was 13.9-fold after 100M 
LPS exposure and was statistically significant (p<0.05) at all LPS concentrations (3-
100g/ml) in comparison to control (0µM; figure 4.7). For HO-1, gene expression was 
maximally increased by a factor 5.8 at 1 hour, 11.7 at 4 hours, and 13.6 at 24 hours after 
exposure to 100g/ml LPS and was significantly (p<0.05) different from control (0M) 
at LPS concentrations above 10g/ml (figure 4.8). Likewise, at 1, 4 and 24 hours NQO-
1 expression was increased to 2.3-fold, 2.6-fold and 4.1-fold relative to GAPDH, 
respectively, following 100g/ml LPS exposure and was statistically significant 
(p<0.05) at all concentrations above 10g/ml (figure 4.9). 
 
Figure 4.1 Effect of 1, 4 and 24 hour exposure to H2O2 (0-1000M) on Nrf2 expression 
in SH-SY5Y cells. Results (n=4) are expressed as the mean (± SD) fold-change in Nrf2 
expression, relative to GAPDH expression. Statistical significance was determined by 
one-way ANOVA with Dunnett correction for multiple comparisons with control (0µM) 
































































Figure 4.2 Effect of 1, 4 and 24 hour exposure to H2O2 (0-1000M) on the HO-1 fold 
changes in SH-SY5Y cells. Results (n=4) are expressed as the mean ± SD HOX- fold 
changes and statistical significance was determined by one-way ANOVA with Dunnett 
correction for multiple comparisons with control (0µM) within each data series 
(*p<0.05), (**p<0.001). 
 
Figure 4.3 Effect of 1, 4 and 24 hour exposure to H2O2 (0-1000M) on the NQO-1 fold 
changes in SH-SY5Y cells. Results (n=4) are expressed as the mean ± SD NQO-1 fold 
changes and statistical significance was determined by one-way ANOVA with Dunnett 




















































































































Figure 4.4 Effect of 1, 4 and 24 hour exposure to pilocarpine (0-100M) on the Nrf2 
fold changes in SH-SY5Y cells. Results (n=4) are expressed as the mean ± SD Nrf2 
fold changes and statistical significance was determined by one-way ANOVA with 
Dunnett correction for multiple comparisons with control (0µM) within each data series 
(*p<0.05), (**p<0.001). 
 
Figure 4.5 Effect of 1, 4 and 24 hour exposure to pilocarpine (0-100M) on the HO-1 
fold changes in SH-SY5Y cells. Results (n=4) are expressed as the mean ± SD HO-1 
fold changes and statistical significance was determined by one-way ANOVA with 




















































































































Figure 4.6 Effect of 1, 4 and 24 hour exposure to pilocarpine (0-100M) on the NQO-1 
fold changes in SH-SY5Y cells. Results (n=4) are expressed as the mean ± SD NQO-1 
fold changes and statistical significance was determined by one-way ANOVA with 
Dunnett correction for multiple comparisons with control (0µM) within each data series 
(*p<0.05), (**p<0.001). 
 
Figure 4.7 Effect of 1, 4 and 24 hour exposure to LPS (0-100M) on the Nrf2 fold 
changes in SH-SY5Y cells. Results (n=4) are expressed as the mean ± SD Nrf2 fold 
changes and statistical significance was determined by one-way ANOVA with Dunnett 

























































































































Figure 4.8 Effect of 1, 4 and 24 hour exposure to LPS (0-100M) on the HO-1 fold 
changes in SH-SY5Y cells. Results (n=4) are expressed as the mean ± SD HO-1 fold 
changes and statistical significance was determined by one-way ANOVA with Dunnett 





Figure 4.9 Effect of 1, 4 and 24 hour exposure to LPS (0-100M) on the NQO-1 fold 
changes in SH-SY5Y cells. Results (n=4) are expressed as the mean ± SD NQO-1 fold 
changes and statistical significance was determined by one-way ANOVA with Dunnett 
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4.3.2 Effect of carbamazepine on basal and H2O2-induced gene expression in SH-
SY5Y cells 
There were no statistically significant changes in Nrf2 expression in SH-SY5Y cells 
after treatment with 1-30µM CBZ for 24 hours, either with or without exposure to 
100µM H2O2 for a further 4 hours (figure 4.10). However, 24 hour treatment with 
100µM CBZ was associated with a significant (p<0.001) increase in both basal (4-fold) 
and H2O2-stimulated (5.3-fold) Nrf2 expression, relative to that of GAPDH, when 
compared with their respective controls (figure 4.10). 
Treatment with CBZ concentrations up to 10M for 24 hours was without significant 
effect on HO-1 expression in SH-SY5Y cells, either with or without exposure to 100µM 
H2O2 for a further 4 hours (figure 4.11). However, higher concentrations of CBZ were 
associated with statistically significant increases in relative HO-1 expression (2.2-fold at 
30M, p<0.05; 2.7-fold at 100M, p<0.001) in comparison to control samples (0µM) 
(figure 4.11). The effect of CBZ was augmented by subsequent exposure to 100M 
H2O2 for 4 hours, with a maximum increase in HO-1 expression of 3.3-fold, but was 
only significantly different from the corresponding control at 100M CBZ (p<0.05; 
figure 4.11). 
There was no statistically significant change in NQO-1 expression, relative to that of 
GAPDH, in SH-SY5Y cells following 24 hour treatment with 1-30µM CBZ, either with 
or without exposure to 100µM H2O2 for a further 4 hours (figure 4.12). NQO-1 
expression was, however, significantly increased in comparison to control (0M) after 
treatment with 100µM CBZ (2.1-fold, p<0.05) and was also increased in cells that were 




Figure 4.10 Effect of 24 hour treatment with CBZ (0-100µM), with and without 
additional exposure to 100µM H2O2 for 4 hours, on Nrf2 expression in SH-SY5Y cells. 
Results (n=4) are expressed as the mean (± SD) fold-change in Nrf2 expression, relative 
to GAPDH expression. Statistical significance was determined by one-way ANOVA 
with Dunnett correction for multiple comparisons with control (0µM) within each data 
series (**p<0.001). 
 
Figure 4.11 Effect of 24 hour treatment with CBZ (0-100µM), with and without 
additional exposure to 100µM H2O2 for 4 hours, on HO-1 expression in SH-SY5Y cells. 
Results (n=4) are expressed as the mean (± SD) fold-change in HO-1 expression, 
relative to GAPDH expression. Statistical significance was determined by one-way 
ANOVA with Dunnett correction for multiple comparisons with control (0µM) within 





























































































































Figure 4.12 Effect of 24 hour treatment with CBZ (0-100µM), with and without 
additional exposure to 100µM H2O2 for 4 hours, on NQO-1 expression in SH-SY5Y 
cells. Results (n=4) are expressed as the mean (± SD) fold-change in NQO-1 
expression, relative to GAPDH expression. Statistical significance was determined by 
one-way ANOVA with Dunnett correction for multiple comparisons with control (0µM) 
within each data series (*p<0.05). 
 
4.3.3 Effect of valproic acid on basal and H2O2-induced gene expression in SH-
SY5Y cells 
There were no significant changes in Nrf2 expression, relative to that of GAPDH, 
following treatment of SH-SY5Y cells with VPA at concentrations up to 300µM for 24 
hours, except where 300M VPA was followed by a 4 hour exposure to 100M H2O2, 
which resulted in a 2.2-fold increase in expression that was statistically different from 
control (p<0.05; figure 4.13). Nrf2 expression was also significantly increased 
following treatment with 1000M VPA, by a factor of 3. (p<0.05) following VPA alone 






























































VPA (10-300µM) was without statistically significant effect on HO-1 expression, 
relative to GAPDH, in SH-SY5Y cells following 24 hour treatment, with or without 
subsequent exposure to 100µM H2O2 for 4 hours (figure 14). In contrast, 1000µM VPA 
was associated with a increase in HO-1 expression, both alone (2.9-fold) and following 
additional exposure to 100µM H2O2 for 4 hours (3.6-fold), which was significantly 
(p<0.001) different from the corresponding control (0M) in both cases (figure 14). 
SH-SY5Y cells showed no significant changes in the expression of NQO-1, relative to 
GAPDH, after treatment with 10-1000µM VPA for 24 hours (figure 15). However, 
when VPA treatment was followed with a further 4 hour exposure to 100M H2O2 there 
was a significant increase in NQO-1 expression at 300M VPA (2.3-fold; p<0.05) and 
also at 1000M VPA (2.9-fold; p<0.001) in comparison to relative gene expression in 
control (0M) samples (figure 15). 
 
Figure 4.13 Effect of 24 hour treatment with VPA (0-1000µM), with and without 
additional exposure to 100µM H2O2 for 4 hours, on Nrf2 expression in SH-SY5Y cells. 
Results (n=4) are expressed as the mean (± SD) fold-change in Nrf2 expression, relative 
to GAPDH expression. Statistical significance was determined by one-way ANOVA 
with Dunnett correction for multiple comparisons with control (0µM) within each data 



























































Figure 4.14 Effect of 24 hour treatment with VPA (0-1000µM), with and without 
additional exposure to 100µM H2O2 for 4 hours, on HO-1 expression in SH-SY5Y cells. 
Results (n=4) are expressed as the mean (± SD) fold-change in HO-1 expression, 
relative to GAPDH expression. Statistical significance was determined by one-way 
ANOVA with Dunnett correction for multiple comparisons with control (0µM) within 
each data series (**p<0.001). 
 
Figure 4.15 Effect of 24 hour treatment with VPA (0-1000µM), with and without 
additional exposure to 100µM H2O2 for 4 hours, on NQO-1 expression in SH-SY5Y 
cells. Results (n=4) are expressed as the mean (± SD) fold-change in NQO-1 
expression, relative to GAPDH expression. Statistical significance was determined by 
one-way ANOVA with Dunnett correction for multiple comparisons with control (0µM) 
































































































































4.3.4 Effect of lamotrigine on basal and H2O2-induced gene expression in SH-SY5Y 
cells 
For the most part, there was no significant change in the expression of Nrf2, relative to 
that of GAPDH, after treatment of SH-SY5Y cells with 1-100µM LTG for 24 hours, 
with or without additional exposure to 100M H2O2 for 4 hours (figure 4.16). However, 
when cells were treated with 100M LTG for 24 hours, followed by 100M H2O2 for 4 
hours, there was a modest but nonetheless statistically significant increase (6.3-fold; 
p<0.05) in the relative expression of Nrf2 when compared to expression in control cells 
(figure 4.16).   
SH-SY5Y cells again showed almost no significant changes in HO-1 expression, 
relative to GAPDH, after treatment with 1-100µM LTG for 24 hours, with or without 
additional exposure to 100M H2O2 for 4 hours (figure 4.17). The only exception was a 
statistically significant (p<0.05) increase (2.3-fold) in the expression of HO-1 following 
combined treatment with 100µM LTG for 24 hours followed by 100µM H2O2 for 4 
hours (figure 17). 
The expression of NQO-1, relative to the housekeeping gene GAPDH, was significantly 
increased, with a maximal increase of 2.9-fold, following combined treatment with LTG 
(1-100M) for 24 hours followed by 100M H2O2 for 4 hours (p<0.05 at 1M, 3M 
and 10M LTG; p<0.001 at 30M and 100M LTG) (figure 4.18). In addition, there 
was a significant effect of 100M LTG alone, with a 2.3-fold increase in NQO-1 
expression that was statistically (p<0.001) different from expression observed in the 




Figure 4.16 Effect of 24 hour treatment with LTG (0-100µM), with and without 
additional exposure to 100µM H2O2 for 4 hours, on Nrf2 expression in SH-SY5Y cells. 
Results (n=4) are expressed as the mean (± SD) fold-change in Nrf2 expression, relative 
to GAPDH expression. Statistical significance was determined by one-way ANOVA 




Figure 4.17 Effect of 24 hour treatment with LTG (0-100µM), with and without 
additional exposure to 100µM H2O2 for 4 hours, on HO-1 expression in SH-SY5Y cells. 
Results (n=4) are expressed as the mean (± SD) fold-change in HO-1 expression, 
relative to GAPDH expression. Statistical significance was determined by one-way 
ANOVA with Dunnett correction for multiple comparisons with control (0µM) within 
























































































































Figure 4.18 Effect of 24 hour treatment with LTG (0-100µM), with and without 
additional exposure to 100µM H2O2 for 4 hours, on NQO-1 expression in SH-SY5Y 
cells. Results (n=4) are expressed as the mean (± SD) fold-change in NQO-1 
expression, relative to GAPDH expression. Statistical significance was determined by 
one-way ANOVA with Dunnett correction for multiple comparisons with control (0µM) 
within each data series (**p<0.001; *p<0.05). 
4.3.5 Effect of levetiracetam on basal and H2O2-induced gene expression in SH-
SY5Y cells 
SH-SY5Y cells showed no significant changes in Nrf2 expression, relative to that of 
GAPDH, following exposure to 1-300µM LEV for 24 hours, with or without further 
exposure to 100µM H2O2 for 4 hours (figure 4.19).  
Likewise, there was no significant change in HO-1 expression, relative to GAPDH, after 
exposure to 1-300µM LEV for 24 hours, with or without further exposure to 100µM 
H2O2 for 4 hours (figure 4.20). 
Finally, the expression of NQO-1 was not significantly altered, compared to control 
(0M), by treatment with 1-300µM LEV for 24 hours, with or without further exposure 
to 100µM H2O2 for 4 hours (figure 4.21).  
* 
* 




































































Figure 4.19 Effect of 24 hour treatment with LEV (0-300µM), with and without 
additional exposure to 100µM H2O2 for 4 hours, on Nrf2 expression in SH-SY5Y cells. 
Results (n=4) are expressed as the mean (± SD) fold-change in Nrf2 expression, relative 
to GAPDH expression. Statistical significance was determined by one-way ANOVA 
with Dunnett correction for multiple comparisons with control (0µM) within each data 
series.  
 
Figure 4.20 Effect of 24 hour treatment with LEV (0-300µM), with and without 
additional exposure to 100µM H2O2 for 4 hours, on HO-1 expression in SH-SY5Y cells. 
Results (n=4) are expressed as the mean (± SD) fold-change in HO-1 expression, 
relative to GAPDH expression. Statistical significance was determined by one-way 
ANOVA with Dunnett correction for multiple comparisons with control (0µM) within 





















































































































Figure 4.21 Effect of 24 hour treatment with LEV (0-300µM), with and without 
additional exposure to 100µM H2O2 for 4 hours, on NQO-1 expression in SH-SY5Y 
cells. Results (n=4) are expressed as the mean (± SD) fold-change in NQO-1 
expression, relative to GAPDH expression. Statistical significance was determined by 
one-way ANOVA with Dunnett correction for multiple comparisons with control (0µM) 










































































Oxidative stress and mitochondrial dysfunction are considered as contributing factors to 
various neurological disorders. Recently, there has been increasing evidence supporting 
the association between oxidative stress and the process of epileptogenesis (Martinc et 
al., 2012). Nrf2 and its related genes, HO-1 and NQO-1, have been suggested to play a 
protective role in a number of neurodegenerative disorders and cancers by virtue of their 
antioxidant action (Lee and Johnson, 2013). The experimental evidence suggests that 
Nrf2 could be a promising therapeutic target for chronic neurological diseases such as 
epilepsy (Patel, 2015). The present study was designed to determine the effects of 
selected oxidative stress inducers and commonly used AEDs on Nrf2 and its related 
gene expression. 
The current study found that exposure of SH-SY5Y cells to different concentrations of 
H2O2, LPS, and pilocarpine positively affected expression of the Nrf2 gene, and those 
encoding HO-1 and NQO-1, in a time and concentration dependent manner. Another 
important finding was that incubation of SH-SY5Y cells with different concentrations 
of CBZ, VPA and LTG, with or without further exposure to H2O2, resulted in an 
increase in the expression of Nrf2 and its downstream genes in a time and concentration 
dependent-manner. This effect was invariably most prominent at the highest AED 
concentrations. Interestingly, another commonly used AED, LEV, had no effect on 
either basal or H2O2-induced, Nrf2-related gene expression.  
In the cell, regulation of Nrf2 levels and its activity occurs at several levels, including 
transcription, translation, degradation, translocation, and post-translational 
modifications (Perez-Leal et al., 2017). One of the most important mechanisms 
determining the increase of Nrf2 protein levels involves a decreased rate of Nrf2 
degradation by Keap-1 protein. 
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In the current study, H2O2 was found to induce the expression of Nrf2 and its related 
genes, HO-1 and NQO-1. These findings are consistent with previously published data 
which reported an up-regulation in Nrf2 expression after H2O2 exposure (Fourquet et 
al., 2010). 
It is known that H2O2 can be metabolized to several ROS, including hydroxyl radicals, 
which are considered to be amongst the most cytotoxic of free radicals. An excess of 
un-eliminated H2O2 and its metabolites can oxidize virtually all types of 
macromolecules: carbohydrates, nucleic acids, lipids and proteins (Yin et al., 2015). 
The increased levels of ROS overwhelm the antioxidant defences and lead to a state of 
oxidative stress. Nrf2 is a master regulator of oxidative stress which contributes to the 
environmental stress response by regulating the expression of genes for antioxidant and 
detoxification enzymes (Vomund et al., 2017). In its inactivated state, Nrf2 is 
sequestered in the cytosol via Keap1 protein and is quickly degraded. Modification of 
Keap1 is necessary for the accumulation of free Nrf2 in the cytoplasm, which then 
translocates into the nucleus (Kobayashi et al., 2004). Under conditions of oxidative 
stress and an excess of ROS, the oxidation or conjugation of key cysteine residues in 
Keap1 increases. The net effect of Keap1 modification is a reduction in its affinity for 
Nrf2, which prevents poly-ubiquitination and proteasomal degradation of Nrf2 in the 
cytosol. This allows accumulated Nrf2 to translocate into the nucleus and binded to 
AREs, leading to the regulated transcription of its target genes (Kobayashi et al., 2004). 
Therefore, the degradation of Keap1 is logically associated with up-regulation of Nrf2 




Figure 4.22: Schematic diagram of the nuclear factor erythroid 2-like 2 (Nrf2) / 
antioxidant response element (ARE) pathway and its activation by oxidative stress. 
Under normal conditions, Nrf2 is constitutively bound to Kelch-like ECH associated 
protein 1 (Keap1) protein in the cytoplasm. Keap1 inhibits Nrf2 signalling by promoting 
Nrf2 ubiquitination (ub) and subsequent degradation through proteasomal pathway. 
Mild oxidative stress and Nrf2 activators cause dissociation of the Nrf2-Keap1 
complex, leading to phosphorylation (P) of Nrf2 and its nuclear translocation. In the 
nucleus, Nrf2 promotes transcriptional activation of gene encoding antioxidant enzymes 
haem oxygenase-1 (HO-1), NAD(P)H quinone oxidoreductase 1 (NQO1), catalase, and 
superoxide dismutase (SOD) (adapted from Chen et al., 2015). 
 
In this study, pilocarpine was found to induce Nrf2 and the expression of its related 
genes. Pilocarpine is a non-selective agonist at muscarinic receptors (M1, M2 and M4). 
Previous reports based on pharmacological data have suggested the existence of at least 
M1, M2 and M3 muscarinic receptor subtypes in SH-SY5Y cells (Adem et al., 1987; 
Lambert et al., 1989; Mei et al., 1989). Furthermore, previous reports have shown that 
those ROS may also participate as second messengers in the regulation of ARE-driven 




A possible explanation for the link between M1 receptors and activation of the 
antioxidant response might be that pilocarpine binding to the M1 receptor activates 
phospholipase C and therefore produces diacylglycerol (DG) and inositol triphosphate 
(IP3), which in turn result in alteration of Ca2+ and K+ currents and increased 
excitability of brain cells (Segal, 1988). The high concentration of Ca2+ promotes the 
release of glutamate. Glutamate promotes the entrance of Na+ and Ca2+ into the cell and, 
as a consequence, removes the Mg2+ block of N-methyl-D-aspartate (NMDA) receptors, 
and allows the entrance of more Ca2+ into the cell, which can lead to excitotoxicity and 
cell death (Li and Wang. 2016). Tissue excitability increases the utilization rate of 
monoamines (Cavalheiro et al. 1994). After binding to their own receptors, these 
monoamines are degraded by monoamine oxidase (MAO) and catechol-o-
methyltransrerase (COMT) enzymes and, during these processes, free radicals can be 
formed. These free radicals are also freed during glucose metabolism and the 
mitochondrial transport chain. In the absence of oxidant injury, Nrf2 interacts with the 
Keap1 protein, and this association promotes Nrf2 degradation through the ubiquitin-
proteasome pathway by Keap-1 protein. On the other hand, excessive production of free 
radicals promotes the modification of Nrf2/Keap1 complexes resulting in stabilization 
of the Nrf2 protein, and its translocation to the nucleus, where it induces transcription of 
phase II genes such as HO-1 and NQO-1 (Tong et al., 2006). In the current study, LPS 
was also found to induce the expression of Nrf2 and its related genes. LPS is the 
endotoxic component of the Gram-negative bacterial cell wall that may activate an acute 
inflammatory response (Mai et al., 2013). The main mechanism of action of LPS is the 
activation of TLRs and NF-B and of a variety of pro-inflammatory genes and 
oxidative damage (Vaisid et al., 2013). Neurons themselves, including SH-SY5Y cells, 
are capable of expressing TLRs (Vaisid et al., 2013; Kim et al., 2015). ROS are central 
to a host of pathologies including inflammation and infection (Reddy et al., 2006) and 
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numerous studies have shown that ROS can regulate NF-κB activation 
(Mirochnitchenko and Inouye 1996; Asehnoune et al., 2004; Powers et al., 2006). TLR2 
activation by LPS has been shown to cause activation of the Nrf2 signalling pathway 
and negatively regulates inflammatory responses (Yin and Cao, 2015). Inflammation 
can induce the expression of Nrf2 downstream genes (Rushworth and MacEwan, 2008), 
and the Nrf2 pathway cross-talks with NF-κB and other signalling pathways to repress 
the inflammatory response (Yang et al., 2014). The key event that leads to Nrf2 
pathway activation appears to be TLR receptor stimulation by LPS, which results in 
ROS release, with the Keap-1 protein undergoing oxidation and the formation of an 
intramolecular disulfide bond (Hu et al., 2011). This conformational change in Keap1 
leads to the release of Nrf2 and its subsequent nuclear translocation and activation of 
antioxidant genes (Yamamoto et al., 2008). 
Contrary to expectations, this study found a pro-oxidant effect of several AEDs, with or 
without further exposure to H2O2, on the expression of Nrf2 and its related genes. CBZ, 
VPA, and LTG were found to increase Nrf2 expression, and that of HO-1 and NQO-1, 
particularly at higher concentrations. Lower AED concentrations, including therapeutic 
concentrations which are considered to be 15-50µM for CBZ (Ching, 2016), 350-
700µM for VPA (Brunton et al., 2011) and 15-40µM for LTG (Wolf, 1992), had little 
or no effect on gene expression. It is encouraging to compare these results with those of 
Pavone and Cardile (2003) who found that there was a similar time- and concentration-
dependent decrease in cell viability and an increase in oxidative stress parameters, 
including total ROS, lactate dehydrogenase, TBARS, and nitric oxide (NO), when rat 
astrocyte cultures were exposed to AEDs. These observations are also consistent with 
the results previously described in chapter 2 of this thesis. In those studies, CBZ, VPA, 
and LTG were found to have a pro-oxidant effect particularly at higher concentrations 
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and so one can speculate that this pro-oxidant effect leads to an increase in the 
expression of Nrf2 and its downstream target genes as an attempt to provide protection 
against cytotoxic damage. As mentioned above, oxidative stress and cell damage are 
important inducers of Nrf2 either by causing damage to cellular components or by direct 
prevention of degradation by the Keap-1 protein. This is the most likely explanation for 
the results observed in this chapter. However, another possible explanation for the pro-
oxidant effects of AEDs, or at least VPA, might be an increase in ROS via the 
activation of peroxisome proliferator‐activated receptors (PPARs) that perform specific 
functions in fatty acid homeostasis and are known to upregulate CYP proteins (Chawla 
et al., 2001).  Another important finding was that LEV, with or without additional H2O2, 
did not show any activation or inhibition of the expression Nrf2 and its related genes at 
any concentration, including those within and above the recognised therapeutic range of 
45-180M (Martinc et al., 2012). This finding contrasts those reported in chapter 2 in 
which higher concentrations of LEV had a significant effect on biochemical markers of 
oxidative stress in SH-SY5Y cells. To the best of our knowledge, very little is known 
about the pro-oxidant and/or antioxidant effects of LEV in in vitro studies (Johannessen 
and Landmark, 2010). It is possible that pre-incubation with LEV might somehow result 
in preservation of the activity of catalase, an antioxidant enzyme that catalyses the 
conversion of H2O2 to water and oxygen, which would explain the antioxidant 
behaviour of LEV against H2O2-induced oxidative stress in SH-SY5Y cells (Oliveira et 
al., 2016). Thus, LEV might help to counteract the overproduction of reactive oxygen 
species and the resulting oxidative damage. 
The methods have been used in this experiment are highly reliable as they have been 
used by many researchers previously. However, the outcomes of this study are limited 
because of low n-numbers, lack of independent validation of findings, and potentially 
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by the use of different passage number of the used cell line, particularly with respect to 
comparison between these results and those in previous chapters. As described in the 
previous chapter, passage number has an impact on growth rates and on physiological 
and chemical characteristics of immortalised cell lines. In addition, and as mentioned 
before in chapter 3, a weakness of in vitro cell cultures is that they are studied in 
isolation and in the absence of their normal environment, which includes interactions 
with other cell types that might be critical to the process being tested. In such cases, in 
vivo testing is often preferred because it is better suited for observing the overall effects 
of experiment conditions or an intervention on a living subject.  
4.4.1 Conclusion 
This study has shown that several experimental inducers of oxidative stress, including 
H2O2, pilocarpine and LPS, caused an increase in the expression of Nrf2, HO-1 and 
NQO-1 gene in SH-SY5Y cells in a time and concentration-dependent manner. In 
addition, several widely used AEDs, including CBZ, VPA and LTG, also increased the 
expression of Nrf2, HO-1 and NQO-1 in SH-SY5Y cells following 24 hour treatment, 
particularly at high concentrations and irrespective of subsequent exposure to H2O2. 
Interestingly, another AED, namely LEV, was without effect on expression of the 
selected genes. These results indicate that H2O2, pilocarpine, and LPS and several AEDs 
most likely have pro-oxidant effects, especially at their highest concentrations, which in 
turn lead to activation of the Nrf2 pathway and the antioxidant response as a cellular 
defence mechanism against expected cytotoxicity. The exception is LEV which has pro-
oxidant potential – see chapter 2 – but perhaps via a mechanism that does not recruit the 
Nrf2 pathway in response. These findings have gone some way towards enhancing our 
understanding of the effects of AEDs on Nrf2 as a master regulator of oxidative stress 
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Nrf2 is a basic leucine zipper transcription factor with a cap ‘n’ collar domain (Kasper 
et al., 2009). It is considered as a redox sensitive transcription factor that induces the 
expression of a variety of genes which serve to protect against the deleterious effects of 
oxidative and chemical stress, thus ensuring normal cellular functions are maintained or 
restored (Tonelli et al., 2017).  
The activity of Nrf2 is primarily governed by an interaction with a homodimer of 
Keap1, a cytosolic repressor protein that facilitates the ubiquitination and subsequent 
proteasomal degradation of Nrf2 via the Cul3 ubiquitin ligase complex (Itoh et al., 
2003). Upon the exposure of cells to toxic insults and/or oxidative stress by 
electrophiles and oxidants, which cause an imbalance in the redox state of the cell, the 
Keap1-directed ubiquitination and degradation of Nrf2 is disrupted, leading to Nrf2 
accumulation in the cytosol followed by its translocation to the nucleus. Here, Nrf2 
binds to its transcriptional partner small masculoaponeurotic fibrosarcoma (Maf) 
proteins to form heterodimers (Motohashi et al., 2004). These Nrf2-Maf combinations 
then bind to the ARE in the promoter regions of cytoprotective target genes (Motohashi 
et al., 2004), which encode a host of antioxidants, xenobiotic detoxification and DNA 
repair enzymes, molecular chaperones, anti-inflammatory response proteins and other 
cytoprotective enzymes (Zhang et al., 2013). The coordinated expression of these genes 
converts toxic compounds to less harmful intermediates whilst repairing any damage 
caused within the cell. 
The high frequency of cysteine residues in the Keap1 sequence confers a relatively high 
reactivity to oxidative inducers (Miseta et al., 2000). Several studies have shown that 
the covalent binding of cysteine residues by Nrf2 activators such as sulforaphane, nitric 
oxide and H2O2 alters the conformation of Keap1, disrupting its association with Nrf2 
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and allowing Nrf2 to translocate to the nucleus (Zhang et al., 2003; Wakabayashi et al., 
2004). Nrf2 protein has a very rapid turnover, with a half-life of less than 20 minutes 
and thus, Nrf2 protein is minimally detectable in unstressed conditions (Kobayashi et 
al., 2004). 
As for many proteins, the cellular mechanisms of Nrf2 and its downstream target genes 
have been largely characterized through western blot analysis. The field has been 
lacking a well-characterized, commercially available, and specific antibody with which 
to detect Nrf2. In western blotting, the proteins may instead be detected using 
colorimetric, chemiluminescence or fluorescence techniques (Kurien and Scofield, 
2009). 
The commonly used detection methods have involved the use of protein-specific 
primary antibody followed by detection using secondary antibodies conjugated with 
either horseradish peroxidase (HRP) or alkaline phosphatase (AP) enzyme. In contrast, 
chemiluminescence is a commonly used detection method by which a chemical reaction 
results in the release of energy in the form of light. The emitted light can be captured on 
x-ray film (Kurien and Scofield, 2009). 
There is a diverse body of literature on Nrf2 involvement in fields ranging from 
antioxidant defence, (Ma, 2004), neurological disorders (Gao et al., 2014) and cancer 
(Namani et al., 2014). Experimental evidence suggests that Nrf2 could be a promising 
therapeutic target for chronic neurological conditions like epilepsy (Patel, 2015). 
Epilepsy remains a major medical problem for which there is no curative 
treatment. Oxidative stress resulting from excessive free-radical release has been 
reported as an underlying mechanism in the initiation and progression of epilepsy and 
excessive oxidative stress contributes to neuronal degeneration in the epileptic focus 
(Shin et al., 2011). In addition, an increase in reactive oxygen species occurs in 
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response to sustained neuronal electrical activity and seizures (Mariani et al., 2005). 
Therefore, antioxidants have been suggested to have therapeutic potential for the 
treatment of epilepsy. The Nrf2-ARE signalling pathway regulates the expression of a 
group of cytoprotective enzymes, such as  HO-1 and  NQO1. Previous studies have 
shown that up-regulation of HO-1 (Ahmad et al., 2006) or NQO-1 (Lim et al., 
2008; Chen et al., 2011) in neurons can protect them against oxidative 
and excitotoxic insults. Recent studies have demonstrated that the Nrf2-ARE signalling 
pathway could represent an important target in protecting the brain from the damage 
induced by ischemic stroke, and the resulting oxidative damage (Zhao et al., 2006), 
and also kainate toxicity (Kraft et al., 2006). However, to our knowledge, the 
neuroprotective effect of activating the Nrf2-ARE signalling pathway has not been 
studied in detail in epilepsy. 
The role of mitochondria in acquired epilepsies, which account for about 60% of all 
seizure disorders, is important but less well understood. Oxidative stress is one of the 
possible contributory mechanisms to the pathogenesis of epilepsy, resulting from 
mitochondrial dysfunction making neurons more vulnerable to additional stress, and 
leading to energy failure and neuronal cell death (Khurana et al., 2013). 
Until now, the major aim of epilepsy treatment has been to control seizures with the 
most appropriate AED without causing any significant side effects. Commonly used 
AEDs, such as CBZ, VPA, LTG and LEV, are employed to provide symptomatic relief 
by inhibiting seizure generation and/or reducing seizure frequency by targeting neuronal 
hyper-excitability. However, they are unable to modulate or alter the underlying 
epileptogenesis process or prevent it in high risk patients. Currently, there is no 
clinically-approved treatment to inhibit the process of epileptogenesis (Choi, 1993; 
Aparicio et al., 2015). Different studies have demonstrated the use of antioxidants in 
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epilepsy, indicating that pre-treatment with vitamin E, vitamin C, and various plant 
extracts or flavonoids can reduce lipid oxidation and restore the activities of SOD and 
CAT and the levels of GSH in the rat hippocampus, striatum and cortex (Aparicio et al., 
2016).  
5.1.1 Aims and objectives 
The present study aimed to investigate the effects of CBZ, VPA, LTG and LEV on the 
expression of Nrf2, HO-1 and NQO-1 proteins as a marker of phase II detoxification 























5.2 Materials and methods 
5.2.1 Materials and chemicals 
Lithium dodecyl sulphate (LDS) sample buffer, sample reducing agent, enhanced 
chemiluminescent substrate, NuPAGE 4-12% bis tris gel (1.5mm, 15-well), anti-NQO-1 
antibody, monoclonal anti-β-actin antibody (raised in mouse), anti-HO-1 antibody, goat 
anti-rabbit IgG (H&L) HRP-conjugated, western blotting filter paper (8cm x 10.5cm), 
and NuPAGE MOPS SDS running buffer (20x) were purchased from Thermo Fisher 
Scientific, Loughborough, UK. Anti-Nrf2 antibody (rabbit polyclonal) was purchased 
from Proteintech, Manchester, UK. Nitrocellulose roll (type SCN, pore size 0.45µm, 
30cm x 3m) was purchased from Gene Flow Ltd., Elmhurst, UK. Precision plus Protein 
Kaleidoscope was purchased from Bio-Rad, Hertfordshire, UK. Other chemicals were 
sourced as described in chapter 2, section 2.2.1 and chapter 3, section 3.2.1. 
5.2.2 Cell culture 
SH-SY5Y cells were cultured as described in chapter 2, section 2.2.2. 
5.2.3 Cell treatment with AEDs 
SH-SY5Y cells were seeded in 12-well plates at a density of 4 x 104 cells / well in 1ml 
culture medium and placed in an incubator containing humidified 95% air and 5% CO2 
at 37oC for 2-3 days until they reached 80-90% confluence. Then, cells were treated 
with CBZ (0, 1, 3, 10, 30 and 100µM), VPA (0, 10, 30, 100, 300 and 1000µM), LTG (0, 
1, 3, 10, 30 and 100µM) or LEV (0, 3, 10, 30, 100 and 300µM) for 24 hours. VPA and 
LTG were dissolved in serum-free medium (SFM; see chapter 2, section 2.2.4) whereas 
CBZ and LEV were dissolved in SFM containing 0.2% DMSO. A further batch of SH-
SY5Y cells was treated with the same AEDs at the same range of concentrations but 
was subsequently exposed to 100µM H2O2 for an additional 4 hours. Cells were washed 
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twice with 1ml PBS, lysed by scraping in 500µl RIPA lysis buffer, transferred to 1.5ml 
Eppendorf tubes, and placed on ice for 30 minutes. Thereafter, the lysates were 
centrifuged at 12000 x g at 4oC for 30 minutes and the resulting supernatant transferred 
to new 1.5ml Eppendorf tubes for protein quantitation. 
5.2.4 Protein quantitation 
Protein in cell lysates was quantified by BCA Protein Assay Kit as described in 
chapter2, section, 2.2.8. 
5.2.5 Preparation of buffers 
A 10x transfer buffer stock was prepared by dissolving 144.1g of glycine and 30.3g of 
Trizma base in 1L distilled water. A 1x working solution of transfer buffer was prepared 
by adding 200ml methanol to 100ml of 10x transfer buffer stock and diluting to 1L with 
distilled water. A 10x solution of Tris buffered saline (TBS) was prepared by dissolving 
80g of NaCl, 2g of KCl and 30.3g of Trizma base in 800ml distilled water, adjusting the 
pH to 7.4 with 1M HCl, and adding distilled water to a final volume of 1L. Lastly, a 1x 
solution of TBS with Tween (TBST) was prepared by adding 1ml of Tween 20 to 
100ml of 10x TBS and diluting to 1L with distilled water.   
5.2.6 Western blotting  
LDS sample buffer (70µl) and sample reducing agent (30µl) were pre-mixed and 5µl of 
the resulting mixture was added to individual samples, each containing 20μg of protein. 
Samples were then heated at 95°C for 5 minutes, centrifuged at 12000 x g at 4oC for 30 
minutes, and kept on ice for further 5 minutes.  
Pre-cast gels (15-well) were used for loading of samples. The gel tank was loaded with 
800ml 1X running buffer. A 5µl volume of protein ladder (Precision plus Protein 
Kaleidoscope) was loaded in the first and last well of each gel and 10µl of up to 13 
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individual samples were loaded in between. bufferThe gel was run at 80 volts in 1x 
NuPAGE MOPS running buffer for 15 minutes (or until samples had run past the 
stacking gel) and then at 200 volts for 1 hour (or until the samples reached the ridge at 
the bottom of the cassette). 
Following electrophoresis, the gel was carefully removed from the tank and placed in 
1x transfer buffer. A gel sandwich was prepared by opposing the gel to pre-cut 
nitrocellulose membrane and enclosing within layers of filter paper and fibre pad as 
illustrated in figure 5.1. The gel sandwich was then blotted in transfer buffer at 100 
volts for 1 hour during which proteins were transferred to the nitrocellulose membrane. 
Thereafter, the gel sandwich was disassembled and the membrane blocked in 10% non-
fat dried milk in 1x TBST for 1 hour (with gentle shaking) to prevent non-specific 
binding of the antibodies.  
Primary antibodies were diluted (1:400 for Nrf2, 1:5000 for both HO-1 and NQO-1 and 
β-actin) in 10% non-fat dried milk in 1x TBST and the nitrocellulose membrane 
incubated with individual primary antibodies overnight at 4°C (with gentle shaking). 
After incubation, the membrane was washed 6 times with 1x TBST at 5 minute 
intervals. After washing, the membrane was incubated with a 1:5000 dilution of 
secondary antibody in 5% non-fat dried milk in 1x TBST at room temperature for 1 
hour. The secondary antibodies were anti-rabbit HRP for Nrf2, HO-1, and β-actin, and 
anti-goat HRP for NQO-1. Thereafter, the membrane was again washed 6 times at 5 
minute intervals in 1x TBST. Enhanced chemiluminescent substrate was then applied 
by mixing solution A and B in 1:1 ration and incubate for 1 minute and the western blot 
was visualised using the ChemiDocTM Touch Imaging system (Bio-Rad, CA, USA) and 




Figure 5.1 Gel sandwich cassette components. Image reproduced from Trans-Blot 
Turbo Instruction Manual (bulletin 10020688) for complete instructions.  
 
5.2.7 Statistical analysis 
All experiments were performed using two technical replicates (i.e. analyses of all 
samples performed in duplicate) and three biological replicates (i.e. n=3 per group). 
Protein expression in individual samples was quantified by expressing optical density 
(OD) of the target protein band (Nrf2, HO-1, NQO-1) normalised to that of the 
corresponding control protein (β-actin) band using Image LabTM software, version 4.1. 
Relative expression in technical replicates (n=2) was averaged and group results (n=3) 
reported as the mean (± SD) normalised OD for each target protein at each 
concentration of each AED. Statistical comparisons were undertaken using either one-
way or two-way ANOVA, as appropriate, with a Dunnett correction for multiple 
comparisons, using Stats Direct software version 2.7.9. Differences were considered 




5.3.1 Effect of carbamazepine on basal and H2O2-induced protein expression in 
SH-SY5Y cells 
Exposure of SH-SY5Y cells to CBZ alone for 24 hours was without significant effect 
on the expression of Nrf2 at concentrations up to 30µM (figure 5.2). At 100µM CBZ 
there was a significant (p<0.05) increase in Nrf2 expression (1.7-fold) in comparison to 
the corresponding control (0µM) value (figure 5.2). When CBZ treatment was followed 
by exposure to 100µM H2O2 for 4 hours to induce oxidative stress, there was a 
statistically significant (p<0.001) elevation in Nrf2 expression at both 30µM CBZ (1.9-
fold) and 100µM CBZ (2.1-fold) in comparison to control (figure 5.2).  
Treatment with CBZ (1-10µM) for 24 hours was without significant effect on HO-1 
expression in SH-SY5Y cells, with or without subsequent exposure to 100 µM H2O2 for 
4 hours (figure 5.3). In contrast, 30µM CBZ and 100µM CBZ were associated with 
significant (p<0.001) increases in the expression of HO-1, compared to control, when 
administered alone (1.7-fold and 2.0-fold, respectively) and also following additional 
exposure to 100µM H2O2 for 4 hours (2-fold and 1.9-fold, respectively) (figure 5.3). 
There was no significant change in NQO-1 expression in SH-SY5Y cells following 24 
hour treatment with CBZ at concentrations up to 10µM, with or without subsequent 
exposure to 100µM H2O2 for further 4 hours (figure 5.4). However, 30µM and 100µM 
CBZ were associated with a statistically significant (p<0.05) increase in the expression 
of NQO-1, compared to control, when administered alone (1.6-fold and 2-fold, 
respectively). Significant increases in NQO-1 expression (p<0.05) were also observed 
when 30µM and 100µM CBZ was followed by exposure to 100µM H2O2 for 4 hours (2-










Figure 5.2: Effect of 24 hour treatment with CBZ (0-100µM), with and without 
additional exposure to 100µM H2O2 for 4 hours, on Nrf2 expression in SH-SY5Y cells. 
Results (n=3) are expressed as the mean (± SD) expression of Nrf2, normalised to that 
of β-actin. Statistical significance was determined by one-way ANOVA with Dunnett 
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Figure 5.3 Effect of 24 hour treatment with CBZ (0-100µM), with and without 
additional exposure to 100µM H2O2 for 4 hours, on HO-1 protein expression in SH-
SY5Y cells. Results (n=3) are expressed as the mean (± SD) protein in HO-1 
expression, relative to β-actin expression. Statistical significance was determined by 
one-way ANOVA with Dunnett correction for multiple comparisons with control (0µM) 
within each data series (*p<0.05; **p<0.001). 
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Figure 5.4 Effect of 24 hour treatment with CBZ (0-100µM), with and without 
additional exposure to 100µM H2O2 for 4 hours, on NQO-1 protein expression in SH-
SY5Y cells. Results (n=3) are expressed as the mean (± SD) protein in NQO-1 
expression, relative to β-actin expression. Statistical significance was determined by 
one-way ANOVA with Dunnett correction for multiple comparisons with control (0µM) 
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5.3.2 Effect of valproic acid on basal and H2O2-induced protein expression in SH-
SY5Y cells 
There was no significant change in Nrf2 expression in SH-SY5Y cells following 24 
hour treatment with VPA at concentrations up to 100µM, with or without subsequent 
exposure to 100µM H2O2 for further 4 hours (figure 5.5). However, 300µM and 
1000µM VPA were associated with a statistically significant (p<0.05) increase in the 
expression of Nrf2, compared to control, when administered alone (1.1-fold and 1.3-
fold, respectively). Significant increases in Nrf2 expression (p<0.001) were also 
observed when 300µM and 1000µM VPA was followed by exposure to 100µM H2O2 
for 4 hours (1.3-fold and 1.4-fold, respectively) (figure 5.5). 
Treatment with VPA (10-100µM) for 24 hours was without significant effect on HO-1 
expression in SH-SY5Y cells, with or without exposure to 100µM H2O2 for 4 hours 
(figure 5.6). In contrast, there was a significant (p<0.05) increase in the expression of 
HO-1, compared to control, following 300µM VPA alone (1.2-fold) and following 
further exposure to 100µM H2O2 (1.3-fold). Statistically significant (p<0.001) increases 
in HO-1 expression were also observed following treatment with 1000µM VPA alone 
(1.3-fold) and after additional exposure to 100µM H2O2 (1.4-fold) (figure 5.6). 
Treatment with VPA (10-300µM) for 24 hours was without significant effect on NQO-1 
expression in SH-SY5Y cells, with or without subsequent exposure to 100 µM H2O2 for 
4 hours (figure 5.7). However, 1000µM VPA was associated with significant (p<0.05) 
increases in the expression of NQO-1, compared to control, when administered alone 
(1.3-fold) and also following additional exposure to 100µM H2O2 for 4 hours (1.32-












Figure 5.5 Effect of 24 hour treatment with VPA (0-1000µM), with and without 
additional exposure to 100µM H2O2 for 4 hours, on Nrf2 protein expression in SH-
SY5Y cells. Results (n=3) are expressed as the mean (± SD) protein in Nrf2 expression, 
relative to β-actin expression. Statistical significance was determined by one-way 
ANOVA with Dunnett correction for multiple comparisons with control (0µM) within 
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Figure 5.6 Effect of 24 hour treatment with VPA (0-1000µM), with and without 
additional exposure to 100µM H2O2 for 4 hours, on HO-1 protein expression in SH-
SY5Y cells. Results (n=3) are expressed as the mean (± SD) protein in HO-1 
expression, relative to β-actin expression. Statistical significance was determined by 
one-way ANOVA with Dunnett correction for multiple comparisons with control (0µM) 
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Figure 5.7 Effect of 24 hour treatment with VPA (0-1000µM), with and without 
additional exposure to 100µM H2O2 for 4 hours, on NQO-1 protein expression in SH-
SY5Y cells. Results (n=3) are expressed as the mean (± SD) protein in NQO-1 
expression, relative to β-actin expression. Statistical significance was determined by 
one-way ANOVA with Dunnett correction for multiple comparisons with control (0µM) 
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5.3.3 Effect of lamotrigine on basal and H2O2-induced protein expression in SH-
SY5Y cells 
Treatment with LTG (1-10µM) for 24 hours was without significant effect on Nrf2 
expression in SH-SY5Y cells, with or without exposure to 100µM H2O2 for 4 hours 
(figure 5.8). In contrast, there was a significant (p<0.05) increase in the expression of 
Nrf2, compared to control, following 30µM LTG alone (1.1-fold) and following further 
exposure to 100µM H2O2 for 4 hours (1.4-fold). Statistically significant (p<0.001) 
increases in Nrf2 expression were also observed following treatment with 100µM LTG 
alone (1.2-fold) and after additional exposure to 100µM H2O2 (1.5-fold) (figure 5.8).  
Treatment of SH-SY5Y cells with LTG (1-30µM) for 24 hours was without effect on 
the expression of HO-1, with or without subsequent exposure to 100 µM H2O2 for 4 
hours (figure 5.9). However, treatment with 100µM LTG was associated with 
significant (p<0.001) increases in the expression of HO-1, compared to control, when 
administered alone (1.6-fold) and also following additional exposure to 100µM H2O2 
for 4 hours (1.7-fold) (figure 5.9). 
Expression of NQO-1 in SH-SY5Y cells was not significantly altered by treatment with 
LTG (1-10µM) for 24 hours, with or without subsequent exposure to 100µM H2O2 for 4 
hours (figure 5.10). At 30µM LTG, there was a significant (p<0.05) increase in the 
expression of NQO-1, compared to control, following LTG treatment alone and also 
following further exposure to 100µM H2O2 (both 1.3-fold). Statistically significant 
(p<0.001) increases in NQO-1 expression were also observed following treatment with 














Figure 5.8 Effect of 24 hour treatment with LTG (0-100µM), with and without 
additional exposure to 100µM H2O2 for 4 hours, on Nrf2 protein expression in SH-
SY5Y cells. Results (n=3) are expressed as the mean (± SD) protein in Nrf2 expression, 
relative to β-actin expression. Statistical significance was determined by one-way 
ANOVA with Dunnett correction for multiple comparisons with control (0µM) within 
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Figure 5.9 Effect of 24 hour treatment with LTG (0-100µM), with and without 
additional exposure to 100µM H2O2 for 4 hours, on HO-1 protein expression in SH-
SY5Y cells. Results (n=3) are expressed as the mean (± SD) protein in HO-1 
expression, relative to β-actin expression. Statistical significance was determined by 
one-way ANOVA with Dunnett correction for multiple comparisons with control (0µM) 
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Figure 5.10 Effect of 24 hour treatment with LTG (0-100µM), with and without 
additional exposure to 100µM H2O2 for 4 hours, on NQO-1 protein expression in SH-
SY5Y cells. Results (n=3) are expressed as the mean (± SD) protein in NQO-1 
expression, relative to β-actin expression. Statistical significance was determined by 
one-way ANOVA with Dunnett correction for multiple comparisons with control (0µM) 
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5.3.4 Effect of levetiracetam on basal and H2O2-induced protein expression in SH-
SY5Y cells 
There were no significant changes in Nrf2 expression, in comparison to control, 
following treatment of SH-SY5Y cells with LEV (3-300µM) for 24 hours, with or 
without subsequent exposure to 100µM H2O2 for a further 4 hours (figure 5.11).  
Likewise, 24 hour exposure to LEV (3-300µM) was without significant effect on the 
expression of HO-1 protein in SH-SY5Y cells when compared to control, with or 
further exposure to 100µM H2O2 for 4 hours (figure 5.12).  
Finally, the expression of NQO-1 in SH-SY5Y cells was not significantly altered, in 
comparison to control, following 24 hour treatment with LEV (3-300µM), with or 

















Figure 5.11 Effect of 24 hour treatment with LEV (0-300µM), with and without 
additional exposure to 100µM H2O2 for 4 hours, on Nrf2 protein expression in SH-
SY5Y cells. Results (n=3) are expressed as the mean (± SD) protein in Nrf2 expression, 
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Figure 5.12 Effect of 24 hour treatment with LEV (0-300µM), with and without 
additional exposure to 100µM H2O2 for 4 hours, on HO-1 protein expression in SH-
SY5Y cells. Results (n=3) are expressed as the mean (± SD) protein in HO-1 
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Figure 5.13 Effect of 24 hour treatment with LEV (0-300µM), with and without 
additional exposure to 100µM H2O2 for 4 hours, on NQO-1 protein expression in SH-
SY5Y cells. Results (n=3) are expressed as the mean (± SD) protein in NQO-1 
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The primary purpose of AEDs is to control the neuronal hyperexcitability that underlies 
the generation of epileptic seizures (Holsti et al., 2007). They are not designed nor 
intended to address the causes of epilepsy per se, or to prevent its development 
following epileptogenic brain insults. One mechanism that has implicated in 
epileptogenesis and in the perpetuation of seizures is oxidative stress (Pearson et al., 
2015). Oxidative stress arises as a result of an imbalance between oxidation and anti-
oxidation, which leads to excessive ROS and reduced anti-oxidative capacity (Aparicio 
et al., 2015). Excessive oxygen free-radicals generated during seizures have been shown 
to dramatically impair the structure and function of neurons (Freitas et al., 2005). Nrf2, 
as a transcription factor, controls the basal and inducible expression of an array of 
antioxidant and detoxification enzymes that act to degrade oxygen free-radicals and 
limit the associated cellular damage (Miller et al., 2015). Disruption of the Nrf2-ARE 
signalling pathway results in an increased susceptibility to oxidative insults and the 
effects of other toxicants (Kwak et al., 2002). Activation of the Nrf2-ARE pathway 
protects neurons against oxidative and excitotoxic damage (Ahmed et al., 2006). Thus, 
susceptibility of neurons to oxidative injury critically depends on effective Nrf2/ARE 
signalling but little is known about physiological signals that regulate this 
neuroprotective pathway in the CNS.  
A growing body of evidence has been focused on the link between oxidative stress and   
neurological disorders (Santos et al., 2008; Khurana et al., 2013), and therefore it is 
essential to clarify if drugs used in treating those disorders can affect cellular responses 
to oxidative insults. If a drug is found to significantly up-regulate Nrf2 and its 
downstream antioxidant target genes, this could be suggestive of protective effects 
against oxidative stress. Nevertheless, this effect might also be observed with a drug 
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that possesses pro-oxidant activity, on the basis that the up-regulation of Nrf2 is part of 
the defence mechanisms of the cell to a pro-oxidant challenge. In this case, additional 
investigations at multiple clearly-defined time-points would be needed to assess 
oxidative stress and antioxidant response in drug treated cells to be able to distinguish 
these outcomes. Conversely, if a drug is found to down-regulate the expression of Nrf2, 
and that of its related target genes, this could point to that drug causing or predisposing 
cells to oxidative stress and the associated macro- and micro-cellular damage. 
The aim of this study was to determine whether four commonly used AEDs (CBZ, 
VPA, LTG and LEV) had any significant effect on the expression of the transcription 
factor Nrf2, which is a master regulator of oxidative stress in living tissues, and on the 
expression of HO-1 and NQO-1 which are nuclear Nrf2-regulated genes. Experiments 
were conducted using SH-SY5Y cells, which were chosen as an in vitro model of 
neuronal-like cells. Drug effects against basal protein expression and also on expression 
induced by H2O2 were explored, the latter in anticipation of protective effects of 
prolonged AED exposure against oxidative stress. 
The results obtained from this study revealed that exposure to a range of concentrations 
of CBZ, VPA and LTG for 24 hours, with and without further exposure to H2O2 for 4 
hours, led to an upregulation in the expression of Nrf2, HO-1 and NQO-1 proteins in a 
largely concentration-dependent manner but which was typically only significant at the 
highest concentrations. Interestingly, and in contrast to other AEDs, there were no 
significant effects of LEV, at any concentration, on basal or H2O2-induced expression of 
any of these proteins. Interestingly, these results are highly cinsistent with the chapter4 
results in which widely used AEDs, including CBZ, VPA and LTG, increased the gene 
expression of Nrf2, HO-1 and NQO-1 in SH-SY5Y cells following 24 hour treatment, 
particularly at high  concentrations and irrespective of subsequent exposure to H2O2. 
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Interestingly, another AED, namely LEV, was without effect on expression of the 
selected genes. 
These results reflect those of Pavone and Cardile (2003), who found that there was a 
time and concentration-dependent decline in cell viability and an increase in oxidative 
stress parameters, including total ROS, lactate dehydrogenase, TBARS, and nitric oxide 
(NO) concentration, following AED exposure in glial cells.  
There are several possible explanations for the link between oxidative stress and AEDs. 
Recently, much attention has been paid to the influence of AEDs, and subsequent 
oxidative stress, on mitochondrial function (Khurana et al., 2013).  
The involvement of oxidative stress in the pathogenesis of epilepsy likely results from 
mitochondrial dysfunction gradually disrupting the intracellular homeostasis, which in 
turn modulates neuronal excitability and synaptic transmission, making neurons more 
vulnerable to additional stresses, and leading to energy failure and neuronal loss. Both 
mitochondrial dysfunction and oxidative stress are considered critical determinants of 
the neuronal death associated with seizures (Cock, 2002) and may also play a role in 
subsequent epileptogenesis and chronic epilepsy. AEDs can also affect mitochondrial 
function in several ways (Khurana et al., 2013). A study by Santos and colleagues 
(2008) explored the in vitro effects of CBZ, phenytoin and phenobarbital on 
mitochondrial function and showed that aromatic AEDs can negatively affect 
mitochondrial function, via the generation of excessive ROS. This resulted in a decrease 
in mitochondrial respiration, respiratory control rate, ATP synthesis and membrane 
potential, impairment of Ca2+ uptake and release, and inhibition of Ca2+-induced 
swelling. They suggested that the rare cases of hepatotoxicity seen with these aromatic 




The effects of VPA in the current study are in accordance with a recent publication 
(Jafarian et al., 2013) that reported a detailed investigation of the metabolic effect of 
VPA in isolated rat liver mitochondria. The authors found that VPA treatment caused an 
increase in mitochondrial ROS production via impairment of respiratory chain complex 
II, which was followed by elevation of lipid peroxidation without GSH oxidation. VPA 
also induced mitochondrial permeability transition pore opening, mitochondrial 
membrane potential collapse, mitochondrial swelling, and cytochrome C release, which 
activates the intrinsic death signalling pathway (Jafarian et al., 2013). Another possible 
explanation for the pro-oxidant effects of VPA may be an increase in the generation of 
ROS via the activation of peroxisome proliferator activated receptors (PPARs) that 
perform specific functions in fatty acid homeostasis and are known to up-regulate CYP 
proteins (Chawla et al., 2001). This is additionally supported by previous observations 
from an in vitro study (Olson et al., 1986) which showed that administration of 500μM 
VPA to rat liver tissue cultures increased the rate of formation of H2O2, with the 
consequent oxidative stress expected to cause nuclear translocation of Nrf2 and an 
increase in the expression of its target genes and their protein products. 
The results obtained with LTG in the current study are in agreement with a recent in 
vivo experiment by Abelaira et al (2011) who reported that acute administration of LTG 
to rats decreased mitochondrial respiratory chain complex I activity in the brain and 
increased the activity of complex II in the amygdala, complex II and III in the prefrontal 
cortex, and complex II and IV in the hippocampus. In contrast, chronic treatment with 
LTG increased activity of complex II and III in the amygdala alone. The authors 
suggested that the observed increases in the activity of complexes II, III and IV might 
arise, at least in part, as compensation for the decrease in complex I activity. Such 
effects of LTG on the mitochondrial respiratory chain might be considered positive, 
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taking into account the impairment in energy metabolism related to oxidative stress and 
cellular damage (Abelaira et al., 2011).  
Thus, it is clear that several of the AEDs employed in the current study have the ability 
to negatively affect mitochondrial function (figure 5.14) and to cause excessive 
oxidative damage through liberation of ROS, which in turn can decrease sequestration 
of Nrf2 by Keap-1, preventing its degradation and increasing its nuclear translocation 
and activation of antioxidant target genes. 
Figure 5.14: Disease mechanisms in mitochondrial epilepsy. There is a complex inter-
relationship between mitochondrial dysfunction, seizures, and cell death. Key molecular 
mechanisms mediating epileptogenesis include neuronal ATP depletion, generation of 
reactive oxygen species (ROS), and abnormal calcium signalling. Complex molecular 
cascades are established, each feeding back on other components of the cascades, 
leading to a vicious spiral of mitochondrial dysfunction, seizure generation, and cell 
death (adapted from Rahman, 2015). 
 
In contrast to other AEDs, LEV was without effect on protein expression in this study.  
The reason for this is unclear but there are some similarities between the behaviour of 
LEV reported here and that described by Oliveira and colleagues (2016). These authors 
found that LEV could help to protect against the oxidative stress induced by several 
ROS by reduction of lipid peroxidation and nitrite-nitrate contents, preservation of 
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catalase activity at control parameters and increase of GSH levels. These results allow 
us to infer the participation of this effect in the neuroprotective mechanism of LEV, and 
reinforce, even indirectly, the hypothesis of oxidative damage in the pathophysiology of 
epilepsy. These findings are also in agreement with other published work (Khurana et 
al., 2013) which showed that therapeutic concentrations of LEV have antioxidant and 
neuroprotective effects through increasing TAO, catalase, and Gpx activity. One 
possible explanation for these results is that pre-incubation of cells with LEV might 
result in preservation of the enzyme catalase, which is an anti-oxidant enzyme 
responsible for the breakdown of H2O2 into water and oxygen.  
As with all experimental investigations, there are a number of limitations that must be 
considered when interpreting the results of this study. The western blot method used to 
quantify protein expression is employed widely and is highly reliable but occasional 
inconsistencies in gel quality and in band resolution can influence results. This is 
evident when comparing differences between individual blots, but is compensated (at 
least in part) by individual normalisation to β-actin expression. Low n-numbers 
potentially undermine the reliability of the findings but this was necessary to 
accommodate the large number of experimental conditions to be tested and the limits on 
available time and resources. The majority of experiments were performed using cells in 
earlier passage numbers, below 10, at a time when SH-SY5Y cells are considered to be 
stable, functional and healthy (Shipley et al., 2016), but nevertheless differences in 







This study has shown that CBZ, VPA and LTG can increase the expression of Nrf2, 
HO-1 and NQO-1 proteins in SH-SY5Y cells, particularly at higher concentrations that 
are likely above the normal therapeutic range. Interestingly, LEV was without effect, 
suggesting that it possesses a different profile of cellular effects from other commonly 
used AEDs. These findings enhance our understanding of the effects of selected AEDs 
on the anti-oxidant / pro-oxidant balance and on the expression of Nrf2, which acts as a 



















Association between NFE2L2 gene variants and 
















Despite the availability of more than 20 AEDs, at least 30% of patients suffering from 
epilepsy show therapeutic failure, which highlights the need for new AEDs with novel 
targets (Kambli et al., 2017). A master transcriptional regulator, Nrf2, has emerged as a 
potential new therapeutic target in epilepsy (Calkins et al., 2009). In 1994, Nrf2 was 
discovered as a cap’n’collar (CNC) basic-region leucine zipper (bZIP) transcription 
factor which modulates the cellular redox status (Hirotsu et al., 2012). Nrf2 recognizes 
AREs in DNA to increase the transcription of phase II antioxidant enzymes which 
include GST, HO-1, NQO-1, glutamate-cysteine ligase catalytic subunit (GCLC) and 
glutamate-cysteine ligase modulatory subunit (GCLM) (Itoh et al., 1997; Thimmulappa 
et al., 2002).  
The Nrf2-ARE signalling pathway is not fully understood. However, recent studies have 
shown that it offers important targets which might be potentially helpful for protecting 
the brain from ischemic stroke and kainate-induced toxicity (Shih et al., 2005; Kraft et 
al., 2006; Zhao et al., 2006). The role of Nrf2 in relation to the contribution of oxidative 
stress during epileptogenesis justifies its selection as a potential target along with the 
pathways that it mediates (Milder et al., 2010; Rowley and Patel, 2013).  
NFE2L2 gene encodes Nrf2. This gene is located on chromosome 2 (Acosta-Herrera et 
al. 2015). Upon activation by an increase in cellular levels of ROS, Nrf2 translocates to 
the nucleus and binds to the AREs, inducing the transcription of NFE2L2-regulated 
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genes (Acosta-Herrera et al. 2015). There is good evidence to suggest that this process 
is activated by brain insults and seizures and that it might be relevant during 
epileptogenesis and as a consequence of recurrent epileptic seizures (Aparicio et al., 
2015). 
Recent epidemiological and association studies have revealed significant associations 
between NFE2L2 sequence variations and the risk of a variety of diseases, which further 
supports NFE2L2 as a susceptibility gene (Cho. 2013). Recent data from Otter et al 
(2014) suggested that there was association between NFE2L2 SNPs and Parkinson’s 
disease risk. Further studies have provided important information on the association 
between NFE2L2 SNPs and chronic gastritis (Arisawa et al., 2007), chronic obstructive 
pulmonary disease (COPD; Hua et al., 2010), ulcerative colitis (Arisawa et al., 2008), 
vitiligo (Guan et al., 2008) and many other diseases. Although NFE2L2 gene variants 
have not previously been reported in epilepsy studies, the current study has chosen to 
investigate several SNPs in this gene and whether they associate with clinical 
characteristics and treatment outcome in a large cohort of people with epilepsy. This 
association study is consistent with the focus on antioxidant mechanisms throughout 
this thesis and any positive association will give a strong signal that Nrf2-mediated 





6.1.1 Aims of study 
To assess the association between the genotype of selected SNPs in the NFE2L2 gene 
and a variety of demographic variables and clinical characteristics in people with 
epilepsy, including AED treatment outcome (defined as remission on any AED). 
6.2 Materials and methods 
6.2.1 Reagents and chemicals 
TaqMan® genotyping mastermix and TaqMan® SNP genotyping assays for selected 
SNPs (rs7557529, rs1806649, rs2886161, rs2001350 and rs10183914) in the NFE2L2 
gene were purchased from Thermo Fisher Scientific, Loughborough, UK. Other 
chemicals were sourced as described in chapter 2, section 2.2.1. 
6.2.2 Patients and DNA samples 
A total of 1523 DNA samples were used in this study. The study population comprised 
unselected individuals with epilepsy recruited via out-patient clinics at the Western 
Infirmary, Glasgow, UK (Glasgow cohort, 914 samples) and the UK-wide Standard and 
New Antiepileptic Drugs trial (SANAD I cohort, 609 samples). These cohorts include 
most of the demographic and clinical variables which were assessed in this association 
study (table 6.1). All patients provided written informed consent for analysis of their 
DNA. Clinical and demographic data on the patient population was derived from 





Table 6.1: Demographic and clinical variables of SANAD I and Glasgow cohorts 
involved in this study. 
Outcomes SANAD cohort  Glasgow cohort  
No. of samples 609 914 
Sex 
  
Male % 53 52 
Female % 47 48 
Ethnicity 
  
European % 64 99 
Unknown % 36 1 
Newly diagnosed 
  
Yes % 83 53 
No % 17 47 
Epilepsy type 
  
Focal % 71 78 
Generalised-Unclassified % 29 22 
EEG outcome 
  
Normal % 45 28 
Abnormal % 47 51 
Unknown % 8 21 
Imaging outcome 
  
Normal % 60 53 
Abnormal focal % 5 21 
Abnormal-unclassified % 14 19 
Unknown % 20 6 
Aetiology 
  
Cryptogenic % 48 51 
Idiopathic % 30 22 
Symptomatic % 22 27 
MTLE-HS 
  
Yes % 1 3 
No % 99 97 
Family history 
  
Yes % 9 31 
No % 91 69 
Neurological exam. 
  
Normal % 92 92 
Abnormal % 8 8 
Learning disability 
  
Yes % 4 2 
No % 96 98 
Remission on any AED 
  
Yes % 61 66 
No % 39 34 
Age average 34 30 
218 
 
6.2.3 SNP selection and inclusion criteria 
The rs7557529, rs1806649, rs2886161, rs2001350 and rs10183914 SNPs in NFE2L2 
(table 6.2) were selected for genotyping on the basis of a global minor allele frequency 
(MAF) exceeding 10% in the dbSNP database (https://www.ncbi.nlm.nih.gov/snp) and 
prior published evidence of association with a common brain disorder. At the time of 
SNP selection, there were no common SNPs (MAF>10%) in NFE2L2 of known or 
predicted functional significance (i.e. in coding sequence, promoter, splice site or 
untranslated regions). The rs7557529 SNP lies upstream of the NFE2L2 gene and has a 
MAF of 39.5%, while rs1806649, rs2886161, rs2001350 and rs10183914 are all 
intronic variants with MAFs of 10.5%, 37.6%, 12.8% and 23.2%, respectively. All five 
SNPs have been implicated, as part of an NFE2L2 haplotype, in the pathogenesis of 
Parkinson’s disease (Van Otter et al., 2010; Van Otter et al., 2014).  
SNP ID Chromosome Gene Position (bp) SNP type Allele  MAF 
rs7557529 2 NFE2L2 177270369 Upstream G/A 0.395 
rs1806649 2 NFE2L2 177253424 Intron G/A 0.105 
rs2886161 2 NFE2L2 177263111 Intron A/G 0.376 
rs2001350 2 NFE2L2 177235697 Intron G/A 0.128 
rs10183914 2 NFE2L2 177232938 Intron G/A 0.232 
Table 6.2: Details of the SNPs genotyped in this study. Global minor allele frequency 






6.2.4 Genotyping  
Genomic DNA samples were genotyped for the five candidate SNPs at the Department 
of Molecular and Clinical Pharmacology, University of Liverpool. TaqMan® SNP 
Genotyping Assays (Thermo Fisher Scientific, Loughborough, UK) were used in 
accordance with the manufacturer’s instructions, which can be found at: 
https://assets.thermofisher.com/TFS-Assets/LSG/manuals/MAN0009593_TaqManSNP_UG.pdf  
The assay is based on the 5’ to 3’ exonuclease activity of DNA polymerase. TaqMan® 
assay contains two specific primers targeting the region flanking the SNP site and two 
TaqMan fluorescent probes with a minor groove binder (MGB). Each probe is labelled 
with a different fluorophore (VIC or FAM). These reporters are attached covalently to 
the 5' end of the two probes. Near the 3 'end, there is a non-fluorescent quencher (NFQ) 
that prevents liberation of the reporter fluorescence if the probe is not degraded. The 
MGB serves to stabilize the double-stranded structure formed between the target and 
the probe. During the PCR reaction, probes that hybridize specifically to DNA 








Figure 6.1 A) Probe binding and primer extension in a TaqMan® SNP Genotyping 
Assay. (B) Allelic discrimination is achieved by the selective annealing of matching 
probe and template sequences, which generates an allele-specific (fluorescent dye-
specific) signal. V=VIC, F=FAM, R=Reporter, Q=Quencher, MGB=Minor grove 
binder (adapted from De La Vega et al., 2005) 
.  
6.2.5 Experimental details 
The genotyping was performed on an Applied Biosystems ABI 7900HT Real Time 
PCR machine using Taqman® genotyping assays and Taqman® Genotyping mastermix 
in 384 well plates. Individual DNA samples were plated in a single well using 1 l of a 
20 ng/l solution and allowed dry overnight. DNA was reconstituted by the addition of 
5 l of reagent mix, which comprised 2.5 l of Taqman® mastermix (2X), 0.125 l of 
Taqman® genotyping assay (20X), and 2.375 l of MilliQ water.   
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PCR was performed as follows: activation of AmpliTaq Gold DNA polymerase at 95°C 
for 10 min, followed by 40 cycles of denaturing at 95°C for 15 sec and extension at 
60°C for 1 minute. Alleles were clustered using fluorescent signals (VICTM and 
FAMTM). Each PCR plate contained 10% duplicates, two negative controls and one 
known heterozygous control for each SNP. Samples with undetermined calls in the 
initial analysis were repeated under the same conditions. Any self-priming of negative 
control(s) was considered to be contamination, and genotyping was repeated.  
6.2.6 Statistical analysis 
All experiments were performed using two technical replicates (i.e. all samples were 
genotyped in duplicate). For univariate analyses, statistical comparisons were 
undertaken using one-way ANOVA or Chi-square test, as appropriate, using Stats 
Direct software version 2.7.9. P-values below 0.05 were considered to indicate 
associations of statistical significance, For multivariate analyses, statistical comparisons 
were undertaken by binary logistic regression analysis using SPSS software version 24, 
with predictors added to or removed from the predictive model using a stepwise 
approach depending on their degree of impact, as indicated by the p value. The 
significance threshold for identification of predictors was set at p=0.05. The MAF for 
each SNP was compared to the global MAF reported on the dbSNP website 
(https://www.ncbi.nlm.nih.gov/snp) and deviation from Hardy Weinberg equilibrium 
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(HWE) was explored using an online calculator (http://ihg.helmholtz-muenchen.de/cgi-
bin/hw/hwa1.pl), with p<0.01 assumed to indicate deviation from expected values.  
 
6.3 Results 
6.3.1 Association between remission on any AED and NFE2L2 genotypes 
A series of univariate analyses were conducted to explore associations between 
individual NFE2L2 SNP genotypes and any reported period of 12-month remission 
from seizures on any AED at any point during clinical follow-up in all patients for 
whom this information was available. All analyses were undertaken using the Chi-
square test and unadjusted p-values below 0.05 were considered to indicate associations 
of statistical significance. Results are summarised below and reported in full in table 
6.3. 
rs7557529: There was no statistically significant association between rs7557529 
genotype frequencies and remission on any AED (p=0.597) (table 6.3). 
rs1806649: There was no statistically significant association between rs1806649 
genotype frequencies and remission on any AED (p=0.372) (table 6.3). 
rs2886161: There was a statistically significant association between rs2886161 
genotype frequency and remission on AED treatment (p<0.0001). Genotype frequencies 
in patients who achieved 12-month remission from seizures during follow-up were 
223 
 
37.4% AA, 50.4% AG and 12.2% GG, compared to 55.5% AA, 35.5% AG and 8.9% 
GG in those who did not achieve any sustained period of remission (table 6.3).  
rs2001350: There was no statistically significant association between rs2001350 
genotype frequencies and remission on any AED (p=0.304) (table 6.3).  
rs10183914: There was no statistically significant association between rs10183914 
genotype frequencies and remission on any AED (p=0.674) (table 6.3). 
6.3.2 Association between remission on AED treatment and clinical and 
demographic covariates 
All clinical and demographic covariates were assessed, using multiple univariate 
analyses, against any reported period of 12-month remission from seizures on any AED 
at any point during clinical follow-up in all patients for whom this information was 
available. Analyses were undertaken using the Chi-square test for categorical variables 
and one-way ANOVA for continuous variables. Unadjusted p-values below 0.05 were 
considered to indicate associations of statistical significance. Results are summarised 
below and reported in full in tables 6.4. 
There was a significant association between abnormal neurological exam (p=0.0006), 
presence of learning disability (p=0.0077), presence of MTLE-HS (p=0.048), 
symptomatic aetiology (p=0.0016), abnormal imaging (p=0.0071), focal epilepsy 
(p=0.0012), and a higher number of pre-treatment seizures (p=0.0001) and the 
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likelihood of not achieving a 12-month period of remission on any AED at any point 
during clinical follow-up. In contrast, there was no association between sex, family 
history, EEG outcome (table 6.4) or age at epilepsy onset (figure 6.2). 
Table 6.3: Univariate analysis of rs7557529, rs1806649, rs2886161, rs2001350, and 
rs10183914 NEFEL2 SNP genotypes and remission on AED treatment within the study 
population. 
 




χ2 - statistic 
 
p value 
 rs7557529 genotypes  
AA AG GG 
Yes 232 372 169  
1.0313 
 
0.5971 No 147 268 121 
 rs1806649 genotypes  
AA AG GG 
Yes 43 276 455  
1.972 
 
0.372 No 40 184 314 
 rs2886161 genotypes  
 AA AG GG 
Yes 255 344 83  
44.127 
 
<0.0001 No 360 230 58 
 rs2001350 genotypes  
 AA AG GG 
Yes 630 152 5  
2.379 
 
0.304 No 427 105 8 
 rs10183914 genotypes  
 AA AG GG 
Yes 90 343 345  
0.788 
 




Table 6.4: Univariate analysis of clinical and demographic variables with remission on 
any antiepileptic drug during follow-up. 
 
 
AED = antiepileptic drug; EEG = electroencephalogram.  
 
Categorical clinical variables 
Remission on any AED  
χ2 - test 
 
p-value No Yes 
Sex 
Male 285 419 0.087 0.767 
Female 265 377 
Family history of epilepsy 
No 424 640 2.153 0.142 
Yes 126 156 
Neurological examination 
Normal 491 751 12 0.0006 
Abnormal 59 45 
Learning disability 
No 529 784 7.261 0.0077 
Yes 21 12 
Mesial temporal lobe epilepsy with hippocampal sclerosis 
No 537 788 3.909 0.048 
Yes 13 8 
Aetiology 
Cryptogenic 288 391 12.905 0.0016 
Idiopathic 110 226 
Symptomatic 150 179 
Imaging outcome 
Normal 299 478 9.886 0.0071 
Abnormal focal 89 92 
Abnormal unspecified & non-specific changes 104 118 
EEG outcome 
Normal EEG 204 288 1.833 0.399 
Abnormal - non-specific EEG 133 207 
Abnormal - epileptiform EEG 121 208 
Epilepsy type 
Focal epilepsy 438 572 10.502 0.0012 
Generalised & unclassified epilepsy 112 224 
Pre-treatment seizure groups 
1-5 seizures 66 175 27.723 0.0001 
6-20 seizures 86 104 




Figure 6.2 Univariate analysis of age of epilepsy variable with remission on any 
antiepileptic drug during follow-up of the study population. 
 
6.3.3 Multivariate analysis of drug treatment outcome 
A multivariate analysis using binary logistic regression was performed to further 
explore associations between NFE2L2 SNP genotypes, demographic and clinical 
variables and the response to AED treatment. All demographic, clinical and genetic 
covariates were assessed, using a multivariate regression model, against any reported 
period of 12-month remission from seizures on any AED at any point during clinical 
follow-up in all patients for whom this information was available (table 6.5). Despite 
observing multiple statistically significant associations using univariate analysis, in 
which each covariate was assessed independently, the multivariate model failed to 
identify any association between demographic, clinical or NFE2L2 genetic variables 

























Remission on any AED 
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Table 6.5: Multivariate analysis of clinical, demographic and NFE2L2 genetic 
covariates and remission on any antiepileptic drug during follow-up. The relative 
impact of each predictor is denoted by the Wald statistic. The p-value indicates the 
probability that the predictor influences remission. 
 





Predictor Wald statistic P value 
Constant 1.647 0.199 
Sex 0.221 0.638 
Family history of epilepsy 2.063 0.151 
Neurological examination 3.549 0.160 
MTLE-HS 0.717 0.397 
Aetiology 1.165 0.558 
Imaging outcome 0.089 0.957 
EEG outcome 0.963 0.326 
Epilepsy type 0.379 0.538 
rs7557529 G>A 2.033 0.362 
rs1806649 G>A 0.052 0.974 
rs2886161 A>G 2.854 0.240 
rs2001350 A>G 4.284 0.117 




The identification of biomarkers for the prediction of disease outcome and better drug 
response, as well as avoidance of adverse drug effects, is a relatively new field of 
interest in medicine in general and, in particular, in epilepsy research (Larson et al., 
2013). The concept of personalized therapy is increasingly recognised in the treatment 
of people with epilepsy, but predictive markers for its prognosis are still very limited 
(Weber et al., 2014). The Nrf2-ARE pathway has been shown to play an important role 
in protection against several diseases, including epilepsy, through opposing oxidative 
imbalances associated with mitochondrial dysfunction (Rowley and Patel, 2013).  
Differences in AED response can be seen between types of epilepsy, seizure types and 
particular seizure syndromes (Semah et al., 1998). Any genes causing epilepsy are thus 
potential candidates for genetic variation that may also influence differences in AED 
response (Spear, 2001; Depondt, 2006). In recent years at least a dozen genes have been 
identified in rare forms of monogenic epilepsies (Graves, 2006). AED target genes, as 
sources of genetic variation, have only recently been the focus of AED 
pharmacogenetics (Depondt and Shorvon, 2006). Mutations in the α-subunit of the 
voltage-gated sodium channel (NaV) were first associated with familial and sporadic 
epilepsies (Wallace et al., 2001b) and early observations indicated that these NaV 
channel mutations could also affect the clinical response to AEDs in genetic epilepsies 
(Guerrini et al., 1998). Further research has additionally implicated the astrocytic 
GABA transporter GAT-3 (encoded by GAT3) with drug responsiveness (Meldrum and 
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Rogawski, 2007, Kim et al., 2011a). GAT3 variation was associated with the 
pharmacoresistance phenotype in a candidate gene association study (Kim et al., 
2011a). Numerous pharmacogenetic studies have implicated ATP binding cassette 
subfamily B member 1 (ABCB1) polymorphisms in multi-drug resistant epilepsy, with 
ABCB1 polymorphisms that affect expression or functionality, including the well-
known 3435C>T polymorphism (Siddiqui et al., 2003), apparently more frequent in 
AED non-responders than in responders (Loscher and Schmidt, 2009).  
Currently, more than 200 genes are known to be regulated by Nrf2, including those 
involved in mechanisms of cytoprotection, metabolism, and mitochondrial function ( 
Aparicio et al., 2015). Moreover, a recent study has suggested that therapies targeting 
the Nrf2 pathway possess significant potential for the treatment of epilepsy, 
neurodegenerative and inflammatory diseases (Mazzuferi et al., 2013). 
At present, the selection of a specific AED for any given patient is based predominately 
on seizure type, syndrome and likely adverse effects (Engel et al., 2013). However, the 
response to that AED at an individual patient level is almost unpredictable, hence a 
degree of trial and error is part of the standard care provided to patients undergoing 
treatment for epilepsy (Weber and Lerche, 2008). There is therefore an urgent need for 
predictive biomarkers, whether demographic, clinical, genetic or otherwise, which may 




With this in mind, the analysis reported in this chapter, focusing on genetic biomarkers 
of disease and treatment outcome, is entirely in line with many ongoing epilepsy 
research studies and with the requirements of epilepsy in general. The analysis took 
advantage of the availability of a large cohort of epilepsy patients who had recently 
undergone detailed clinical phenotyping of their basic demographic characteristics, key 
clinical aspects of their epilepsy, and examination of their response to treatment with 
AEDs. Many of the patients had been enrolled in prior studies of newly-diagnosed 
epilepsy, in which information had been collected prospectively from the point of 
diagnosis and initiation of AED treatment. In addition, a DNA sample was available for 
all patients, which was genotyped for five common variants in the NFE2L2 gene, which 
encodes Nrf2. Demographic variables (i.e. age, sex), clinical variables (i.e. type of 
epilepsy, EEG outcome), and genetic variables (i.e. genotype of NFE2L2 SNPs) were 
then combined in a multi-dimensional (univariate & multivariate) analysis that was 
designed to find biomarkers for treatment outcome in epilepsy. A similar strategy is 
being pursued by many other researchers (Lagarde et al., 2018; Rawat et al., 2018).  
Genetic variants have been the focus of many epilepsy research studies, particularly in 
recent years, and have been studied in various populations (Lee, 2018). In the current 
study, it was shown that a specific SNP (i.e. rs2886161) in the NFE2L2 gene was 
associated with remission on AED treatment (table 6.3). There was, however, no other 
notable association between NFE2L2 genotypes (rs7557529, rs1806649, rs2001350, and 
10183914) and remission in this study. To our knowledge, there is no previously 
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published work that has directly investigated the contribution of NFE2L2 gene variants 
in epilepsy or in the context of response to treatment in epilepsy, so there is no 
opportunity to validate these observations. Moreover, the absence of association might 
be due to clinical heterogeneity (variability in the clinical characteristics of the two 
different cohorts) as two different disease cohorts have been analysed together. Analysis 
of clinical data in the current study suggested that normal neurological examination, 
absence of learning disability, idiopathic aetiology, absence of MTLE-HS, generalised 
or unclassified epilepsy, normal neuroimaging investigations, and a low number of 
seizures prior to initiation of drug treatment were all associated with a higher likelihood 
of remission on AED therapy, which is in line with already published data (French, 
2002). 
Seizure freedom (i.e. remission) is the primary goal of AED therapy and a number of 
prognostic clinical factors have been reported in previous studies. It is widely 
recognised that nearly 50% of newly diagnosed epilepsy patients become seizure-free 
on the first ever AED, with >90% doing so at moderate or even modest dosing (Kwan 
and Brodie, 2001). Bonnett and colleagues (2012) investigated several prognostic 
factors (i.e. age, sex, number of seizures, EEG outcomes, etc.) in a large randomised 
controlled trial of patients with newly-diagnosed epilepsy commencing their first ever 
AED. Treatment failure increased as age and total number of pre-treatment seizures 
increased and was significantly more likely in women than in men and in patients with 
EEG abnormality than in patients with a normal EEG (Bonnett et al., 2012). 
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Interestingly, the current analysis failed to show an association between treatment 
outcome and sex, age or EEG findings, even though many of the same patients (i.e. 
those from the SANAD study) were included in both cohorts. Similarly, the current 
analysis also showed an association between treatment outcome and the presence of 
MTLE-HS and/or learning disability, which was not reported by Bonnett et al (2012), 
although this has also been recognised in other studies, in which patients with MTLE-
HS may never experience complete seizure freedom, even after surgery (Wiebe et al., 
2001; Tellez-Zenteno et al., 2005; Wendling et al., 2013). 
Despite observing multiple independent associations with AED treatment outcome 
following univariate analyses, a multivariate approach in which clinical, demographic 
and genetic variable were combined using stepwise regression within a single statistical 
model was without significant findings. This would suggest that none of the 
associations observed in the univariate analyses was particularly strong or that the 
inclusion of non-significant genetic covariates in the multivariate model may have 
reduced the sensitivity (or power) to detect true associations. A different approach, 
where only those covariates shown to be statistically significant at the univariate level 
were included in the multivariate model may have been more revealing.    
Thus, the attempt to identify genetic predictors of treatment outcome within the 
NFE2L2 gene was largely unsuccessful, with no evidence to suggest that common 
genetic variants in this gene had any influence on the response to AED therapy. This is 
maybe unsurprising as the functional effects of the selected SNPs on Nrf2 function are 
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unclear. Although the cohort size was significantly larger than many other published 
studies, the approach of using selected SNPs from candidate genes is no longer 
favoured. The majority of previous studies that have used this methodology to identify 
significant associations between genotype and treatment outcome have never been 
replicated. Epilepsy genetics is now moving towards much larger-scale, international 
collaboration style studies and epilepsy researchers are beginning to understand the 
challenges of small scale studies (Ottman et al., 2018), but still there is a lot to be done 
in this regard.  
Most of the biomarker studies published to date have included heterogeneous 
populations of epilepsy patients which might make it difficult to a genetic biomarker 
(Engel et al., 2013). They are often small-scale and driven by specific hypotheses that 
do not apply to all patients. There is also some confusion in the epilepsy research 
community about what constitutes a biomarker and what we can learn from studies 
conducted in humans and in animals. Animal models of epilepsy are useful for testing 
drugs but they do not always offer a good insight into the clinical situation 
(Kandratavicius et al., 2014). There is a need for a much more standardized approach 
and for larger, well-defined cohort studies that maximise the potential, statistical 







This analysis has shown expected associations between a number of clinical and 
demographic variables (i.e. number of pre-treatment seizures, abnormal neurological 
examination, presence of a learning disability, aetiology of epilepsy, etc.) and remission 
on AED treatment. There was also a modest univariate association between NFE2L2 
genotype rs2886161 and treatment outcome. However, there were no statistically 
significant associations between the rs7557529, rs1806649, rs2001350 and rs10183914 
SNPs and the remission on any AED. Similarly, a multivariate predictive model did not 
show any significant contribution of NFE2L2 SNP genotypes, demographic and clinical 
predictors and the response to AED treatment.  
Although derived from analysis of a large cohort of patients, these findings should be 
treated with caution because of concerns about false-positive findings and the failure of 
a detailed multivariate analysis to identify any reliable interaction between NFE2L2 
genotype and treatment outcome. Despite our hypothesis about the involvement of the 
Nrf2-ARE pathway in epilepsy, there was no evidence from this pharmacogenomics 
investigation that common variants in the NFE2L2 gene, which encodes Nrf2, have any 



























Epilepsy continues to be a major burden on the global health system. The high rates of 
pharmaco-resistance in addition to a lack of specific measures to predict treatment 
response have increased the need for sensitive and specific biomarkers for this disease. 
Epilepsy is associated with increased mortality, significant comorbidities, unique 
stigmatization of affected individuals, and high societal cost. Moreover, common AEDs 
merely provide symptomatic treatment without having any influence on disease course 
(Brandt et al., 2006). Thus, there is a pressing need to develop alternative therapeutic 
approaches that prevent epileptogenesis after brain insults. New antiseizure treatments 
are unlikely to bridge this treatment gap. Therefore, it has been suggested that the next 
generation of drugs should potentially be able to delay or prevent the onset of epilepsy 
in susceptible individuals (anti-epileptogenesis) or to halt or reverse its progression 
and/or improve the neuropathology and the associated comorbidities (disease-
modifying) (Varvel et al., 2015). Oxidative stress has been shown to play a key role in 
epileptogenesis after the first seizure. Through progressive neurobiological changes, the 
first seizure becomes a cause for recurrent seizures (Martinc et al., 2012). Much 
evidence supports the idea that oxidative stress is involved in the pathogenesis of 
epilepsy and that antioxidants or free radical scavengers can ameliorate seizure activity 
and neuronal damage in various epilepsy models (Shin et al., 2011). Hence, new agents 
with antioxidant properties can be expected to have therapeutic potential against 
epilepsy. Breaking this vicious cycle through the neutralization of ROS and/or RNS 






7.2 Overview of experiments 
The work presented in this thesis was designed to explore various neurobiological 
aspects of oxidative stress and the effects of antiepileptic drugs on key molecules and 
proteins involved in this insidious process. The first experimental chapter (chapter 2) set 
out to determine the effect of H2O2, LPS, and pilocarpine on several markers of 
oxidative stress, i.e. MDA concentration, SOD activity, and GSH/GSSG ratio, in SH-
SY5Y cells in order to establish the optimal experimental conditions (i.e. times, 
concentrations, preferred inducer, etc.) with which to later assess drug effects. The 
subsequent experimental chapter (chapter 3) focused on the biochemical actions of the 
four most widely prescribed AEDs, i.e. CBZ, VPA, LEV and LTG, on MDA, SOD and 
GSH/GSSG as markers of oxidative stress. Chapters 4 and 5 then explored AED effects 
on the expression of several phase II detoxification antioxidant genes (Nrf2, HOX-1, 
and NQO-1) at the mRNA and protein level, respectively. The final experimental 
chapter (chapter 6) had a somewhat different focus, looking instead at the potential 
contribution of known common variants in the NFE2L2 gene (which encodes Nrf2) to 
multiple clinical characteristics, including treatment outcome, using DNA samples and 
clinical information from a large cohort of people with epilepsy. This work has 
accordingly provided an excellent training in experimental design, in the use of several 
established and contemporary laboratory techniques, and in translational research that 
relies on clinical data and human biological samples.   
7.3 Optimising induction of oxidative stress 
The initial results showed that incubation of SH-SY5Y cells with H2O2, LPS, and 
pilocarpine decreased the cell viability and increased oxidative stress by increasing 
MDA concentration, and by decreasing SOD activity and GSH/GSSG ratio in a time-
and concentration-dependent manner. Later studies also showed corresponding effects 
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on the expression of Nrf2 and its target genes HO-1 and NQO-1. Taken together, these 
experiments indicated that exposure of SH-SY5Y cells to 100M H2O2 for 4 hours 
resulted in optimum induction of oxidative stress, i.e. maximal change in biochemical 
markers of oxidative stress at acceptable cell viability (>80%). This became the 
standard experimental approach in later experiments. These results reflect those of Kang 
et al (2014) who also showed a concentration-dependent decrease in SH-SY5Y cell 
viability after exposure to H2O2, with cell viability remaining above 80% even after 24 
hours exposure to 100µM H2O2. The strong pro-oxidant activity of H2O2 has been 
suggested to be due to its direct damaging effect, as it is a highly diffusible ROS that 
can cross the plasma membrane (Forman, 2007). In addition, treatment with H2O2 has 
been shown to produce more O- by activation of NADPH oxidase and subsequently the 
formation of ONOO- through superoxide scavenging of nitric oxide (Beckman et al., 
1990; Pryor and Squadrito, 1995). These findings, and also those described in chapter 4, 
are similarly consistent with a previous study which reported an up-regulation in Nrf2 
expression after H2O2 exposure (Fourquet et al., 2010), which may be explained by a 
direct effect of H2O2 on the Nrf2-Keap 1 dissociation and Nrf2 nuclear translocation. 
In contrast to H2O2, cellular exposure to LPS may trigger the release of inflammatory 
mediators, such as TNF-α, which can, in turn, result in oxidative stress and 
inflammation leading to a reduction in cell viability (Choudhury et al., 2015; Ruiz-
Miyazawa, 2015). In line with the current results, previous studies have demonstrated a 
similar increase in MDA concentration and decreases in GSH concentration and SOD 
activity in different experimental models and cell lines after exposure to LPS (Pourganji 
et al., 2014; Gou et al., 2015; Frimmel et al., 2016). The key event that leads to Nrf2 
pathway activation appears to be TLR receptor activation by LPS, which results in ROS 
release, with the Keap-1 protein undergoing oxidation and dissociation of Nrf2 (Hu et 
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al., 2011). When using pilocarpine as an inducer, the current work again supported 
evidence from previous observations which showed concentration-dependent effects of 
pilocarpine on lipid peroxidation, decreases in GSH level and SOD activity, plus 
increased NO, TNF-α, and IL-6, all of which play an important role in inflammation 
and oxidative stress (Freitas et al., 2004; Santos et al., 2011; Kabel. 2014; Noor et al., 
2015). In addition, it has been suggested that ROS are immediately increased after M1 
receptor stimulation by pilocarpine, with ROS potentially participating as second 
messengers in the regulation of ARE-driven genes by disrupting the Nrf2/Keap1 
interaction (Mangelus et al., 2001; Nguyen et al., 2003).  
In addition to optimising the conditions for induction of oxidative stress in terms of 
preferred inducer, concentration and duration of exposure, early experiments also 
considered morphology of the SH-SY5Y cells themselves. There was no significant 
difference in the change in MDA concentration, SOD activity and GSH/GSSG ratio 
caused by 100µM H2O2 when comparing differentiated and undifferentiated SH-SY5Y 
cells. This confirmed that undifferentiated SH-SY5Y cells are sensitive to oxidative 
damage and are a suitable in vitro system for these experiments. Undifferentiated SH-
SY5Y cells are often considered more appropriate for studying neurotoxicity and 
neuroprotection in experimental neurological disease research (Cheung et al., 2009) 
because differentiation can be associated with a number of issues that might impact on 
the interpretation of experimental results, including proteomic changes, cellular 
proliferation and apoptosis. It is also reported that in studies assessing cellular stresses, 
including oxidative and metabolic stress, differentiation may be undesirable due to the 





7.4 Effects of antiepileptic drugs 
Much of the experimental work in this thesis focused on the effects of four AEDs, CBZ, 
VPA, LEV and LTG, which are the four most commonly-prescribed drugs for the 
treatment of epilepsy in the UK and amongst the most widely used across the globe. All 
four AEDs decreased the viability of SH-SY5Y cells in a time-and concentration-
dependent manner and negatively affected oxidative stress markers by increasing MDA 
concentrations and decreasing SOD activity and GSH/GSSG ratio, with and without 
additional exposure to 100µM H2O2 for 4 hours. Three of the four AEDs (CBZ, VPA, 
LTG) also increased the expression of Nrf2, HOX-1, and NQO-1 at both gene and 
protein level following 24 hour exposure, again with or without 100µM H2O2 for a 
further 4 hours. In contrast, LEV had no effect on gene or protein expression. 
These findings are consistent with those of other researchers who also showed 
concentration-dependent cytotoxic effects of CBZ and VPA (Ambrósio et al., 2000 
Dodurga et al., 2014). Pro-oxidant effects of CBZ and VPA have also been reported, 
which may be linked to their cytotoxic effects (Thomas et al., 2006; Santos et al., 2008). 
One possible explanation for these results may be the propensity for CBZ and VPA to 
generate toxic epoxy and peroxy metabolites which are believed to play an important 
role in cellular mitochondrial toxicity and ROS liberation (Tong et al., 2005; Tutanc et 
al., 2015). In respect of LTG, there is, to the best of our knowledge, just one report that 
has assessed its effect on oxidative damage. Using a rat liver tissue model, Poorrostami 
et al (2014) showed that LTG could increase MDA concentration 2-fold and decrease 
catalase activity 3-fold in comparison to control. The mechanism behind LTG-induced 
liver injury is not clearly explained, although some reports have suggested this may be 
caused by an immune reaction to the arene oxide metabolite of LTG, leading to an 
inflammatory process and oxidative stress (Maggs et al., 2000; Mecarelli et al., 2005). 
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These findings are in agreement with the up-regulation in the expression of Nrf2, HO-1 
and NQO-1 genes and proteins after exposure to these AEDs reported in chapters 4 and 
5 of this thesis. Accordingly, one can speculate that the pro-oxidant effects of CBZ, 
VPA and LTG leads to an increase in the expression of Nrf2 and its downstream target 
genes as an attempt to provide protection against cytotoxic damage. 
No previous laboratory studies have assessed the pro-oxidant and/or anti-oxidant 
behaviour of LEV. There is a single report that investigated the effect of LEV on 
oxidative stress markers in epilepsy patients and which showed an increase in the 
urinary level of 15F-2t-isoprostane, which is a reliable marker of oxidative damage 
(Ozden et al., 2010). Contrary to our expectations, LEV did not have any effect on the 
expression of Nrf2 or its target genes in the current study. It is possible that pre-
incubation with LEV may have resulted in the preservation of the activity of catalase, an 
antioxidant enzyme that catalyses the conversion of H2O2 to water and oxygen, which 
might then explain the antioxidant behaviour of LEV against H2O2-induced oxidative 
stress in SH-SY5Y cells (Oliveira et al., 2016). Thus, LEV might help to protect against 
the overproduction of ROS and the resulting oxidative damage. 
7.5 Genetic variation in the antioxidant response 
The work described in the final experimental chapter of this thesis (chapter 6) took 
advantage of the availability of DNA samples and related clinical information from a 
large cohort of people with epilepsy. It focused on the association between common 
variants in the NFE2L2 gene, which encodes Nrf2, and characteristics of the study 
population, including several demographic and clinical variables related to epilepsy and 
its response to AED treatment. NFE2L2 SNP genotypes were generated de novo using 
Taqman genotyping, while phenotypes were extracted from existing databases. A 
variety of modest but significant associations were identified using univariate analysis. 
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These included a higher prevalence of the rs2886161 in those experiencing remission on 
any AED treatment. In addition, associations were found between a number of clinical 
and demographic variables (i.e. number of pre-treatment seizures, abnormal 
neurological examination, presence of a learning disability, aetiology of epilepsy, 
abnormal EEG, etc.) and remission on any AED. It is found that fewer seizures prior to 
initiation of AED treatment, earlier age at onset of epilepsy, less frequent seizure (1-5 
seizures) and normal neuroimaging,  and EEG outcomes are all associated with a 
greater likelihood of achieving seizure freedom (i.e. remission), which is the primary 
goal of AED therapy. Moreover, this study indicated that patients with mesial temporal 
lobe epilepsy with hippocampal sclerosis and learning disability are less likely to 
respond to drug treatment, and therefore less likely to achieve remission. 
The additional SNPs in NFE2L2 (rs7557529, 1806649, rs2001350, rs10183914) failed 
to show any association with any feature of the epilepsy and none of the above 
associations survived re-analysis using a multivariate approach, suggesting that the 
initial observations may have been false positive findings. This conclusion was 
reinforced by the fact that several known associations between clinical characteristics 
and treatment outcome in epilepsy remained evident after multivariate regression 
analysis. These included abnormal neurological examination, learning disability, 
aetiology, epilepsy type, age at onset, and the number of pre-treatment seizures, all of 
which have been shown in previous studies to have a significant influence of the 
likelihood of achieving remission from seizures following AED treatment or the time to 
achieve remission (Kwan and Brodie, 2001; Bonnett, 2012). To the best of our 
knowledge, no previous studies have specifically explored the association between 
NFE2L2 genotype and treatment outcome in epilepsy and the results reported here 
suggest that any such investigation is not warranted.  
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7.6 Summary of experimental findings 
(1) H2O2, LPS and pilocarpine decreased cell viability and attenuated basal antioxidant 
mechanisms in a time-and concentration-dependent manner in human neuroblastoma 
(SH-SY5Y) cells. Exposure to 100µM H2O2 for 4 hours was considered optimal for 
further investigations because it showed efficient induction of oxidative stress with 
minimum cell death (less than 20%) within a manageable timeframe, when compared 
with other experimental conditions investigated. 
(2) No significant differences were noted between differentiated and undifferentiated 
SH-SY5Y cells in terms of their response to exposure to oxidative challenge with 
100µM H2O2. On that basis, and given previous reports highlighting concerns 
associated with the differentiation process and their potential impact on experimental 
results, undifferentiated SH-SY5Y cells were used in all subsequent investigations. 
(3) CBZ, VPA, LEV, and LTG had negative effects on the pro-oxidant / anti-oxidant 
balance which were both time- and concentration-dependent, were especially 
pronounced at the highest concentrations, and were exacerbated by subsequent exposure 
of cells to H2O2. Oxidative stress produced by H2O2 was enhanced, rather than 
ameliorated, by exposure to AEDs. The pro-oxidant behaviour of AEDs that was 
observed throughout these experiments was unexpected but may be related, at least in 
part, to the generation of toxic metabolites, resulting in cell stress and apoptosis. 
(4) H2O2, LPS and pilocarpine increased the expression of Nrf2, HO-1 and NQO-1 at 
both mRNA and protein level in a time-and concentration-dependent manner. CBZ, 
VPA and LTG did likewise and their effects were further exacerbated by subsequent 
exposure to H2O2. In contrast, LEV did not induce expression of Nrf2, HO-1 or NQO-1. 
It is reasonable to speculate the pro-oxidant effects seen with several AEDs leads, in 
turn, to activation of the Nrf2-ARE pathway as a cellular defence mechanism against 
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cytotoxicity. LEV also showed pro-oxidant potential in biochemical assays but no 
evident activation of the Nrf2-ARE pathway, suggesting fundamental differences in the 
cellular response to this drug which remain unexplained.  
(5) There were modest statistical associations between known common variants in the 
NFE2L2 gene, which encodes Nrf2, and isolated clinical characteristic in a large cohort 
of people with epilepsy. These included associations between one intronic variant in 
NFE2L2 (i.e. rs2886161) and the outcome of AED treatment. However, no significant 
association was found between other intronic variants in NFE2L2 (i.e. rs7557529, 
1806649, rs2001350, rs10183914) and the AED treatment outcome. This analysis has 
shown expected associations between a number of clinical and demographic variables 
(i.e. number of pre-treatment seizures, abnormal neurological examination, presence of 
a learning disability, aetiology of epilepsy, abnormal EEG, etc.) and remission on any 
AED. Similarly, a multivariate predictive model did not show any significant 
contribution of NFE2L2 SNP genotypes, demographic and clinical predictors and the 
response to AED treatment.  
Although there is good evidence to support a role of oxidative stress and the Nrf2-ARE 
pathway in epilepsy, it would appear that this is not influenced by common variation in 








7.7 Limitations and challenges of the work 
As with any series of experiments, there are inevitable inconsistencies and limitations 
which mean that results should be interpreted with a degree of caution.  
A major limitation of the work described in this thesis was the low number of biological 
replicates, with many studies employing an n-number of just 3. This was necessary to 
accommodate the complex experimental design used and the large number of 
concentrations, conditions and comparisons explored but it has an inevitable impact on 
the statistical validity of the findings. As such, more emphasis should be placed on the 
pattern of results (i.e. time- and concentration-dependence) than on the p-value 
associated with any isolated observation. Other related concerns include the lack of 
independent verification of results in another batch of SH-SY5Y cells (or in a different 
cell line), which would give important validity to the observations, and a limited range 
of time-points, which perhaps failed to capture the full extent of the cellular response to 
oxidative challenge or AED exposure. In the interests of time, it was not possible to 
explore either of these issues.  
SH-SY5Y cells were always used at a passage number of between 6 and 12 in an effort 
to standardise experiments and enable comparison between results obtained in different 
phases of the work. Even within this relatively narrow window, it is recognised that 
passage number has an influence on growth rates and on physiological and chemical 
characteristics of immortalized cell lines. Although its influence is questionable, this is 
another potential confounder whose effect could have been minimised by increased n-
numbers and independent verification. Another concern about the use of in vitro cell 
cultures is the fact that they are studied in isolation and in the absence of their normal 
environment, which includes interactions with other cell types that might be critical to 
the process being tested.  
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The laboratory methods used in the experiments described in this thesis are widely used 
in biomedical research and can be considered reliable. However, the western blot 
method used to investigate protein expression was occasionally associated with 
inconsistencies in gel quality and in-band resolution, which had the potential to 
influence quantification of expression. This was most evident when comparing data 
between blots, but is compensated (at least in part) by ‘within gel’ normalization to β-
actin expression.  
The biochemical assays used to quantify oxidative stress are long-established and robust 
but the use of just three markers (i.e. MDA concentration, SOD activity and 
GSH/GSSG ratio) might not be sufficient to reflect the actual cellular redox status. 
Measuring total antioxidant (TAO) activity and including assays for catalase activity 
(which is specific for H2O2 neutralization) and Gpx activity may have provided a more 
comprehensive picture of cellular response to oxidative challenge and AED exposure 
and may have helped to elucidate the distinct action of LEV.    
Finally, it is recognised that the candidate gene approach and SNP selection strategy 
used in the association analysis reported in chapter 6 was not particularly modern or 
robust, with SNPs selected predominantly on the basis of minor allele frequency rather 
than on any known or predicted functional effects on Nrf2 expression or activity. 
Furthermore, clinical heterogeneity within the two selected study cohorts may be 
another reason for the lack of association observed with Nrf2 SNPs. This was however 
an exploratory analysis, seeking verification of Nrf2 involvement in epilepsy and 
therefore justifying a candidate gene analysis, and the number of samples/cases 
included greatly exceeded those typically reported in similar studies, improving the 




7.8 Recommendations and future work 
Exploration of the relationship between oxidative stress, epilepsy and commonly used 
AEDs is an important and potentially fruitful area for future research that aims to 
understand the underlying mechanisms of epileptogenesis and to identify novel drug 
targets. Future studies should seek to validate their findings using in vivo models of 
seizures and epilepsy. This would allow chronic exposure to AEDs, which is much 
more clinically relevant, concomitant investigation of drug pharmacokinetics and their 
pharmacodynamic effects, and a better understanding of how seizures themselves affect 
oxidative stress and whether this has any impact on the behaviour of AEDs. Likewise, 
more effort is required to explore the full range of oxidative stress markers, with the 
addition of measures of TAO activity, Gpx activity, catalase activity and LDH activity 
likely to give a more complete picture of the cellular response to oxidative insults and 
AED treatment. Finally, for any future genetic association analysis, it would be 
reasonable to target a panel of genes that more broadly represent mitochondrial 
function, cellular redox status and the anti-oxidant response, rather than just a single gen 
like Nrf2. More robust SNP selection, focussing more on functional significance rather 
than just allele frequency, would increase the likelihood of identifying associations 
between inter-individual genetic variation, epilepsy and response to AED therapy. 
7.9 Conclusions 
These findings imply that several existing AEDs have pro-oxidant rather than 
antioxidant effects, albeit at relatively high concentrations. This may limit their 
antiseizure activity and/or contribute to their adverse effect profile. There was no 
evidence from this pharmacogenomics investigation that common variants in the 
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